id	sid	tid	token	lemma	pos
dpc-6010	1	1	dermatology	dermatology	NOUN
dpc-6010	1	2	:	:	PUNCT
dpc-6010	1	3	practical	practical	ADJ
dpc-6010	1	4	and	and	CCONJ
dpc-6010	1	5	conceptual	conceptual	ADJ
dpc-6010	1	6	original	original	ADJ
dpc-6010	1	7	article	article	NOUN
dpc-6010	1	8	|	|	ADV
dpc-6010	1	9	dermatol	dermatol	ADJ
dpc-6010	1	10	pract	pract	NOUN
dpc-6010	1	11	concept	concept	NOUN
dpc-6010	1	12	.	.	PUNCT
dpc-6010	2	1	2025;15(4):6010	2025;15(4):6010	NUM
dpc-6010	2	2	1	1	NUM
dpc-6010	2	3	brodalumab	brodalumab	NOUN
dpc-6010	2	4	efficacy	efficacy	NOUN
dpc-6010	2	5	in	in	ADP
dpc-6010	2	6	psoriasis	psoriasis	NOUN
dpc-6010	2	7	patients	patient	NOUN
dpc-6010	2	8	with	with	ADP
dpc-6010	2	9	inadequate	inadequate	ADJ
dpc-6010	2	10	response	response	NOUN
dpc-6010	2	11	to	to	ADP
dpc-6010	2	12	il-23	il-23	NOUN
dpc-6010	2	13	or	or	CCONJ
dpc-6010	2	14	il-12/23	il-12/23	ADJ
dpc-6010	2	15	inhibitors	inhibitor	NOUN
dpc-6010	2	16	:	:	PUNCT
dpc-6010	2	17	multicenter	multicenter	NOUN
dpc-6010	2	18	italian	italian	ADJ
dpc-6010	2	19	retrospective	retrospective	ADJ
dpc-6010	2	20	analysis	analysis	NOUN
dpc-6010	2	21	il	il	PROPN
dpc-6010	2	22	pso	pso	PROPN
dpc-6010	2	23	(	(	PUNCT
dpc-6010	2	24	italian	italian	ADJ
dpc-6010	2	25	landscape	landscape	NOUN
dpc-6010	2	26	psoriasis	psoriasis	NOUN
dpc-6010	2	27	)	)	PUNCT
dpc-6010	2	28	diego	diego	PROPN
dpc-6010	2	29	orsini1,2	orsini1,2	PROPN
dpc-6010	2	30	,	,	PUNCT
dpc-6010	2	31	maria	maria	PROPN
dpc-6010	2	32	concetta	concetta	PROPN
dpc-6010	2	33	fargnoli2	fargnoli2	PROPN
dpc-6010	2	34	,	,	PUNCT
dpc-6010	2	35	martina	martina	PROPN
dpc-6010	2	36	burlando3	burlando3	PROPN
dpc-6010	2	37	,	,	PUNCT
dpc-6010	2	38	4	4	NUM
dpc-6010	2	39	,	,	PUNCT
dpc-6010	2	40	anna	anna	PROPN
dpc-6010	2	41	campanati5	campanati5	PROPN
dpc-6010	2	42	,	,	PUNCT
dpc-6010	2	43	elena	elena	PROPN
dpc-6010	2	44	campione6	campione6	PROPN
dpc-6010	2	45	,	,	PUNCT
dpc-6010	2	46	claudio	claudio	PROPN
dpc-6010	2	47	guarneri7	guarneri7	PROPN
dpc-6010	2	48	,	,	PUNCT
dpc-6010	2	49	alessandra	alessandra	PROPN
dpc-6010	2	50	narcisi8	narcisi8	PROPN
dpc-6010	2	51	,	,	PUNCT
dpc-6010	2	52	paolo	paolo	PROPN
dpc-6010	2	53	pella9	pella9	PROPN
dpc-6010	2	54	,	,	PUNCT
dpc-6010	2	55	paolo	paolo	PROPN
dpc-6010	2	56	romita10	romita10	NOUN
dpc-6010	2	57	,	,	PUNCT
dpc-6010	2	58	massimo	massimo	PROPN
dpc-6010	2	59	travaglini11	travaglini11	PROPN
dpc-6010	2	60	,	,	PUNCT
dpc-6010	2	61	leonardo	leonardo	PROPN
dpc-6010	2	62	zichichi12	zichichi12	PROPN
dpc-6010	2	63	,	,	PUNCT
dpc-6010	2	64	luisa	luisa	PROPN
dpc-6010	2	65	maria	maria	PROPN
dpc-6010	2	66	halina	halina	PROPN
dpc-6010	2	67	arancio13	arancio13	PROPN
dpc-6010	2	68	,	,	PUNCT
dpc-6010	2	69	chiara	chiara	PROPN
dpc-6010	2	70	assorgi25	assorgi25	NOUN
dpc-6010	2	71	,	,	PUNCT
dpc-6010	2	72	ginevra	ginevra	PROPN
dpc-6010	2	73	baggini14	baggini14	NOUN
dpc-6010	2	74	,	,	PUNCT
dpc-6010	2	75	riccardo	riccardo	NOUN
dpc-6010	2	76	balestri15	balestri15	NOUN
dpc-6010	2	77	,	,	PUNCT
dpc-6010	2	78	luca	luca	PROPN
dpc-6010	2	79	bianchi6	bianchi6	PROPN
dpc-6010	2	80	,	,	PUNCT
dpc-6010	2	81	alexandra	alexandra	PROPN
dpc-6010	2	82	maria	maria	PROPN
dpc-6010	2	83	giovanna	giovanna	PROPN
dpc-6010	2	84	brunasso16	brunasso16	PROPN
dpc-6010	2	85	,	,	PUNCT
dpc-6010	2	86	anna	anna	PROPN
dpc-6010	2	87	elisabetta	elisabetta	PROPN
dpc-6010	2	88	cagni17	cagni17	PROPN
dpc-6010	2	89	,	,	PUNCT
dpc-6010	2	90	giacomo	giacomo	PROPN
dpc-6010	2	91	caldarola18,19	caldarola18,19	PROPN
dpc-6010	2	92	,	,	PUNCT
dpc-6010	2	93	gianluca	gianluca	PROPN
dpc-6010	2	94	calianno10	calianno10	PROPN
dpc-6010	2	95	,	,	PUNCT
dpc-6010	2	96	antonio	antonio	PROPN
dpc-6010	2	97	carpentieri11	carpentieri11	PROPN
dpc-6010	2	98	,	,	PUNCT
dpc-6010	2	99	martino	martino	PROPN
dpc-6010	2	100	carriero20	carriero20	PROPN
dpc-6010	2	101	,	,	PUNCT
dpc-6010	2	102	andrea	andrea	PROPN
dpc-6010	2	103	carugno21	carugno21	PROPN
dpc-6010	2	104	,	,	PUNCT
dpc-6010	2	105	franco	franco	PROPN
dpc-6010	2	106	cona22	cona22	PROPN
dpc-6010	2	107	,	,	PUNCT
dpc-6010	2	108	antonio	antonio	PROPN
dpc-6010	2	109	costanzo8	costanzo8	PROPN
dpc-6010	2	110	,	,	PUNCT
dpc-6010	2	111	emanuele	emanuele	PROPN
dpc-6010	2	112	cozzani3	cozzani3	PROPN
dpc-6010	2	113	,	,	PUNCT
dpc-6010	2	114	4	4	NUM
dpc-6010	2	115	,	,	PUNCT
dpc-6010	2	116	giacomo	giacomo	NOUN
dpc-6010	2	117	dal	dal	NOUN
dpc-6010	2	118	bello23	bello23	PROPN
dpc-6010	2	119	,	,	PUNCT
dpc-6010	2	120	paolo	paolo	PROPN
dpc-6010	2	121	dapavo42	dapavo42	PROPN
dpc-6010	2	122	,	,	PUNCT
dpc-6010	2	123	annunziata	annunziata	PROPN
dpc-6010	2	124	dattola25	dattola25	PROPN
dpc-6010	2	125	,	,	PUNCT
dpc-6010	2	126	antonio	antonio	PROPN
dpc-6010	2	127	di	di	PROPN
dpc-6010	2	128	tano7	tano7	PROPN
dpc-6010	2	129	,	,	PUNCT
dpc-6010	2	130	federico	federico	PROPN
dpc-6010	2	131	diotallevi5	diotallevi5	PROPN
dpc-6010	2	132	,	,	PUNCT
dpc-6010	2	133	marianna	marianna	PROPN
dpc-6010	2	134	donnarumma26	donnarumma26	PROPN
dpc-6010	2	135	,	,	PUNCT
dpc-6010	2	136	elena	elena	PROPN
dpc-6010	2	137	de	de	PROPN
dpc-6010	2	138	col	col	PROPN
dpc-6010	2	139	27	27	NUM
dpc-6010	2	140	,	,	PUNCT
dpc-6010	2	141	maria	maria	PROPN
dpc-6010	2	142	esposito28	esposito28	PROPN
dpc-6010	2	143	,	,	PUNCT
dpc-6010	2	144	carmen	carmen	PROPN
dpc-6010	2	145	silvia	silvia	PROPN
dpc-6010	2	146	fiorella29	fiorella29	PROPN
dpc-6010	2	147	,	,	PUNCT
dpc-6010	2	148	marco	marco	PROPN
dpc-6010	2	149	galluzzo6	galluzzo6	PROPN
dpc-6010	2	150	,	,	PUNCT
dpc-6010	2	151	francesca	francesca	PROPN
dpc-6010	2	152	graziola30	graziola30	PROPN
dpc-6010	2	153	,	,	PUNCT
dpc-6010	2	154	giovanni	giovanni	PROPN
dpc-6010	2	155	carlo	carlo	PROPN
dpc-6010	2	156	lazzaro	lazzaro	PROPN
dpc-6010	2	157	danzuso24	danzuso24	PROPN
dpc-6010	2	158	,	,	PUNCT
dpc-6010	2	159	matteo	matteo	PROPN
dpc-6010	2	160	licciardello31	licciardello31	PROPN
dpc-6010	2	161	,	,	PUNCT
dpc-6010	2	162	agostina	agostina	PROPN
dpc-6010	2	163	legori32	legori32	PROPN
dpc-6010	2	164	,	,	PUNCT
dpc-6010	2	165	viviana	viviana	PROPN
dpc-6010	2	166	lora2	lora2	PROPN
dpc-6010	2	167	,	,	PUNCT
dpc-6010	2	168	piergiorgio	piergiorgio	NOUN
dpc-6010	2	169	malagoli33	malagoli33	PROPN
dpc-6010	2	170	,	,	PUNCT
dpc-6010	2	171	matteo	matteo	PROPN
dpc-6010	2	172	megna34	megna34	PROPN
dpc-6010	2	173	,	,	PUNCT
dpc-6010	2	174	federica	federica	PROPN
dpc-6010	2	175	mola35	mola35	PROPN
dpc-6010	2	176	,	,	PUNCT
dpc-6010	2	177	gaia	gaia	PROPN
dpc-6010	2	178	moretta36	moretta36	PROPN
dpc-6010	2	179	,	,	PUNCT
dpc-6010	2	180	andrea	andrea	PROPN
dpc-6010	2	181	muracchioli37	muracchioli37	PROPN
dpc-6010	2	182	,	,	PUNCT
dpc-6010	2	183	attilia	attilia	PROPN
dpc-6010	2	184	musumeci38	musumeci38	PROPN
dpc-6010	2	185	,	,	PUNCT
dpc-6010	2	186	maria	maria	PROPN
dpc-6010	2	187	letizia	letizia	PROPN
dpc-6010	2	188	musumeci39	musumeci39	PROPN
dpc-6010	2	189	,	,	PUNCT
dpc-6010	2	190	gianluca	gianluca	PROPN
dpc-6010	2	191	pagnanelli36	pagnanelli36	PROPN
dpc-6010	2	192	,	,	PUNCT
dpc-6010	2	193	vincenzo	vincenzo	NOUN
dpc-6010	2	194	panasiti40	panasiti40	NOUN
dpc-6010	2	195	,	,	PUNCT
dpc-6010	2	196	eugenio	eugenio	PROPN
dpc-6010	2	197	provenzano41	provenzano41	PROPN
dpc-6010	2	198	,	,	PUNCT
dpc-6010	2	199	simone	simone	NOUN
dpc-6010	2	200	ribero42	ribero42	NOUN
dpc-6010	2	201	,	,	PUNCT
dpc-6010	2	202	daniele	daniele	PROPN
dpc-6010	2	203	rizzo12	rizzo12	PROPN
dpc-6010	2	204	,	,	PUNCT
dpc-6010	2	205	marco	marco	PROPN
dpc-6010	2	206	rubatto46	rubatto46	PROPN
dpc-6010	2	207	,	,	PUNCT
dpc-6010	2	208	oriele	oriele	PROPN
dpc-6010	2	209	sarno43	sarno43	PROPN
dpc-6010	2	210	,	,	PUNCT
dpc-6010	2	211	davide	davide	PROPN
dpc-6010	2	212	strippoli44	strippoli44	PROPN
dpc-6010	2	213	,	,	PUNCT
dpc-6010	2	214	fabrizio	fabrizio	PROPN
dpc-6010	2	215	vaira45	vaira45	NOUN
dpc-6010	2	216	,	,	PUNCT
dpc-6010	2	217	dario	dario	PROPN
dpc-6010	2	218	graceffa2	graceffa2	NOUN
dpc-6010	2	219	1	1	NUM
dpc-6010	2	220	departmental	departmental	ADJ
dpc-6010	2	221	faculty	faculty	NOUN
dpc-6010	2	222	of	of	ADP
dpc-6010	2	223	medicine	medicine	NOUN
dpc-6010	2	224	,	,	PUNCT
dpc-6010	2	225	unicamillus	unicamillus	ADJ
dpc-6010	2	226	“	"	PUNCT
dpc-6010	2	227	saint	saint	ADJ
dpc-6010	2	228	camillus	camillus	PROPN
dpc-6010	2	229	international	international	PROPN
dpc-6010	2	230	university	university	PROPN
dpc-6010	2	231	of	of	ADP
dpc-6010	2	232	health	health	PROPN
dpc-6010	2	233	and	and	CCONJ
dpc-6010	2	234	medical	medical	ADJ
dpc-6010	2	235	sciences	science	NOUN
dpc-6010	2	236	”	"	PUNCT
dpc-6010	2	237	,	,	PUNCT
dpc-6010	2	238	rome	rome	PROPN
dpc-6010	2	239	,	,	PUNCT
dpc-6010	2	240	italy	italy	PROPN
dpc-6010	2	241	2	2	NUM
dpc-6010	2	242	san	san	PROPN
dpc-6010	2	243	gallicano	gallicano	PROPN
dpc-6010	2	244	dermatological	dermatological	PROPN
dpc-6010	2	245	institute	institute	NOUN
dpc-6010	2	246	(	(	PUNCT
dpc-6010	2	247	irccs	irccs	PROPN
dpc-6010	2	248	)	)	PUNCT
dpc-6010	2	249	,	,	PUNCT
dpc-6010	2	250	rome	rome	PROPN
dpc-6010	2	251	,	,	PUNCT
dpc-6010	2	252	italy	italy	PROPN
dpc-6010	2	253	3	3	NUM
dpc-6010	2	254	section	section	NOUN
dpc-6010	2	255	of	of	ADP
dpc-6010	2	256	dermatology	dermatology	NOUN
dpc-6010	2	257	,	,	PUNCT
dpc-6010	2	258	department	department	NOUN
dpc-6010	2	259	of	of	ADP
dpc-6010	2	260	health	health	PROPN
dpc-6010	2	261	sciences	sciences	PROPN
dpc-6010	2	262	(	(	PUNCT
dpc-6010	2	263	dissal	dissal	NOUN
dpc-6010	2	264	)	)	PUNCT
dpc-6010	2	265	,	,	PUNCT
dpc-6010	2	266	university	university	NOUN
dpc-6010	2	267	of	of	ADP
dpc-6010	2	268	genoa	genoa	PROPN
dpc-6010	2	269	,	,	PUNCT
dpc-6010	2	270	genoa	genoa	PROPN
dpc-6010	2	271	,	,	PUNCT
dpc-6010	2	272	italy	italy	PROPN
dpc-6010	2	273	4	4	NUM
dpc-6010	2	274	irccs	ircc	VERB
dpc-6010	2	275	san	san	PROPN
dpc-6010	2	276	martino	martino	PROPN
dpc-6010	2	277	university	university	PROPN
dpc-6010	2	278	hospital	hospital	PROPN
dpc-6010	2	279	,	,	PUNCT
dpc-6010	2	280	genoa	genoa	PROPN
dpc-6010	2	281	,	,	PUNCT
dpc-6010	2	282	italy	italy	PROPN
dpc-6010	2	283	5	5	NUM
dpc-6010	2	284	dermatological	dermatological	ADJ
dpc-6010	2	285	clinic	clinic	NOUN
dpc-6010	2	286	,	,	PUNCT
dpc-6010	2	287	department	department	NOUN
dpc-6010	2	288	of	of	ADP
dpc-6010	2	289	clinical	clinical	ADJ
dpc-6010	2	290	and	and	CCONJ
dpc-6010	2	291	molecular	molecular	ADJ
dpc-6010	2	292	sciences	science	NOUN
dpc-6010	2	293	,	,	PUNCT
dpc-6010	2	294	polytechnic	polytechnic	ADJ
dpc-6010	2	295	marche	marche	PROPN
dpc-6010	2	296	university	university	PROPN
dpc-6010	2	297	,	,	PUNCT
dpc-6010	2	298	ancona	ancona	PROPN
dpc-6010	2	299	,	,	PUNCT
dpc-6010	2	300	italy	italy	PROPN
dpc-6010	2	301	6	6	NUM
dpc-6010	2	302	dermatology	dermatology	NOUN
dpc-6010	2	303	,	,	PUNCT
dpc-6010	2	304	department	department	NOUN
dpc-6010	2	305	of	of	ADP
dpc-6010	2	306	systems	system	NOUN
dpc-6010	2	307	medicine	medicine	NOUN
dpc-6010	2	308	,	,	PUNCT
dpc-6010	2	309	university	university	NOUN
dpc-6010	2	310	of	of	ADP
dpc-6010	2	311	rome	rome	PROPN
dpc-6010	2	312	tor	tor	PROPN
dpc-6010	2	313	vergata	vergata	PROPN
dpc-6010	2	314	,	,	PUNCT
dpc-6010	2	315	rome	rome	PROPN
dpc-6010	2	316	,	,	PUNCT
dpc-6010	2	317	italy	italy	PROPN
dpc-6010	2	318	7	7	NUM
dpc-6010	2	319	department	department	PROPN
dpc-6010	2	320	of	of	ADP
dpc-6010	2	321	biomedical	biomedical	ADJ
dpc-6010	2	322	and	and	CCONJ
dpc-6010	2	323	dental	dental	ADJ
dpc-6010	2	324	sciences	science	NOUN
dpc-6010	2	325	and	and	CCONJ
dpc-6010	2	326	morpho	morpho	PROPN
dpc-6010	2	327	functional	functional	ADJ
dpc-6010	2	328	imaging	imaging	NOUN
dpc-6010	2	329	,	,	PUNCT
dpc-6010	2	330	section	section	NOUN
dpc-6010	2	331	of	of	ADP
dpc-6010	2	332	dermatology	dermatology	NOUN
dpc-6010	2	333	,	,	PUNCT
dpc-6010	2	334	university	university	PROPN
dpc-6010	2	335	of	of	ADP
dpc-6010	2	336	messina	messina	PROPN
dpc-6010	2	337	,	,	PUNCT
dpc-6010	2	338	italy	italy	PROPN
dpc-6010	2	339	8	8	NUM
dpc-6010	2	340	dermatology	dermatology	NOUN
dpc-6010	2	341	unit	unit	NOUN
dpc-6010	2	342	,	,	PUNCT
dpc-6010	2	343	irccs	ircc	VERB
dpc-6010	2	344	humanitas	humanitas	NOUN
dpc-6010	2	345	research	research	NOUN
dpc-6010	2	346	hospital	hospital	NOUN
dpc-6010	2	347	,	,	PUNCT
dpc-6010	2	348	rozzano	rozzano	PROPN
dpc-6010	2	349	,	,	PUNCT
dpc-6010	2	350	italy	italy	PROPN
dpc-6010	2	351	9	9	NUM
dpc-6010	2	352	dermatology	dermatology	NOUN
dpc-6010	2	353	unit	unit	NOUN
dpc-6010	2	354	,	,	PUNCT
dpc-6010	2	355	ospedale	ospedale	PROPN
dpc-6010	2	356	degli	degli	NOUN
dpc-6010	2	357	infermi	infermi	PROPN
dpc-6010	2	358	,	,	PUNCT
dpc-6010	2	359	biella	biella	PROPN
dpc-6010	2	360	,	,	PUNCT
dpc-6010	2	361	italy	italy	PROPN
dpc-6010	2	362	10	10	NUM
dpc-6010	2	363	section	section	NOUN
dpc-6010	2	364	of	of	ADP
dpc-6010	2	365	dermatology	dermatology	NOUN
dpc-6010	2	366	and	and	CCONJ
dpc-6010	2	367	venereology	venereology	NOUN
dpc-6010	2	368	,	,	PUNCT
dpc-6010	2	369	department	department	NOUN
dpc-6010	2	370	of	of	ADP
dpc-6010	2	371	precision	precision	NOUN
dpc-6010	2	372	and	and	CCONJ
dpc-6010	2	373	regenerative	regenerative	ADJ
dpc-6010	2	374	medicine	medicine	NOUN
dpc-6010	2	375	and	and	CCONJ
dpc-6010	2	376	ionian	ionian	ADJ
dpc-6010	2	377	area	area	NOUN
dpc-6010	2	378	(	(	PUNCT
dpc-6010	2	379	dimepre	dimepre	NOUN
dpc-6010	2	380	-	-	PROPN
dpc-6010	2	381	j	j	NOUN
dpc-6010	2	382	)	)	PUNCT
dpc-6010	2	383	,	,	PUNCT
dpc-6010	2	384	university	university	NOUN
dpc-6010	2	385	of	of	ADP
dpc-6010	2	386	bari	bari	NOUN
dpc-6010	2	387	“	"	PUNCT
dpc-6010	2	388	aldo	aldo	PROPN
dpc-6010	2	389	moro	moro	PROPN
dpc-6010	2	390	”	"	PUNCT
dpc-6010	2	391	,	,	PUNCT
dpc-6010	2	392	bari	bari	NOUN
dpc-6010	2	393	,	,	PUNCT
dpc-6010	2	394	italy	italy	PROPN
dpc-6010	2	395	11	11	NUM
dpc-6010	2	396	u.o.s.d	u.o.s.d	PROPN
dpc-6010	2	397	.	.	PUNCT
dpc-6010	3	1	dermatologica	dermatologica	PROPN
dpc-6010	3	2	centro	centro	PROPN
dpc-6010	3	3	per	per	ADP
dpc-6010	3	4	la	la	X
dpc-6010	3	5	cura	cura	PROPN
dpc-6010	3	6	della	della	PROPN
dpc-6010	3	7	psoriasi	psoriasi	PROPN
dpc-6010	3	8	,	,	PUNCT
dpc-6010	3	9	ospedale	ospedale	PROPN
dpc-6010	3	10	a.	a.	NOUN
dpc-6010	3	11	perrino	perrino	PROPN
dpc-6010	3	12	,	,	PUNCT
dpc-6010	3	13	brindisi	brindisi	PROPN
dpc-6010	3	14	,	,	PUNCT
dpc-6010	3	15	italy	italy	PROPN
dpc-6010	3	16	12	12	NUM
dpc-6010	3	17	dermatology	dermatology	NOUN
dpc-6010	3	18	unit	unit	NOUN
dpc-6010	3	19	,	,	PUNCT
dpc-6010	3	20	ospedale	ospedale	PROPN
dpc-6010	3	21	s	s	PART
dpc-6010	3	22	a	a	DET
dpc-6010	3	23	antonio	antonio	NOUN
dpc-6010	3	24	abate	abate	NOUN
dpc-6010	3	25	,	,	PUNCT
dpc-6010	3	26	asp	asp	PROPN
dpc-6010	3	27	trapani	trapani	PROPN
dpc-6010	3	28	,	,	PUNCT
dpc-6010	3	29	91016	91016	NUM
dpc-6010	3	30	,	,	PUNCT
dpc-6010	3	31	erice	erice	NOUN
dpc-6010	3	32	,	,	PUNCT
dpc-6010	3	33	italy	italy	PROPN
dpc-6010	3	34	13	13	NUM
dpc-6010	3	35	fondazione	fondazione	NOUN
dpc-6010	3	36	irccs	irccs	NOUN
dpc-6010	3	37	cà	cà	PROPN
dpc-6010	3	38	granda	granda	PROPN
dpc-6010	3	39	ospedale	ospedale	PROPN
dpc-6010	3	40	maggiore	maggiore	PROPN
dpc-6010	3	41	policlinico	policlinico	PROPN
dpc-6010	3	42	milano	milano	PROPN
dpc-6010	3	43	;	;	PUNCT
dpc-6010	3	44	asst	asst	NOUN
dpc-6010	3	45	crema	crema	NOUN
dpc-6010	3	46	,	,	PUNCT
dpc-6010	3	47	italy	italy	PROPN
dpc-6010	3	48	14	14	NUM
dpc-6010	3	49	outpatient	outpatient	NOUN
dpc-6010	3	50	clinic	clinic	NOUN
dpc-6010	3	51	,	,	PUNCT
dpc-6010	3	52	section	section	NOUN
dpc-6010	3	53	 	 	SPACE
dpc-6010	3	54	of	of	ADP
dpc-6010	3	55	dermatology	dermatology	NOUN
dpc-6010	3	56	,	,	PUNCT
dpc-6010	3	57	asl	asl	PROPN
dpc-6010	3	58	al	al	PROPN
dpc-6010	3	59	,	,	PUNCT
dpc-6010	3	60	alessandria	alessandria	PROPN
dpc-6010	3	61	,	,	PUNCT
dpc-6010	3	62	italy	italy	PROPN
dpc-6010	3	63	15	15	NUM
dpc-6010	3	64	division	division	NOUN
dpc-6010	3	65	of	of	ADP
dpc-6010	3	66	dermatology	dermatology	NOUN
dpc-6010	3	67	,	,	PUNCT
dpc-6010	3	68	psoriasis	psoriasis	NOUN
dpc-6010	3	69	outpatient	outpatient	NOUN
dpc-6010	3	70	service	service	NOUN
dpc-6010	3	71	,	,	PUNCT
dpc-6010	3	72	apss	apss	PROPN
dpc-6010	3	73	,	,	PUNCT
dpc-6010	3	74	trento	trento	PROPN
dpc-6010	3	75	,	,	PUNCT
dpc-6010	3	76	italy	italy	PROPN
dpc-6010	3	77	16	16	NUM
dpc-6010	3	78	department	department	PROPN
dpc-6010	3	79	of	of	ADP
dpc-6010	3	80	internal	internal	ADJ
dpc-6010	3	81	medicine	medicine	NOUN
dpc-6010	3	82	-	-	PUNCT
dpc-6010	3	83	dermatology	dermatology	NOUN
dpc-6010	3	84	,	,	PUNCT
dpc-6010	3	85	villa	villa	PROPN
dpc-6010	3	86	scassi	scassi	PROPN
dpc-6010	3	87	hospital	hospital	PROPN
dpc-6010	3	88	,	,	PUNCT
dpc-6010	3	89	asl3	asl3	PROPN
dpc-6010	3	90	,	,	PUNCT
dpc-6010	3	91	genoa	genoa	PROPN
dpc-6010	3	92	,	,	PUNCT
dpc-6010	3	93	italy	italy	PROPN
dpc-6010	3	94	17	17	NUM
dpc-6010	3	95	unità	unità	PROPN
dpc-6010	3	96	operativa	operativa	PROPN
dpc-6010	3	97	dipartimentale	dipartimentale	PROPN
dpc-6010	3	98	di	di	PROPN
dpc-6010	3	99	dermatologia	dermatologia	PROPN
dpc-6010	3	100	e	e	PROPN
dpc-6010	3	101	venereologia	venereologia	PROPN
dpc-6010	3	102	,	,	PUNCT
dpc-6010	3	103	irccs	ircc	VERB
dpc-6010	3	104	san	san	PROPN
dpc-6010	3	105	gerardo	gerardo	PROPN
dpc-6010	3	106	,	,	PUNCT
dpc-6010	3	107	milan	milan	PROPN
dpc-6010	3	108	,	,	PUNCT
dpc-6010	3	109	italy	italy	PROPN
dpc-6010	3	110	18	18	NUM
dpc-6010	3	111	dermatology	dermatology	NOUN
dpc-6010	3	112	unit	unit	NOUN
dpc-6010	3	113	,	,	PUNCT
dpc-6010	3	114	agostino	agostino	PROPN
dpc-6010	3	115	gemelli	gemelli	PROPN
dpc-6010	3	116	university	university	PROPN
dpc-6010	3	117	polyclinic	polyclinic	PROPN
dpc-6010	3	118	foundation	foundation	PROPN
dpc-6010	3	119	,	,	PUNCT
dpc-6010	3	120	irccs	irccs	NOUN
dpc-6010	3	121	,	,	PUNCT
dpc-6010	3	122	rome	rome	PROPN
dpc-6010	3	123	,	,	PUNCT
dpc-6010	3	124	italy	italy	PROPN
dpc-6010	3	125	19	19	NUM
dpc-6010	3	126	section	section	NOUN
dpc-6010	3	127	of	of	ADP
dpc-6010	3	128	dermatology	dermatology	NOUN
dpc-6010	3	129	,	,	PUNCT
dpc-6010	3	130	department	department	NOUN
dpc-6010	3	131	of	of	ADP
dpc-6010	3	132	translational	translational	ADJ
dpc-6010	3	133	medicine	medicine	NOUN
dpc-6010	3	134	and	and	CCONJ
dpc-6010	3	135	surgery	surgery	NOUN
dpc-6010	3	136	,	,	PUNCT
dpc-6010	3	137	catholic	catholic	PROPN
dpc-6010	3	138	university	university	PROPN
dpc-6010	3	139	of	of	ADP
dpc-6010	3	140	the	the	DET
dpc-6010	3	141	sacred	sacred	ADJ
dpc-6010	3	142	heart	heart	NOUN
dpc-6010	3	143	,	,	PUNCT
dpc-6010	3	144	rome	rome	PROPN
dpc-6010	3	145	,	,	PUNCT
dpc-6010	3	146	italy	italy	PROPN
dpc-6010	3	147	20	20	NUM
dpc-6010	3	148	dermatology	dermatology	NOUN
dpc-6010	3	149	outpatient	outpatient	NOUN
dpc-6010	3	150	,	,	PUNCT
dpc-6010	3	151	asl	asl	PROPN
dpc-6010	3	152	taranto	taranto	PROPN
dpc-6010	3	153	,	,	PUNCT
dpc-6010	3	154	italy	italy	PROPN
dpc-6010	3	155	2	2	NUM
dpc-6010	3	156	original	original	ADJ
dpc-6010	3	157	article	article	NOUN
dpc-6010	3	158	|	|	ADV
dpc-6010	3	159	dermatol	dermatol	ADJ
dpc-6010	3	160	pract	pract	NOUN
dpc-6010	3	161	concept	concept	NOUN
dpc-6010	3	162	.	.	PUNCT
dpc-6010	4	1	2025;15(4):6010	2025;15(4):6010	NUM
dpc-6010	4	2	21	21	NUM
dpc-6010	4	3	dermatology	dermatology	NOUN
dpc-6010	4	4	unit	unit	NOUN
dpc-6010	4	5	,	,	PUNCT
dpc-6010	4	6	department	department	NOUN
dpc-6010	4	7	of	of	ADP
dpc-6010	4	8	medicine	medicine	NOUN
dpc-6010	4	9	and	and	CCONJ
dpc-6010	4	10	surgery	surgery	NOUN
dpc-6010	4	11	,	,	PUNCT
dpc-6010	4	12	university	university	NOUN
dpc-6010	4	13	of	of	ADP
dpc-6010	4	14	insubria	insubria	PROPN
dpc-6010	4	15	,	,	PUNCT
dpc-6010	4	16	varese	varese	PROPN
dpc-6010	4	17	,	,	PUNCT
dpc-6010	4	18	italy	italy	PROPN
dpc-6010	4	19	22	22	NUM
dpc-6010	4	20	umberto	umberto	PROPN
dpc-6010	4	21	i	i	PRON
dpc-6010	4	22	,	,	PUNCT
dpc-6010	4	23	city	city	NOUN
dpc-6010	4	24	hospital	hospital	NOUN
dpc-6010	4	25	of	of	ADP
dpc-6010	4	26	enna	enna	PROPN
dpc-6010	4	27	,	,	PUNCT
dpc-6010	4	28	enna	enna	PROPN
dpc-6010	4	29	,	,	PUNCT
dpc-6010	4	30	italy	italy	PROPN
dpc-6010	4	31	23	23	NUM
dpc-6010	4	32	section	section	NOUN
dpc-6010	4	33	of	of	ADP
dpc-6010	4	34	dermatology	dermatology	NOUN
dpc-6010	4	35	,	,	PUNCT
dpc-6010	4	36	department	department	NOUN
dpc-6010	4	37	of	of	ADP
dpc-6010	4	38	medicine	medicine	NOUN
dpc-6010	4	39	,	,	PUNCT
dpc-6010	4	40	asst	asst	PROPN
dpc-6010	4	41	di	di	X
dpc-6010	4	42	mantova	mantova	PROPN
dpc-6010	4	43	,	,	PUNCT
dpc-6010	4	44	mantova	mantova	PROPN
dpc-6010	4	45	,	,	PUNCT
dpc-6010	4	46	italy	italy	PROPN
dpc-6010	4	47	24	24	NUM
dpc-6010	4	48	u.o.s.d	u.o.s.d	PROPN
dpc-6010	4	49	dermatologia	dermatologia	NOUN
dpc-6010	4	50	,	,	PUNCT
dpc-6010	4	51	a.o	a.o	PROPN
dpc-6010	4	52	.	.	PROPN
dpc-6010	4	53	‘	'	PUNCT
dpc-6010	4	54	s.elia	s.elia	NOUN
dpc-6010	4	55	’	'	PUNCT
dpc-6010	4	56	caltanissetta	caltanissetta	NOUN
dpc-6010	4	57	,	,	PUNCT
dpc-6010	4	58	caltanissetta	caltanissetta	PROPN
dpc-6010	4	59	,	,	PUNCT
dpc-6010	4	60	italy	italy	PROPN
dpc-6010	4	61	25	25	NUM
dpc-6010	4	62	dermatology	dermatology	NOUN
dpc-6010	4	63	unit	unit	NOUN
dpc-6010	4	64	,	,	PUNCT
dpc-6010	4	65	department	department	NOUN
dpc-6010	4	66	of	of	ADP
dpc-6010	4	67	clinical	clinical	ADJ
dpc-6010	4	68	internal	internal	ADJ
dpc-6010	4	69	,	,	PUNCT
dpc-6010	4	70	anesthesiological	anesthesiological	ADJ
dpc-6010	4	71	and	and	CCONJ
dpc-6010	4	72	cardiovascular	cardiovascular	ADJ
dpc-6010	4	73	science	science	NOUN
dpc-6010	4	74	,	,	PUNCT
dpc-6010	4	75	university	university	NOUN
dpc-6010	4	76	of	of	ADP
dpc-6010	4	77	la	la	PROPN
dpc-6010	4	78	sapienza	sapienza	PROPN
dpc-6010	4	79	,	,	PUNCT
dpc-6010	4	80	rome	rome	PROPN
dpc-6010	4	81	,	,	PUNCT
dpc-6010	4	82	italy	italy	PROPN
dpc-6010	4	83	26	26	NUM
dpc-6010	4	84	dermatology	dermatology	NOUN
dpc-6010	4	85	unit	unit	NOUN
dpc-6010	4	86	,	,	PUNCT
dpc-6010	4	87	“	"	PUNCT
dpc-6010	4	88	andrea	andrea	PROPN
dpc-6010	4	89	tortora	tortora	PROPN
dpc-6010	4	90	”	"	PUNCT
dpc-6010	4	91	hospital	hospital	NOUN
dpc-6010	4	92	,	,	PUNCT
dpc-6010	4	93	asl	asl	PROPN
dpc-6010	4	94	salerno	salerno	PROPN
dpc-6010	4	95	,	,	PUNCT
dpc-6010	4	96	pagani	pagani	PROPN
dpc-6010	4	97	,	,	PUNCT
dpc-6010	4	98	italy	italy	PROPN
dpc-6010	4	99	27	27	NUM
dpc-6010	4	100	unit	unit	NOUN
dpc-6010	4	101	of	of	ADP
dpc-6010	4	102	dermatology	dermatology	NOUN
dpc-6010	4	103	,	,	PUNCT
dpc-6010	4	104	civil	civil	ADJ
dpc-6010	4	105	hospital	hospital	NOUN
dpc-6010	4	106	of	of	ADP
dpc-6010	4	107	imperia	imperia	PROPN
dpc-6010	4	108	,	,	PUNCT
dpc-6010	4	109	imperia	imperia	PROPN
dpc-6010	4	110	,	,	PUNCT
dpc-6010	4	111	italy	italy	PROPN
dpc-6010	4	112	28	28	NUM
dpc-6010	4	113	department	department	PROPN
dpc-6010	4	114	of	of	ADP
dpc-6010	4	115	biotechnological	biotechnological	ADJ
dpc-6010	4	116	and	and	CCONJ
dpc-6010	4	117	applied	apply	VERB
dpc-6010	4	118	clinical	clinical	ADJ
dpc-6010	4	119	sciences	science	NOUN
dpc-6010	4	120	,	,	PUNCT
dpc-6010	4	121	university	university	NOUN
dpc-6010	4	122	of	of	ADP
dpc-6010	4	123	l’aquila	l’aquila	PROPN
dpc-6010	4	124	,	,	PUNCT
dpc-6010	4	125	l’aquila	l’aquila	PROPN
dpc-6010	4	126	,	,	PUNCT
dpc-6010	4	127	italy	italy	PROPN
dpc-6010	4	128	29	29	NUM
dpc-6010	4	129	division	division	NOUN
dpc-6010	4	130	of	of	ADP
dpc-6010	4	131	dermatology	dermatology	NOUN
dpc-6010	4	132	,	,	PUNCT
dpc-6010	4	133	“	"	PUNCT
dpc-6010	4	134	mons	mon	NOUN
dpc-6010	4	135	.	.	PUNCT
dpc-6010	5	1	dimiccoli	dimiccoli	NOUN
dpc-6010	5	2	”	"	PUNCT
dpc-6010	5	3	hospital	hospital	NOUN
dpc-6010	5	4	,	,	PUNCT
dpc-6010	5	5	barletta	barletta	PROPN
dpc-6010	5	6	,	,	PUNCT
dpc-6010	5	7	italy	italy	PROPN
dpc-6010	5	8	30	30	NUM
dpc-6010	5	9	dermatologic	dermatologic	ADJ
dpc-6010	5	10	clinic	clinic	NOUN
dpc-6010	5	11	,	,	PUNCT
dpc-6010	5	12	aou	aou	PROPN
dpc-6010	5	13	maggiore	maggiore	PROPN
dpc-6010	5	14	della	della	PROPN
dpc-6010	5	15	carità	carità	PROPN
dpc-6010	5	16	hospital	hospital	PROPN
dpc-6010	5	17	,	,	PUNCT
dpc-6010	5	18	novara	novara	PROPN
dpc-6010	5	19	,	,	PUNCT
dpc-6010	5	20	italy	italy	PROPN
dpc-6010	5	21	31	31	NUM
dpc-6010	5	22	section	section	NOUN
dpc-6010	5	23	 	 	SPACE
dpc-6010	5	24	of	of	ADP
dpc-6010	5	25	dermatology	dermatology	NOUN
dpc-6010	5	26	,	,	PUNCT
dpc-6010	5	27	koelliker	koelliker	NOUN
dpc-6010	5	28	hospital	hospital	PROPN
dpc-6010	5	29	,	,	PUNCT
dpc-6010	5	30	turin	turin	PROPN
dpc-6010	5	31	,	,	PUNCT
dpc-6010	5	32	italy	italy	PROPN
dpc-6010	5	33	32	32	NUM
dpc-6010	5	34	uo	uo	NOUN
dpc-6010	5	35	dermatologia	dermatologia	NOUN
dpc-6010	5	36	irccs	ircc	VERB
dpc-6010	5	37	ospedale	ospedale	PROPN
dpc-6010	5	38	galeazzi	galeazzi	PROPN
dpc-6010	5	39	&	&	CCONJ
dpc-6010	5	40	università	università	PROPN
dpc-6010	5	41	degli	degli	PROPN
dpc-6010	5	42	studi	studi	PROPN
dpc-6010	5	43	di	di	X
dpc-6010	5	44	milano	milano	PROPN
dpc-6010	5	45	,	,	PUNCT
dpc-6010	5	46	milan	milan	PROPN
dpc-6010	5	47	,	,	PUNCT
dpc-6010	5	48	italy	italy	PROPN
dpc-6010	5	49	33	33	NUM
dpc-6010	5	50	department	department	PROPN
dpc-6010	5	51	of	of	ADP
dpc-6010	5	52	dermatology	dermatology	NOUN
dpc-6010	5	53	,	,	PUNCT
dpc-6010	5	54	dermatology	dermatology	NOUN
dpc-6010	5	55	unit	unit	NOUN
dpc-6010	5	56	azienda	azienda	PROPN
dpc-6010	5	57	ospedaliera	ospedaliera	NOUN
dpc-6010	5	58	san	san	PROPN
dpc-6010	5	59	donato	donato	PROPN
dpc-6010	5	60	milanese	milanese	NOUN
dpc-6010	5	61	,	,	PUNCT
dpc-6010	5	62	20097	20097	NUM
dpc-6010	5	63	milan	milan	PROPN
dpc-6010	5	64	,	,	PUNCT
dpc-6010	5	65	italy	italy	PROPN
dpc-6010	5	66	34	34	NUM
dpc-6010	5	67	section	section	NOUN
dpc-6010	5	68	of	of	ADP
dpc-6010	5	69	dermatology	dermatology	NOUN
dpc-6010	5	70	,	,	PUNCT
dpc-6010	5	71	department	department	NOUN
dpc-6010	5	72	of	of	ADP
dpc-6010	5	73	clinical	clinical	ADJ
dpc-6010	5	74	medicine	medicine	NOUN
dpc-6010	5	75	and	and	CCONJ
dpc-6010	5	76	surgery	surgery	NOUN
dpc-6010	5	77	,	,	PUNCT
dpc-6010	5	78	university	university	NOUN
dpc-6010	5	79	of	of	ADP
dpc-6010	5	80	naples	naples	PROPN
dpc-6010	5	81	federico	federico	PROPN
dpc-6010	5	82	ii	ii	PROPN
dpc-6010	5	83	,	,	PUNCT
dpc-6010	5	84	naples	naples	PROPN
dpc-6010	5	85	,	,	PUNCT
dpc-6010	5	86	italy	italy	PROPN
dpc-6010	5	87	35	35	NUM
dpc-6010	5	88	dermatology	dermatology	NOUN
dpc-6010	5	89	unit	unit	NOUN
dpc-6010	5	90	,	,	PUNCT
dpc-6010	5	91	asst	asst	NOUN
dpc-6010	5	92	lariana	lariana	NOUN
dpc-6010	5	93	,	,	PUNCT
dpc-6010	5	94	como	como	PROPN
dpc-6010	5	95	,	,	PUNCT
dpc-6010	5	96	italy	italy	PROPN
dpc-6010	5	97	36	36	NUM
dpc-6010	5	98	department	department	PROPN
dpc-6010	5	99	of	of	ADP
dpc-6010	5	100	dermatology	dermatology	NOUN
dpc-6010	5	101	,	,	PUNCT
dpc-6010	5	102	istituto	istituto	X
dpc-6010	5	103	dermopatico	dermopatico	NOUN
dpc-6010	5	104	dell’immacolata	dell’immacolata	PROPN
dpc-6010	5	105	irccs	irccs	PROPN
dpc-6010	5	106	roma	roma	PROPN
dpc-6010	5	107	,	,	PUNCT
dpc-6010	5	108	roma	roma	PROPN
dpc-6010	5	109	,	,	PUNCT
dpc-6010	5	110	italy	italy	PROPN
dpc-6010	5	111	37	37	NUM
dpc-6010	5	112	unit	unit	NOUN
dpc-6010	5	113	of	of	ADP
dpc-6010	5	114	dermatology	dermatology	NOUN
dpc-6010	5	115	,	,	PUNCT
dpc-6010	5	116	san	san	PROPN
dpc-6010	5	117	bartolomeo	bartolomeo	PROPN
dpc-6010	5	118	hospital	hospital	NOUN
dpc-6010	5	119	,	,	PUNCT
dpc-6010	5	120	la	la	PROPN
dpc-6010	5	121	spezia	spezia	PROPN
dpc-6010	5	122	,	,	PUNCT
dpc-6010	5	123	italy	italy	PROPN
dpc-6010	5	124	38	38	NUM
dpc-6010	5	125	uosd	uosd	ADJ
dpc-6010	5	126	dermatologia	dermatologia	NOUN
dpc-6010	5	127	,	,	PUNCT
dpc-6010	5	128	arnas	arnas	PROPN
dpc-6010	5	129	garibaldi	garibaldi	PROPN
dpc-6010	5	130	,	,	PUNCT
dpc-6010	5	131	catania	catania	PROPN
dpc-6010	5	132	,	,	PUNCT
dpc-6010	5	133	italy	italy	PROPN
dpc-6010	5	134	39	39	NUM
dpc-6010	5	135	uoc	uoc	PROPN
dpc-6010	5	136	dermatologia	dermatologia	NOUN
dpc-6010	5	137	,	,	PUNCT
dpc-6010	5	138	university	university	PROPN
dpc-6010	5	139	of	of	ADP
dpc-6010	5	140	catania	catania	PROPN
dpc-6010	5	141	,	,	PUNCT
dpc-6010	5	142	po	po	X
dpc-6010	5	143	“	"	PUNCT
dpc-6010	5	144	g.	g.	PROPN
dpc-6010	5	145	rodolico	rodolico	PROPN
dpc-6010	5	146	”	"	PUNCT
dpc-6010	5	147	,	,	PUNCT
dpc-6010	5	148	aou	aou	PROPN
dpc-6010	5	149	policlinico	policlinico	PROPN
dpc-6010	5	150	“	"	PUNCT
dpc-6010	5	151	g.	g.	PROPN
dpc-6010	5	152	rodolico	rodolico	PROPN
dpc-6010	5	153	-	-	PUNCT
dpc-6010	5	154	san	san	PROPN
dpc-6010	5	155	marco	marco	PROPN
dpc-6010	5	156	”	"	PUNCT
dpc-6010	5	157	,	,	PUNCT
dpc-6010	5	158	catania	catania	PROPN
dpc-6010	5	159	,	,	PUNCT
dpc-6010	5	160	italy	italy	PROPN
dpc-6010	5	161	40	40	NUM
dpc-6010	5	162	fondazione	fondazione	NOUN
dpc-6010	5	163	policlinico	policlinico	PROPN
dpc-6010	5	164	universitario	universitario	PROPN
dpc-6010	5	165	campus	campus	PROPN
dpc-6010	5	166	bio	bio	PROPN
dpc-6010	5	167	medico	medico	PROPN
dpc-6010	5	168	,	,	PUNCT
dpc-6010	5	169	rome	rome	PROPN
dpc-6010	5	170	,	,	PUNCT
dpc-6010	5	171	italy	italy	PROPN
dpc-6010	5	172	41	41	NUM
dpc-6010	5	173	dermatology	dermatology	NOUN
dpc-6010	5	174	unit	unit	NOUN
dpc-6010	5	175	,	,	PUNCT
dpc-6010	5	176	azienda	azienda	PROPN
dpc-6010	5	177	ospedaliera	ospedaliera	PROPN
dpc-6010	5	178	di	di	PROPN
dpc-6010	5	179	cosenza	cosenza	PROPN
dpc-6010	5	180	,	,	PUNCT
dpc-6010	5	181	cosenza	cosenza	PROPN
dpc-6010	5	182	,	,	PUNCT
dpc-6010	5	183	italy	italy	PROPN
dpc-6010	5	184	42	42	NUM
dpc-6010	5	185	department	department	PROPN
dpc-6010	5	186	of	of	ADP
dpc-6010	5	187	medical	medical	ADJ
dpc-6010	5	188	sciences	science	NOUN
dpc-6010	5	189	,	,	PUNCT
dpc-6010	5	190	section	section	NOUN
dpc-6010	5	191	of	of	ADP
dpc-6010	5	192	dermatology	dermatology	NOUN
dpc-6010	5	193	,	,	PUNCT
dpc-6010	5	194	university	university	PROPN
dpc-6010	5	195	of	of	ADP
dpc-6010	5	196	turin	turin	PROPN
dpc-6010	5	197	,	,	PUNCT
dpc-6010	5	198	turin	turin	PROPN
dpc-6010	5	199	,	,	PUNCT
dpc-6010	5	200	italy	italy	PROPN
dpc-6010	5	201	43	43	NUM
dpc-6010	5	202	department	department	PROPN
dpc-6010	5	203	of	of	ADP
dpc-6010	5	204	dermatology	dermatology	NOUN
dpc-6010	5	205	and	and	CCONJ
dpc-6010	5	206	dermosurgery	dermosurgery	NOUN
dpc-6010	5	207	,	,	PUNCT
dpc-6010	5	208	aosg	aosg	VERB
dpc-6010	5	209	san	san	PROPN
dpc-6010	5	210	giuseppe	giuseppe	PROPN
dpc-6010	5	211	moscati	moscati	PROPN
dpc-6010	5	212	,	,	PUNCT
dpc-6010	5	213	avellino	avellino	PROPN
dpc-6010	5	214	,	,	PUNCT
dpc-6010	5	215	italy	italy	PROPN
dpc-6010	5	216	44	44	NUM
dpc-6010	5	217	dermatology	dermatology	NOUN
dpc-6010	5	218	unit	unit	NOUN
dpc-6010	5	219	,	,	PUNCT
dpc-6010	5	220	manzoni	manzoni	PROPN
dpc-6010	5	221	hospital	hospital	NOUN
dpc-6010	5	222	,	,	PUNCT
dpc-6010	5	223	asst	asst	NOUN
dpc-6010	5	224	-	-	PUNCT
dpc-6010	5	225	lecco	lecco	PROPN
dpc-6010	5	226	,	,	PUNCT
dpc-6010	5	227	lecco	lecco	PROPN
dpc-6010	5	228	,	,	PUNCT
dpc-6010	5	229	italy	italy	PROPN
dpc-6010	5	230	45	45	NUM
dpc-6010	5	231	unit	unit	NOUN
dpc-6010	5	232	of	of	ADP
dpc-6010	5	233	dermatology	dermatology	NOUN
dpc-6010	5	234	,	,	PUNCT
dpc-6010	5	235	irccs	ircc	VERB
dpc-6010	5	236	ospedale	ospedale	PROPN
dpc-6010	5	237	san	san	PROPN
dpc-6010	5	238	raffaele	raffaele	PROPN
dpc-6010	5	239	,	,	PUNCT
dpc-6010	5	240	milan	milan	PROPN
dpc-6010	5	241	,	,	PUNCT
dpc-6010	5	242	italy	italy	PROPN
dpc-6010	5	243	46	46	NUM
dpc-6010	5	244	candiolo	candiolo	PROPN
dpc-6010	5	245	cancer	cancer	PROPN
dpc-6010	5	246	institute	institute	PROPN
dpc-6010	5	247	,	,	PUNCT
dpc-6010	5	248	fpo	fpo	PROPN
dpc-6010	5	249	—	—	PUNCT
dpc-6010	5	250	irccs	irccs	ADJ
dpc-6010	5	251	,	,	PUNCT
dpc-6010	5	252	candiolo	candiolo	PROPN
dpc-6010	5	253	,	,	PUNCT
dpc-6010	5	254	italy	italy	PROPN
dpc-6010	5	255	key	key	ADJ
dpc-6010	5	256	words	word	NOUN
dpc-6010	5	257	:	:	PUNCT
dpc-6010	5	258	brodalumab	brodalumab	NOUN
dpc-6010	5	259	,	,	PUNCT
dpc-6010	5	260	psoriasis	psoriasis	NOUN
dpc-6010	5	261	,	,	PUNCT
dpc-6010	5	262	comorbidity	comorbidity	NOUN
dpc-6010	5	263	,	,	PUNCT
dpc-6010	5	264	il-7	il-7	VERB
dpc-6010	5	265	inhibitors	inhibitor	NOUN
dpc-6010	5	266	,	,	PUNCT
dpc-6010	6	1	il-23	il-23	NOUN
dpc-6010	6	2	inhibitors	inhibitor	NOUN
dpc-6010	6	3	,	,	PUNCT
dpc-6010	6	4	switch	switch	VERB
dpc-6010	6	5	citation	citation	NOUN
dpc-6010	6	6	:	:	PUNCT
dpc-6010	6	7	orsini	orsini	PROPN
dpc-6010	6	8	d	d	PROPN
dpc-6010	6	9	,	,	PUNCT
dpc-6010	6	10	fargnoli	fargnoli	PROPN
dpc-6010	6	11	mc	mc	PROPN
dpc-6010	6	12	,	,	PUNCT
dpc-6010	6	13	burlando	burlando	PROPN
dpc-6010	6	14	m	m	PROPN
dpc-6010	6	15	,	,	PUNCT
dpc-6010	6	16	et	et	PROPN
dpc-6010	6	17	al	al	PROPN
dpc-6010	6	18	.	.	PUNCT
dpc-6010	6	19	brodalumab	brodalumab	NOUN
dpc-6010	6	20	effectiveness	effectiveness	NOUN
dpc-6010	6	21	on	on	ADP
dpc-6010	6	22	psoriasis	psoriasis	NOUN
dpc-6010	6	23	patients	patient	NOUN
dpc-6010	6	24	who	who	PRON
dpc-6010	6	25	failed	fail	VERB
dpc-6010	6	26	anti	anti	ADJ
dpc-6010	6	27	-	-	ADJ
dpc-6010	6	28	interleukin	interleukin	ADJ
dpc-6010	6	29	23	23	NUM
dpc-6010	6	30	or	or	CCONJ
dpc-6010	6	31	12/23	12/23	NUM
dpc-6010	6	32	:	:	PUNCT
dpc-6010	6	33	a	a	DET
dpc-6010	6	34	multicenter	multicenter	NOUN
dpc-6010	6	35	,	,	PUNCT
dpc-6010	6	36	retrospective	retrospective	ADJ
dpc-6010	6	37	study	study	NOUN
dpc-6010	6	38	–	–	PUNCT
dpc-6010	6	39	il	il	PROPN
dpc-6010	6	40	pso	pso	NOUN
dpc-6010	6	41	(	(	PUNCT
dpc-6010	6	42	italian	italian	ADJ
dpc-6010	6	43	landscape	landscape	NOUN
dpc-6010	6	44	psoriasis	psoriasis	NOUN
dpc-6010	6	45	)	)	PUNCT
dpc-6010	6	46	.	.	PUNCT
dpc-6010	7	1	dermatol	dermatol	NOUN
dpc-6010	7	2	pract	pract	PROPN
dpc-6010	7	3	concept	concept	NOUN
dpc-6010	7	4	.	.	PUNCT
dpc-6010	8	1	2025;15(4):6010	2025;15(4):6010	NUM
dpc-6010	8	2	.	.	PUNCT
dpc-6010	9	1	doi	doi	PROPN
dpc-6010	9	2	:	:	PUNCT
dpc-6010	9	3	https://doi	https://doi	PROPN
dpc-6010	9	4	.org/10.5826	.org/10.5826	PROPN
dpc-6010	9	5	/	/	SYM
dpc-6010	9	6	dpc.1504a6010	dpc.1504a6010	PROPN
dpc-6010	9	7	accepted	accept	VERB
dpc-6010	9	8	:	:	PUNCT
dpc-6010	9	9	march	march	PROPN
dpc-6010	9	10	6	6	NUM
dpc-6010	9	11	,	,	PUNCT
dpc-6010	9	12	2025	2025	NUM
dpc-6010	9	13	;	;	PUNCT
dpc-6010	9	14	published	publish	VERB
dpc-6010	9	15	:	:	PUNCT
dpc-6010	10	1	october	october	PROPN
dpc-6010	10	2	2025	2025	NUM
dpc-6010	10	3	copyright	copyright	NOUN
dpc-6010	10	4	:	:	PUNCT
dpc-6010	10	5	©	©	PROPN
dpc-6010	10	6	2025	2025	NUM
dpc-6010	10	7	orsini	orsini	PROPN
dpc-6010	10	8	et	et	PROPN
dpc-6010	10	9	al	al	PROPN
dpc-6010	10	10	.	.	PUNCT
dpc-6010	11	1	this	this	PRON
dpc-6010	11	2	is	be	AUX
dpc-6010	11	3	an	an	DET
dpc-6010	11	4	open	open	ADJ
dpc-6010	11	5	-	-	PUNCT
dpc-6010	11	6	access	access	NOUN
dpc-6010	11	7	article	article	NOUN
dpc-6010	11	8	distributed	distribute	VERB
dpc-6010	11	9	under	under	ADP
dpc-6010	11	10	the	the	DET
dpc-6010	11	11	terms	term	NOUN
dpc-6010	11	12	of	of	ADP
dpc-6010	11	13	the	the	DET
dpc-6010	11	14	creative	creative	ADJ
dpc-6010	11	15	commons	common	NOUN
dpc-6010	11	16	attributionnoncommercial	attributionnoncommercial	ADJ
dpc-6010	11	17	license	license	NOUN
dpc-6010	11	18	(	(	PUNCT
dpc-6010	11	19	by	by	ADP
dpc-6010	11	20	-	-	PUNCT
dpc-6010	11	21	nc-4.0	nc-4.0	NOUN
dpc-6010	11	22	)	)	PUNCT
dpc-6010	11	23	,	,	PUNCT
dpc-6010	11	24	https://creativecommons.org/licenses/by-nc/4.0/	https://creativecommons.org/licenses/by-nc/4.0/	PROPN
dpc-6010	11	25	,	,	PUNCT
dpc-6010	11	26	which	which	PRON
dpc-6010	11	27	permits	permit	VERB
dpc-6010	11	28	unrestricted	unrestricted	ADJ
dpc-6010	11	29	noncommercial	noncommercial	ADJ
dpc-6010	11	30	use	use	NOUN
dpc-6010	11	31	,	,	PUNCT
dpc-6010	11	32	distribution	distribution	NOUN
dpc-6010	11	33	,	,	PUNCT
dpc-6010	11	34	and	and	CCONJ
dpc-6010	11	35	reproduction	reproduction	NOUN
dpc-6010	11	36	in	in	ADP
dpc-6010	11	37	any	any	DET
dpc-6010	11	38	medium	medium	NOUN
dpc-6010	11	39	,	,	PUNCT
dpc-6010	11	40	provided	provide	VERB
dpc-6010	11	41	the	the	DET
dpc-6010	11	42	original	original	ADJ
dpc-6010	11	43	authors	author	NOUN
dpc-6010	11	44	and	and	CCONJ
dpc-6010	11	45	source	source	NOUN
dpc-6010	11	46	are	be	AUX
dpc-6010	11	47	credited	credit	VERB
dpc-6010	11	48	.	.	PUNCT
dpc-6010	12	1	funding	funding	NOUN
dpc-6010	12	2	:	:	PUNCT
dpc-6010	12	3	none	none	NOUN
dpc-6010	12	4	.	.	PUNCT
dpc-6010	13	1	competing	compete	VERB
dpc-6010	13	2	interests	interest	NOUN
dpc-6010	13	3	:	:	PUNCT
dpc-6010	13	4	d.	d.	PROPN
dpc-6010	13	5	orsini	orsini	PROPN
dpc-6010	13	6	has	have	AUX
dpc-6010	13	7	been	be	AUX
dpc-6010	13	8	a	a	DET
dpc-6010	13	9	speaker	speaker	NOUN
dpc-6010	13	10	and/or	and/or	CCONJ
dpc-6010	13	11	consultant	consultant	NOUN
dpc-6010	13	12	for	for	ADP
dpc-6010	13	13	abbvie	abbvie	PROPN
dpc-6010	13	14	,	,	PUNCT
dpc-6010	13	15	leopharma	leopharma	PROPN
dpc-6010	13	16	,	,	PUNCT
dpc-6010	13	17	ucb	ucb	PROPN
dpc-6010	13	18	,	,	PUNCT
dpc-6010	13	19	bristol	bristol	PROPN
dpc-6010	13	20	-	-	PUNCT
dpc-6010	13	21	meyer	meyer	PROPN
dpc-6010	13	22	-	-	PUNCT
dpc-6010	13	23	squibb	squibb	PROPN
dpc-6010	13	24	,	,	PUNCT
dpc-6010	13	25	and	and	CCONJ
dpc-6010	13	26	boehringer	boehringer	PROPN
dpc-6010	13	27	ingelheim	ingelheim	PROPN
dpc-6010	13	28	.	.	PUNCT
dpc-6010	14	1	r.	r.	PROPN
dpc-6010	14	2	balestri	balestri	PROPN
dpc-6010	14	3	has	have	AUX
dpc-6010	14	4	received	receive	VERB
dpc-6010	14	5	support	support	NOUN
dpc-6010	14	6	for	for	ADP
dpc-6010	14	7	attending	attend	VERB
dpc-6010	14	8	meetings	meeting	NOUN
dpc-6010	14	9	and/or	and/or	CCONJ
dpc-6010	14	10	travel	travel	VERB
dpc-6010	14	11	from	from	ADP
dpc-6010	14	12	abbvie	abbvie	PROPN
dpc-6010	14	13	,	,	PUNCT
dpc-6010	14	14	amgen	amgen	PROPN
dpc-6010	14	15	,	,	PUNCT
dpc-6010	14	16	leo	leo	PROPN
dpc-6010	14	17	pharma	pharma	PROPN
dpc-6010	14	18	,	,	PUNCT
dpc-6010	14	19	lilly	lilly	PROPN
dpc-6010	14	20	,	,	PUNCT
dpc-6010	14	21	novartis	novartis	PROPN
dpc-6010	14	22	,	,	PUNCT
dpc-6010	14	23	and	and	CCONJ
dpc-6010	14	24	sanofi	sanofi	PROPN
dpc-6010	14	25	.	.	PUNCT
dpc-6010	15	1	m.	m.	NOUN
dpc-6010	15	2	burlando	burlando	PROPN
dpc-6010	15	3	acted	act	VERB
dpc-6010	15	4	as	as	ADP
dpc-6010	15	5	a	a	DET
dpc-6010	15	6	speaker	speaker	NOUN
dpc-6010	15	7	or	or	CCONJ
dpc-6010	15	8	consultant	consultant	NOUN
dpc-6010	15	9	for	for	ADP
dpc-6010	15	10	abbvie	abbvie	PROPN
dpc-6010	15	11	,	,	PUNCT
dpc-6010	15	12	eli	eli	PROPN
dpc-6010	15	13	lilly	lilly	PROPN
dpc-6010	15	14	,	,	PUNCT
dpc-6010	15	15	janssen	janssen	PROPN
dpc-6010	15	16	,	,	PUNCT
dpc-6010	15	17	leo	leo	PROPN
dpc-6010	15	18	-	-	PUNCT
dpc-6010	15	19	pharma	pharma	PROPN
dpc-6010	15	20	,	,	PUNCT
dpc-6010	15	21	ucb	ucb	PROPN
dpc-6010	15	22	,	,	PUNCT
dpc-6010	15	23	novartis	novartis	PROPN
dpc-6010	15	24	,	,	PUNCT
dpc-6010	15	25	bristol	bristol	PROPN
dpc-6010	15	26	-	-	PUNCT
dpc-6010	15	27	meyer	meyer	PROPN
dpc-6010	15	28	-	-	PUNCT
dpc-6010	15	29	squibb	squibb	PROPN
dpc-6010	15	30	,	,	PUNCT
dpc-6010	15	31	and	and	CCONJ
dpc-6010	15	32	boehringer	boehringer	PROPN
dpc-6010	15	33	ingelheim	ingelheim	PROPN
dpc-6010	15	34	.	.	PUNCT
dpc-6010	16	1	g.	g.	PROPN
dpc-6010	16	2	caldarola	caldarola	PROPN
dpc-6010	16	3	has	have	AUX
dpc-6010	16	4	received	receive	VERB
dpc-6010	16	5	honoraria	honoraria	NOUN
dpc-6010	16	6	as	as	ADP
dpc-6010	16	7	speaker	speaker	NOUN
dpc-6010	16	8	and	and	CCONJ
dpc-6010	16	9	consultant	consultant	NOUN
dpc-6010	16	10	for	for	ADP
dpc-6010	16	11	abbvie	abbvie	PROPN
dpc-6010	16	12	,	,	PUNCT
dpc-6010	16	13	almirall	almirall	ADJ
dpc-6010	16	14	,	,	PUNCT
dpc-6010	16	15	biogen	biogen	PROPN
dpc-6010	16	16	,	,	PUNCT
dpc-6010	16	17	eli	eli	PROPN
dpc-6010	16	18	lilly	lilly	PROPN
dpc-6010	16	19	,	,	PUNCT
dpc-6010	16	20	leo	leo	PROPN
dpc-6010	16	21	pharma	pharma	PROPN
dpc-6010	16	22	,	,	PUNCT
dpc-6010	16	23	novartis	novartis	PROPN
dpc-6010	16	24	,	,	PUNCT
dpc-6010	16	25	janssen	janssen	PROPN
dpc-6010	16	26	,	,	PUNCT
dpc-6010	16	27	sanofi	sanofi	PROPN
dpc-6010	16	28	,	,	PUNCT
dpc-6010	16	29	pfizer	pfizer	NOUN
dpc-6010	16	30	,	,	PUNCT
dpc-6010	16	31	and	and	CCONJ
dpc-6010	16	32	ucb	ucb	PROPN
dpc-6010	16	33	pharma	pharma	PROPN
dpc-6010	16	34	outside	outside	ADP
dpc-6010	16	35	the	the	DET
dpc-6010	16	36	submitted	submit	VERB
dpc-6010	16	37	work	work	NOUN
dpc-6010	16	38	.	.	PUNCT
dpc-6010	17	1	a.	a.	PROPN
dpc-6010	17	2	campanati	campanati	PROPN
dpc-6010	17	3	has	have	AUX
dpc-6010	17	4	served	serve	VERB
dpc-6010	17	5	as	as	ADP
dpc-6010	17	6	a	a	DET
dpc-6010	17	7	speaker	speaker	NOUN
dpc-6010	17	8	,	,	PUNCT
dpc-6010	17	9	consultant	consultant	NOUN
dpc-6010	17	10	,	,	PUNCT
dpc-6010	17	11	or	or	CCONJ
dpc-6010	17	12	advisory	advisory	ADJ
dpc-6010	17	13	board	board	NOUN
dpc-6010	17	14	member	member	NOUN
dpc-6010	17	15	for	for	ADP
dpc-6010	17	16	abbvie	abbvie	PROPN
dpc-6010	17	17	,	,	PUNCT
dpc-6010	17	18	almirall	almirall	PROPN
dpc-6010	17	19	,	,	PUNCT
dpc-6010	17	20	amgen	amgen	PROPN
dpc-6010	17	21	,	,	PUNCT
dpc-6010	17	22	eli	eli	PROPN
dpc-6010	17	23	-	-	PUNCT
dpc-6010	17	24	lilly	lilly	PROPN
dpc-6010	17	25	,	,	PUNCT
dpc-6010	17	26	leo	leo	PROPN
dpc-6010	17	27	pharma	pharma	PROPN
dpc-6010	17	28	,	,	PUNCT
dpc-6010	17	29	janssen	janssen	NOUN
dpc-6010	17	30	-	-	PUNCT
dpc-6010	17	31	cilag	cilag	PROPN
dpc-6010	17	32	,	,	PUNCT
dpc-6010	17	33	novartis	novartis	NOUN
dpc-6010	17	34	,	,	PUNCT
dpc-6010	17	35	pfizer	pfizer	NOUN
dpc-6010	17	36	,	,	PUNCT
dpc-6010	17	37	sanofi	sanofi	NOUN
dpc-6010	17	38	-	-	PUNCT
dpc-6010	17	39	aventis	aventis	PROPN
dpc-6010	17	40	,	,	PUNCT
dpc-6010	17	41	boehringer	boehringer	PROPN
dpc-6010	17	42	ingelheim	ingelheim	PROPN
dpc-6010	17	43	,	,	PUNCT
dpc-6010	17	44	and	and	CCONJ
dpc-6010	17	45	ucb	ucb	PROPN
dpc-6010	17	46	pharma	pharma	PROPN
dpc-6010	17	47	.	.	PUNCT
dpc-6010	18	1	e.	e.	PROPN
dpc-6010	18	2	campione	campione	PROPN
dpc-6010	18	3	has	have	AUX
dpc-6010	18	4	served	serve	VERB
dpc-6010	18	5	as	as	ADP
dpc-6010	18	6	advisory	advisory	ADJ
dpc-6010	18	7	board	board	NOUN
dpc-6010	18	8	member	member	NOUN
dpc-6010	18	9	,	,	PUNCT
dpc-6010	18	10	received	receive	VERB
dpc-6010	18	11	fees	fee	NOUN
dpc-6010	18	12	for	for	ADP
dpc-6010	18	13	lectures	lecture	NOUN
dpc-6010	18	14	,	,	PUNCT
dpc-6010	18	15	and/or	and/or	CCONJ
dpc-6010	18	16	research	research	NOUN
dpc-6010	18	17	grants	grant	NOUN
dpc-6010	18	18	by	by	ADP
dpc-6010	18	19	almirall	almirall	PROPN
dpc-6010	18	20	,	,	PUNCT
dpc-6010	18	21	amgen	amgen	PROPN
dpc-6010	18	22	,	,	PUNCT
dpc-6010	18	23	abbvie	abbvie	PROPN
dpc-6010	18	24	,	,	PUNCT
dpc-6010	18	25	bristol	bristol	PROPN
dpc-6010	18	26	myers	myers	PROPN
dpc-6010	18	27	squibb	squibb	PROPN
dpc-6010	18	28	,	,	PUNCT
dpc-6010	18	29	incyte	incyte	PROPN
dpc-6010	18	30	,	,	PUNCT
dpc-6010	18	31	leo	leo	PROPN
dpc-6010	18	32	pharma	pharma	PROPN
dpc-6010	18	33	,	,	PUNCT
dpc-6010	18	34	and	and	CCONJ
dpc-6010	18	35	ucb	ucb	PROPN
dpc-6010	18	36	.	.	PUNCT
dpc-6010	19	1	a.	a.	PROPN
dpc-6010	19	2	carugno	carugno	PROPN
dpc-6010	19	3	has	have	AUX
dpc-6010	19	4	been	be	AUX
dpc-6010	19	5	a	a	DET
dpc-6010	19	6	speaker	speaker	NOUN
dpc-6010	19	7	and/or	and/or	CCONJ
dpc-6010	19	8	consultant	consultant	NOUN
dpc-6010	19	9	for	for	ADP
dpc-6010	19	10	almirall	almirall	ADJ
dpc-6010	19	11	,	,	PUNCT
dpc-6010	19	12	amgen	amgen	PROPN
dpc-6010	19	13	,	,	PUNCT
dpc-6010	19	14	abbvie	abbvie	PROPN
dpc-6010	19	15	,	,	PUNCT
dpc-6010	19	16	boehringer	boehringer	PROPN
dpc-6010	19	17	ingelheim	ingelheim	PROPN
dpc-6010	19	18	,	,	PUNCT
dpc-6010	19	19	eli	eli	PROPN
dpc-6010	19	20	lilly	lilly	PROPN
dpc-6010	19	21	,	,	PUNCT
dpc-6010	19	22	leo	leo	PROPN
dpc-6010	19	23	pharma	pharma	PROPN
dpc-6010	19	24	,	,	PUNCT
dpc-6010	19	25	janssen	janssen	NOUN
dpc-6010	19	26	-	-	PUNCT
dpc-6010	19	27	cilag	cilag	PROPN
dpc-6010	19	28	,	,	PUNCT
dpc-6010	19	29	novartis	novartis	NOUN
dpc-6010	19	30	,	,	PUNCT
dpc-6010	19	31	and	and	CCONJ
dpc-6010	19	32	ucb	ucb	PROPN
dpc-6010	19	33	pharma	pharma	PROPN
dpc-6010	19	34	.	.	PUNCT
dpc-6010	20	1	a.	a.	PROPN
dpc-6010	20	2	costanzo	costanzo	PROPN
dpc-6010	20	3	has	have	AUX
dpc-6010	20	4	been	be	AUX
dpc-6010	20	5	a	a	DET
dpc-6010	20	6	consultant	consultant	NOUN
dpc-6010	20	7	and/or	and/or	CCONJ
dpc-6010	20	8	speaker	speaker	NOUN
dpc-6010	20	9	for	for	ADP
dpc-6010	20	10	abbvie	abbvie	PROPN
dpc-6010	20	11	,	,	PUNCT
dpc-6010	20	12	almirall	almirall	PROPN
dpc-6010	20	13	,	,	PUNCT
dpc-6010	20	14	amgen	amgen	PROPN
dpc-6010	20	15	,	,	PUNCT
dpc-6010	20	16	janssen	janssen	PROPN
dpc-6010	20	17	,	,	PUNCT
dpc-6010	20	18	leo	leo	PROPN
dpc-6010	20	19	pharma	pharma	PROPN
dpc-6010	20	20	,	,	PUNCT
dpc-6010	20	21	eli	eli	PROPN
dpc-6010	20	22	lilly	lilly	PROPN
dpc-6010	20	23	,	,	PUNCT
dpc-6010	20	24	galderma	galderma	PROPN
dpc-6010	20	25	,	,	PUNCT
dpc-6010	20	26	boehringer	boehringer	NOUN
dpc-6010	20	27	,	,	PUNCT
dpc-6010	20	28	novartis	novartis	NOUN
dpc-6010	20	29	,	,	PUNCT
dpc-6010	20	30	pfizer	pfizer	NOUN
dpc-6010	20	31	,	,	PUNCT
dpc-6010	20	32	sandoz	sandoz	PROPN
dpc-6010	20	33	,	,	PUNCT
dpc-6010	20	34	and	and	CCONJ
dpc-6010	20	35	ucb	ucb	PROPN
dpc-6010	20	36	.	.	PROPN
dpc-6010	21	1	e.	e.	PROPN
dpc-6010	21	2	cozzani	cozzani	PROPN
dpc-6010	21	3	acted	act	VERB
dpc-6010	21	4	as	as	ADP
dpc-6010	21	5	a	a	DET
dpc-6010	21	6	speaker	speaker	NOUN
dpc-6010	21	7	or	or	CCONJ
dpc-6010	21	8	consultant	consultant	NOUN
dpc-6010	21	9	for	for	ADP
dpc-6010	21	10	abbvie	abbvie	PROPN
dpc-6010	21	11	,	,	PUNCT
dpc-6010	21	12	almirall	almirall	PROPN
dpc-6010	21	13	,	,	PUNCT
dpc-6010	21	14	eli	eli	PROPN
dpc-6010	21	15	lilly	lilly	PROPN
dpc-6010	21	16	,	,	PUNCT
dpc-6010	21	17	leo	leo	PROPN
dpc-6010	21	18	-	-	PUNCT
dpc-6010	21	19	pharma	pharma	PROPN
dpc-6010	21	20	,	,	PUNCT
dpc-6010	21	21	and	and	CCONJ
dpc-6010	21	22	novartis	novartis	PROPN
dpc-6010	21	23	.	.	PUNCT
dpc-6010	22	1	g.	g.	PROPN
dpc-6010	22	2	dal	dal	PROPN
dpc-6010	22	3	bello	bello	PROPN
dpc-6010	22	4	has	have	AUX
dpc-6010	22	5	been	be	AUX
dpc-6010	22	6	a	a	DET
dpc-6010	22	7	consultant	consultant	NOUN
dpc-6010	22	8	for	for	ADP
dpc-6010	22	9	abbvie	abbvie	PROPN
dpc-6010	22	10	,	,	PUNCT
dpc-6010	22	11	eli	eli	PROPN
dpc-6010	22	12	lilly	lilly	PROPN
dpc-6010	22	13	,	,	PUNCT
dpc-6010	22	14	janssen	janssen	PROPN
dpc-6010	22	15	,	,	PUNCT
dpc-6010	22	16	sanofi	sanofi	PROPN
dpc-6010	22	17	,	,	PUNCT
dpc-6010	22	18	ucb	ucb	PROPN
dpc-6010	22	19	,	,	PUNCT
dpc-6010	22	20	and	and	CCONJ
dpc-6010	22	21	novartis	novartis	PROPN
dpc-6010	22	22	.	.	PUNCT
dpc-6010	23	1	a.	a.	PROPN
dpc-6010	23	2	dattola	dattola	PROPN
dpc-6010	23	3	has	have	AUX
dpc-6010	23	4	served	serve	VERB
dpc-6010	23	5	as	as	ADP
dpc-6010	23	6	a	a	DET
dpc-6010	23	7	speaker	speaker	NOUN
dpc-6010	23	8	,	,	PUNCT
dpc-6010	23	9	consultant	consultant	NOUN
dpc-6010	23	10	,	,	PUNCT
dpc-6010	23	11	or	or	CCONJ
dpc-6010	23	12	advisory	advisory	ADJ
dpc-6010	23	13	board	board	NOUN
dpc-6010	23	14	member	member	NOUN
dpc-6010	23	15	for	for	ADP
dpc-6010	23	16	abbvie	abbvie	PROPN
dpc-6010	23	17	,	,	PUNCT
dpc-6010	23	18	almirall	almirall	PROPN
dpc-6010	23	19	,	,	PUNCT
dpc-6010	23	20	amgen	amgen	PROPN
dpc-6010	23	21	,	,	PUNCT
dpc-6010	23	22	eli	eli	PROPN
dpc-6010	23	23	lilly	lilly	PROPN
dpc-6010	23	24	,	,	PUNCT
dpc-6010	23	25	leo	leo	PROPN
dpc-6010	23	26	pharma	pharma	PROPN
dpc-6010	23	27	,	,	PUNCT
dpc-6010	23	28	janssen	janssen	PROPN
dpc-6010	23	29	,	,	PUNCT
dpc-6010	23	30	novartis	novartis	PROPN
dpc-6010	23	31	,	,	PUNCT
dpc-6010	23	32	boehringer	boehringer	PROPN
dpc-6010	23	33	ingelheim	ingelheim	PROPN
dpc-6010	23	34	,	,	PUNCT
dpc-6010	23	35	and	and	CCONJ
dpc-6010	23	36	ucb	ucb	PROPN
dpc-6010	23	37	pharma	pharma	PROPN
dpc-6010	23	38	outside	outside	ADP
dpc-6010	23	39	the	the	DET
dpc-6010	23	40	submitted	submit	VERB
dpc-6010	23	41	work	work	NOUN
dpc-6010	23	42	.	.	PUNCT
dpc-6010	24	1	m.	m.	PROPN
dpc-6010	24	2	esposito	esposito	PROPN
dpc-6010	24	3	has	have	AUX
dpc-6010	24	4	served	serve	VERB
dpc-6010	24	5	as	as	ADP
dpc-6010	24	6	speaker	speaker	NOUN
dpc-6010	24	7	/	/	SYM
dpc-6010	24	8	consultant	consultant	NOUN
dpc-6010	24	9	for	for	ADP
dpc-6010	24	10	abbvie	abbvie	PROPN
dpc-6010	24	11	,	,	PUNCT
dpc-6010	24	12	amgen	amgen	PROPN
dpc-6010	24	13	,	,	PUNCT
dpc-6010	24	14	almirall	almirall	ADJ
dpc-6010	24	15	,	,	PUNCT
dpc-6010	24	16	eli	eli	PROPN
dpc-6010	24	17	lilly	lilly	PROPN
dpc-6010	24	18	,	,	PUNCT
dpc-6010	24	19	janssen	janssen	PROPN
dpc-6010	24	20	,	,	PUNCT
dpc-6010	24	21	leopharma	leopharma	PROPN
dpc-6010	24	22	,	,	PUNCT
dpc-6010	24	23	novartis	novartis	PROPN
dpc-6010	24	24	,	,	PUNCT
dpc-6010	24	25	pfizer	pfizer	NOUN
dpc-6010	24	26	,	,	PUNCT
dpc-6010	24	27	sanofi	sanofi	PROPN
dpc-6010	24	28	,	,	PUNCT
dpc-6010	24	29	and	and	CCONJ
dpc-6010	24	30	ucb	ucb	PROPN
dpc-6010	24	31	.	.	PUNCT
dpc-6010	25	1	m.c	m.c	PROPN
dpc-6010	25	2	.	.	PROPN
dpc-6010	25	3	fargnoli	fargnoli	PROPN
dpc-6010	25	4	has	have	AUX
dpc-6010	25	5	served	serve	VERB
dpc-6010	25	6	on	on	ADP
dpc-6010	25	7	advisory	advisory	ADJ
dpc-6010	25	8	boards	board	NOUN
dpc-6010	25	9	,	,	PUNCT
dpc-6010	25	10	received	receive	VERB
dpc-6010	25	11	honoraria	honorarium	NOUN
dpc-6010	25	12	for	for	ADP
dpc-6010	25	13	lectures	lecture	NOUN
dpc-6010	25	14	and/or	and/or	CCONJ
dpc-6010	25	15	research	research	NOUN
dpc-6010	25	16	grants	grant	NOUN
dpc-6010	25	17	from	from	ADP
dpc-6010	25	18	amgen	amgen	PROPN
dpc-6010	25	19	,	,	PUNCT
dpc-6010	25	20	almirall	almirall	ADJ
dpc-6010	25	21	,	,	PUNCT
dpc-6010	25	22	abbvie	abbvie	PROPN
dpc-6010	25	23	,	,	PUNCT
dpc-6010	25	24	boehringer	boehringer	PROPN
dpc-6010	25	25	-	-	PUNCT
dpc-6010	25	26	ingelheim	ingelheim	PROPN
dpc-6010	25	27	,	,	PUNCT
dpc-6010	25	28	bms	bms	PROPN
dpc-6010	25	29	,	,	PUNCT
dpc-6010	25	30	galderma	galderma	NOUN
dpc-6010	25	31	,	,	PUNCT
dpc-6010	25	32	kyowa	kyowa	PROPN
dpc-6010	25	33	kyrin	kyrin	NOUN
dpc-6010	25	34	,	,	PUNCT
dpc-6010	25	35	incyte	incyte	PROPN
dpc-6010	25	36	,	,	PUNCT
dpc-6010	25	37	leo	leo	PROPN
dpc-6010	25	38	pharma	pharma	PROPN
dpc-6010	25	39	,	,	PUNCT
dpc-6010	25	40	pierre	pierre	PROPN
dpc-6010	25	41	fabre	fabre	PROPN
dpc-6010	25	42	,	,	PUNCT
dpc-6010	25	43	ucb	ucb	PROPN
dpc-6010	25	44	,	,	PUNCT
dpc-6010	25	45	lilly	lilly	PROPN
dpc-6010	25	46	,	,	PUNCT
dpc-6010	25	47	pfizer	pfizer	PROPN
dpc-6010	25	48	,	,	PUNCT
dpc-6010	25	49	janssen	janssen	PROPN
dpc-6010	25	50	,	,	PUNCT
dpc-6010	25	51	msd	msd	PROPN
dpc-6010	25	52	,	,	PUNCT
dpc-6010	25	53	novartis	novartis	PROPN
dpc-6010	25	54	,	,	PUNCT
dpc-6010	25	55	sanofi	sanofi	PROPN
dpc-6010	25	56	,	,	PUNCT
dpc-6010	25	57	regeneron	regeneron	PROPN
dpc-6010	25	58	,	,	PUNCT
dpc-6010	25	59	and	and	CCONJ
dpc-6010	25	60	sun	sun	PROPN
dpc-6010	25	61	pharma	pharma	PROPN
dpc-6010	25	62	.	.	PUNCT
dpc-6010	26	1	c.	c.	PROPN
dpc-6010	26	2	guarneri	guarneri	PROPN
dpc-6010	26	3	has	have	AUX
dpc-6010	26	4	received	receive	VERB
dpc-6010	26	5	consultation	consultation	NOUN
dpc-6010	26	6	fees	fee	NOUN
dpc-6010	26	7	and/or	and/or	CCONJ
dpc-6010	26	8	grants	grant	NOUN
dpc-6010	26	9	for	for	ADP
dpc-6010	26	10	research	research	NOUN
dpc-6010	26	11	projects	project	NOUN
dpc-6010	26	12	,	,	PUNCT
dpc-6010	26	13	advisory	advisory	ADJ
dpc-6010	26	14	panels	panel	NOUN
dpc-6010	26	15	,	,	PUNCT
dpc-6010	26	16	and	and	CCONJ
dpc-6010	26	17	giving	give	VERB
dpc-6010	26	18	educational	educational	ADJ
dpc-6010	26	19	lectures	lecture	NOUN
dpc-6010	26	20	from	from	ADP
dpc-6010	26	21	wyeth	wyeth	ADJ
dpc-6010	26	22	-	-	PUNCT
dpc-6010	26	23	pfizer	pfizer	NOUN
dpc-6010	26	24	,	,	PUNCT
dpc-6010	26	25	abbott	abbott	PROPN
dpc-6010	26	26	immunology	immunology	NOUN
dpc-6010	26	27	-	-	PUNCT
dpc-6010	26	28	abbvie	abbvie	PROPN
dpc-6010	26	29	,	,	PUNCT
dpc-6010	26	30	janssen	janssen	NOUN
dpc-6010	26	31	-	-	PUNCT
dpc-6010	26	32	cilag	cilag	PROPN
dpc-6010	26	33	,	,	PUNCT
dpc-6010	26	34	novartis	novartis	PROPN
dpc-6010	26	35	,	,	PUNCT
dpc-6010	26	36	leo	leo	PROPN
dpc-6010	26	37	-	-	PUNCT
dpc-6010	26	38	pharma	pharma	PROPN
dpc-6010	26	39	,	,	PUNCT
dpc-6010	26	40	leopharma	leopharma	PROPN
dpc-6010	26	41	denmark	denmark	PROPN
dpc-6010	26	42	,	,	PUNCT
dpc-6010	26	43	ely	ely	NOUN
dpc-6010	26	44	-	-	PUNCT
dpc-6010	26	45	lilly	lilly	ADJ
dpc-6010	26	46	,	,	PUNCT
dpc-6010	26	47	celgene	celgene	NOUN
dpc-6010	26	48	,	,	PUNCT
dpc-6010	26	49	merck	merck	NOUN
dpc-6010	26	50	-	-	PUNCT
dpc-6010	26	51	serono	serono	PROPN
dpc-6010	26	52	,	,	PUNCT
dpc-6010	26	53	ucb	ucb	PROPN
dpc-6010	26	54	pharma	pharma	PROPN
dpc-6010	26	55	,	,	PUNCT
dpc-6010	26	56	sanofi	sanofi	NOUN
dpc-6010	26	57	-	-	PUNCT
dpc-6010	26	58	aventis	aventis	PROPN
dpc-6010	26	59	,	,	PUNCT
dpc-6010	26	60	amgen	amgen	PROPN
dpc-6010	26	61	,	,	PUNCT
dpc-6010	26	62	and	and	CCONJ
dpc-6010	26	63	almirall	almirall	ADJ
dpc-6010	26	64	.	.	PUNCT
dpc-6010	27	1	p.	p.	NOUN
dpc-6010	27	2	malagoli	malagoli	NOUN
dpc-6010	27	3	has	have	AUX
dpc-6010	27	4	been	be	AUX
dpc-6010	27	5	a	a	DET
dpc-6010	27	6	speaker	speaker	NOUN
dpc-6010	27	7	for	for	ADP
dpc-6010	27	8	abbvie	abbvie	PROPN
dpc-6010	27	9	,	,	PUNCT
dpc-6010	27	10	lilly	lilly	PROPN
dpc-6010	27	11	,	,	PUNCT
dpc-6010	27	12	novartis	novartis	PROPN
dpc-6010	27	13	,	,	PUNCT
dpc-6010	27	14	janssen	janssen	NOUN
dpc-6010	27	15	-	-	PUNCT
dpc-6010	27	16	cilag	cilag	PROPN
dpc-6010	27	17	,	,	PUNCT
dpc-6010	27	18	celgene	celgene	NOUN
dpc-6010	27	19	,	,	PUNCT
dpc-6010	27	20	leopharma	leopharma	PROPN
dpc-6010	27	21	,	,	PUNCT
dpc-6010	27	22	and	and	CCONJ
dpc-6010	27	23	almirall	almirall	ADJ
dpc-6010	27	24	.	.	PUNCT
dpc-6010	28	1	a.	a.	PROPN
dpc-6010	28	2	narcisi	narcisi	PROPN
dpc-6010	28	3	has	have	AUX
dpc-6010	28	4	served	serve	VERB
dpc-6010	28	5	on	on	ADP
dpc-6010	28	6	advisory	advisory	ADJ
dpc-6010	28	7	boards	board	NOUN
dpc-6010	28	8	,	,	PUNCT
dpc-6010	28	9	received	receive	VERB
dpc-6010	28	10	honoraria	honorarium	NOUN
dpc-6010	28	11	for	for	ADP
dpc-6010	28	12	lectures	lecture	NOUN
dpc-6010	28	13	and	and	CCONJ
dpc-6010	28	14	research	research	NOUN
dpc-6010	28	15	grants	grant	NOUN
dpc-6010	28	16	from	from	ADP
dpc-6010	28	17	almirall	almirall	ADJ
dpc-6010	28	18	,	,	PUNCT
dpc-6010	28	19	abbvie	abbvie	PROPN
dpc-6010	28	20	,	,	PUNCT
dpc-6010	28	21	bms	bms	PROPN
dpc-6010	28	22	,	,	PUNCT
dpc-6010	28	23	leo	leo	PROPN
dpc-6010	28	24	pharma	pharma	PROPN
dpc-6010	28	25	,	,	PUNCT
dpc-6010	28	26	celgene	celgene	NOUN
dpc-6010	28	27	,	,	PUNCT
dpc-6010	28	28	eli	eli	PROPN
dpc-6010	28	29	lilly	lilly	PROPN
dpc-6010	28	30	,	,	PUNCT
dpc-6010	28	31	janssen	janssen	PROPN
dpc-6010	28	32	,	,	PUNCT
dpc-6010	28	33	novartis	novartis	PROPN
dpc-6010	28	34	,	,	PUNCT
dpc-6010	28	35	sanofi	sanofi	PROPN
dpc-6010	28	36	-	-	PUNCT
dpc-6010	28	37	genzyme	genzyme	PROPN
dpc-6010	28	38	,	,	PUNCT
dpc-6010	28	39	amgen	amgen	PROPN
dpc-6010	28	40	,	,	PUNCT
dpc-6010	28	41	and	and	CCONJ
dpc-6010	28	42	boehringer	boehringer	PROPN
dpc-6010	28	43	ingelheim	ingelheim	PROPN
dpc-6010	28	44	.	.	PUNCT
dpc-6010	29	1	authorship	authorship	NOUN
dpc-6010	29	2	:	:	PUNCT
dpc-6010	29	3	all	all	DET
dpc-6010	29	4	authors	author	NOUN
dpc-6010	29	5	have	have	AUX
dpc-6010	29	6	contributed	contribute	VERB
dpc-6010	29	7	significantly	significantly	ADV
dpc-6010	29	8	to	to	ADP
dpc-6010	29	9	this	this	DET
dpc-6010	29	10	publication	publication	NOUN
dpc-6010	29	11	.	.	PUNCT
dpc-6010	30	1	corresponding	correspond	VERB
dpc-6010	30	2	author	author	NOUN
dpc-6010	30	3	:	:	PUNCT
dpc-6010	30	4	diego	diego	PROPN
dpc-6010	30	5	orsini	orsini	PROPN
dpc-6010	30	6	md	md	PROPN
dpc-6010	30	7	,	,	PUNCT
dpc-6010	30	8	phd	phd	PROPN
dpc-6010	30	9	.	.	PUNCT
dpc-6010	31	1	clinical	clinical	ADJ
dpc-6010	31	2	dermatology	dermatology	NOUN
dpc-6010	31	3	unit	unit	NOUN
dpc-6010	31	4	,	,	PUNCT
dpc-6010	31	5	san	san	PROPN
dpc-6010	31	6	gallicano	gallicano	PROPN
dpc-6010	31	7	dermatological	dermatological	PROPN
dpc-6010	31	8	institute	institute	NOUN
dpc-6010	31	9	(	(	PUNCT
dpc-6010	31	10	irccs	irccs	PROPN
dpc-6010	31	11	)	)	PUNCT
dpc-6010	31	12	,	,	PUNCT
dpc-6010	31	13	via	via	ADP
dpc-6010	31	14	elio	elio	PROPN
dpc-6010	31	15	chianesi	chianesi	PROPN
dpc-6010	31	16	,	,	PUNCT
dpc-6010	31	17	52	52	NUM
dpc-6010	31	18	,	,	PUNCT
dpc-6010	31	19	00144	00144	NUM
dpc-6010	31	20	roma	roma	PROPN
dpc-6010	31	21	(	(	PUNCT
dpc-6010	31	22	rm	rm	PROPN
dpc-6010	31	23	)	)	PUNCT
dpc-6010	31	24	.	.	PUNCT
dpc-6010	32	1	e	e	X
dpc-6010	32	2	-	-	NOUN
dpc-6010	32	3	mail	mail	NOUN
dpc-6010	32	4	:	:	PUNCT
dpc-6010	32	5	diego.orsini@ifo.it	diego.orsini@ifo.it	DET
dpc-6010	32	6	original	original	ADJ
dpc-6010	32	7	article	article	NOUN
dpc-6010	32	8	|	|	ADV
dpc-6010	32	9	dermatol	dermatol	ADJ
dpc-6010	32	10	pract	pract	NOUN
dpc-6010	32	11	concept	concept	NOUN
dpc-6010	32	12	.	.	PUNCT
dpc-6010	33	1	2025;15(4):6010	2025;15(4):6010	NUM
dpc-6010	33	2	3	3	NUM
dpc-6010	33	3	introduction	introduction	NOUN
dpc-6010	33	4	the	the	DET
dpc-6010	33	5	recent	recent	ADJ
dpc-6010	33	6	worldwide	worldwide	ADJ
dpc-6010	33	7	deployment	deployment	NOUN
dpc-6010	33	8	of	of	ADP
dpc-6010	33	9	anti	anti	ADJ
dpc-6010	33	10	-	-	ADJ
dpc-6010	33	11	interleukin	interleukin	ADJ
dpc-6010	33	12	(	(	PUNCT
dpc-6010	33	13	il)-17	il)-17	PROPN
dpc-6010	33	14	and	and	CCONJ
dpc-6010	33	15	anti	anti	ADJ
dpc-6010	33	16	-	-	ADJ
dpc-6010	33	17	il-23	il-23	ADJ
dpc-6010	33	18	drugs	drug	NOUN
dpc-6010	33	19	has	have	AUX
dpc-6010	33	20	revolutionized	revolutionize	VERB
dpc-6010	33	21	the	the	DET
dpc-6010	33	22	treatment	treatment	NOUN
dpc-6010	33	23	paradigm	paradigm	NOUN
dpc-6010	33	24	of	of	ADP
dpc-6010	33	25	psoriatic	psoriatic	ADJ
dpc-6010	33	26	disease	disease	NOUN
dpc-6010	33	27	,	,	PUNCT
dpc-6010	33	28	allowing	allow	VERB
dpc-6010	33	29	a	a	DET
dpc-6010	33	30	dramatic	dramatic	ADJ
dpc-6010	33	31	improvement	improvement	NOUN
dpc-6010	33	32	in	in	ADP
dpc-6010	33	33	the	the	DET
dpc-6010	33	34	rate	rate	NOUN
dpc-6010	33	35	of	of	ADP
dpc-6010	33	36	achievement	achievement	NOUN
dpc-6010	33	37	and	and	CCONJ
dpc-6010	33	38	maintenance	maintenance	NOUN
dpc-6010	33	39	of	of	ADP
dpc-6010	33	40	clinical	clinical	ADJ
dpc-6010	33	41	remission	remission	NOUN
dpc-6010	33	42	[	[	X
dpc-6010	33	43	1	1	NUM
dpc-6010	33	44	,	,	PUNCT
dpc-6010	33	45	2	2	NUM
dpc-6010	33	46	]	]	PUNCT
dpc-6010	33	47	.	.	PUNCT
dpc-6010	34	1	however	however	ADV
dpc-6010	34	2	,	,	PUNCT
dpc-6010	34	3	regardless	regardless	ADV
dpc-6010	34	4	of	of	ADP
dpc-6010	34	5	psoriasis	psoriasis	NOUN
dpc-6010	34	6	forms	form	NOUN
dpc-6010	34	7	and	and	CCONJ
dpc-6010	34	8	the	the	DET
dpc-6010	34	9	disease	disease	NOUN
dpc-6010	34	10	domains	domain	NOUN
dpc-6010	34	11	involved	involve	VERB
dpc-6010	34	12	,	,	PUNCT
dpc-6010	34	13	a	a	DET
dpc-6010	34	14	variable	variable	ADJ
dpc-6010	34	15	percentage	percentage	NOUN
dpc-6010	34	16	of	of	ADP
dpc-6010	34	17	patients	patient	NOUN
dpc-6010	34	18	still	still	ADV
dpc-6010	34	19	experience	experience	VERB
dpc-6010	34	20	primary	primary	ADJ
dpc-6010	34	21	therapeutic	therapeutic	ADJ
dpc-6010	34	22	failure	failure	NOUN
dpc-6010	34	23	,	,	PUNCT
dpc-6010	34	24	incomplete	incomplete	ADJ
dpc-6010	34	25	response	response	NOUN
dpc-6010	34	26	,	,	PUNCT
dpc-6010	34	27	or	or	CCONJ
dpc-6010	34	28	progressive	progressive	ADJ
dpc-6010	34	29	loss	loss	NOUN
dpc-6010	34	30	of	of	ADP
dpc-6010	34	31	treatment	treatment	NOUN
dpc-6010	34	32	efficacy	efficacy	NOUN
dpc-6010	34	33	(	(	PUNCT
dpc-6010	34	34	secondary	secondary	ADJ
dpc-6010	34	35	therapeutic	therapeutic	ADJ
dpc-6010	34	36	failure	failure	NOUN
dpc-6010	34	37	)	)	PUNCT
dpc-6010	34	38	.	.	PUNCT
dpc-6010	35	1	in	in	ADP
dpc-6010	35	2	this	this	DET
dpc-6010	35	3	context	context	NOUN
dpc-6010	35	4	,	,	PUNCT
dpc-6010	35	5	switching	switch	VERB
dpc-6010	35	6	treatments	treatment	NOUN
dpc-6010	35	7	among	among	ADP
dpc-6010	35	8	different	different	ADJ
dpc-6010	35	9	mechanisms	mechanism	NOUN
dpc-6010	35	10	of	of	ADP
dpc-6010	35	11	action	action	NOUN
dpc-6010	35	12	has	have	AUX
dpc-6010	35	13	been	be	AUX
dpc-6010	35	14	explored	explore	VERB
dpc-6010	35	15	in	in	ADP
dpc-6010	35	16	previous	previous	ADJ
dpc-6010	35	17	studies	study	NOUN
dpc-6010	35	18	conducted	conduct	VERB
dpc-6010	35	19	on	on	ADP
dpc-6010	35	20	psoriatic	psoriatic	ADJ
dpc-6010	35	21	patients	patient	NOUN
dpc-6010	35	22	[	[	X
dpc-6010	35	23	3	3	NUM
dpc-6010	35	24	-	-	SYM
dpc-6010	35	25	5	5	NUM
dpc-6010	35	26	]	]	PUNCT
dpc-6010	35	27	.	.	PUNCT
dpc-6010	36	1	however	however	ADV
dpc-6010	36	2	,	,	PUNCT
dpc-6010	36	3	criteria	criterion	NOUN
dpc-6010	36	4	providing	provide	VERB
dpc-6010	36	5	a	a	DET
dpc-6010	36	6	clear	clear	ADJ
dpc-6010	36	7	clinical	clinical	ADJ
dpc-6010	36	8	rationale	rationale	NOUN
dpc-6010	36	9	for	for	ADP
dpc-6010	36	10	such	such	ADJ
dpc-6010	36	11	transitions	transition	NOUN
dpc-6010	36	12	are	be	AUX
dpc-6010	36	13	lacking	lack	VERB
dpc-6010	36	14	,	,	PUNCT
dpc-6010	36	15	and	and	CCONJ
dpc-6010	36	16	no	no	DET
dpc-6010	36	17	clear	clear	ADJ
dpc-6010	36	18	guidance	guidance	NOUN
dpc-6010	36	19	is	be	AUX
dpc-6010	36	20	provided	provide	VERB
dpc-6010	36	21	by	by	ADP
dpc-6010	36	22	international	international	ADJ
dpc-6010	36	23	guidelines	guideline	NOUN
dpc-6010	36	24	to	to	ADP
dpc-6010	36	25	date	date	NOUN
dpc-6010	36	26	.	.	PUNCT
dpc-6010	37	1	considering	consider	VERB
dpc-6010	37	2	that	that	SCONJ
dpc-6010	37	3	most	most	ADJ
dpc-6010	37	4	patients	patient	NOUN
dpc-6010	37	5	treated	treat	VERB
dpc-6010	37	6	with	with	ADP
dpc-6010	37	7	anti	anti	ADJ
dpc-6010	37	8	-	-	ADJ
dpc-6010	37	9	il	il	ADJ
dpc-6010	37	10	drugs	drug	NOUN
dpc-6010	37	11	have	have	AUX
dpc-6010	37	12	previously	previously	ADV
dpc-6010	37	13	experienced	experience	VERB
dpc-6010	37	14	failure	failure	NOUN
dpc-6010	37	15	of	of	ADP
dpc-6010	37	16	at	at	ADV
dpc-6010	37	17	least	least	ADV
dpc-6010	37	18	one	one	NUM
dpc-6010	37	19	traditional	traditional	ADJ
dpc-6010	37	20	dmards	dmard	NOUN
dpc-6010	37	21	and	and	CCONJ
dpc-6010	37	22	in	in	ADP
dpc-6010	37	23	some	some	DET
dpc-6010	37	24	cases	case	NOUN
dpc-6010	37	25	even	even	ADV
dpc-6010	37	26	one	one	NUM
dpc-6010	37	27	or	or	CCONJ
dpc-6010	37	28	more	more	ADJ
dpc-6010	37	29	biologics	biologic	NOUN
dpc-6010	37	30	,	,	PUNCT
dpc-6010	37	31	the	the	DET
dpc-6010	37	32	most	most	ADV
dpc-6010	37	33	obvious	obvious	ADJ
dpc-6010	37	34	and	and	CCONJ
dpc-6010	37	35	widely	widely	ADV
dpc-6010	37	36	used	use	VERB
dpc-6010	37	37	strategy	strategy	NOUN
dpc-6010	37	38	to	to	PART
dpc-6010	37	39	manage	manage	VERB
dpc-6010	37	40	this	this	DET
dpc-6010	37	41	difficult	difficult	ADJ
dpc-6010	37	42	subgroup	subgroup	NOUN
dpc-6010	37	43	of	of	ADP
dpc-6010	37	44	patients	patient	NOUN
dpc-6010	37	45	is	be	AUX
dpc-6010	37	46	to	to	PART
dpc-6010	37	47	attempt	attempt	VERB
dpc-6010	37	48	an	an	DET
dpc-6010	37	49	interclass	interclass	NOUN
dpc-6010	37	50	switch	switch	NOUN
dpc-6010	37	51	from	from	ADP
dpc-6010	37	52	an	an	DET
dpc-6010	37	53	anti	anti	NOUN
dpc-6010	37	54	-	-	NOUN
dpc-6010	37	55	il-23	il-23	NOUN
dpc-6010	37	56	to	to	ADP
dpc-6010	37	57	an	an	DET
dpc-6010	37	58	anti	anti	NOUN
dpc-6010	37	59	-	-	ADJ
dpc-6010	37	60	il-17	il-17	ADJ
dpc-6010	37	61	and	and	CCONJ
dpc-6010	37	62	vice	vice	ADV
dpc-6010	37	63	versa	versa	ADV
dpc-6010	37	64	.	.	PUNCT
dpc-6010	38	1	brodalumab	brodalumab	NOUN
dpc-6010	38	2	is	be	AUX
dpc-6010	38	3	the	the	DET
dpc-6010	38	4	only	only	ADJ
dpc-6010	38	5	monoclonal	monoclonal	NOUN
dpc-6010	38	6	antibody	antibody	NOUN
dpc-6010	38	7	directed	direct	VERB
dpc-6010	38	8	toward	toward	ADP
dpc-6010	38	9	the	the	DET
dpc-6010	38	10	il-17	il-17	NUM
dpc-6010	38	11	receptor	receptor	NOUN
dpc-6010	38	12	a.	a.	NOUN
dpc-6010	38	13	because	because	SCONJ
dpc-6010	38	14	of	of	ADP
dpc-6010	38	15	this	this	DET
dpc-6010	38	16	peculiar	peculiar	ADJ
dpc-6010	38	17	mechanism	mechanism	NOUN
dpc-6010	38	18	of	of	ADP
dpc-6010	38	19	action	action	NOUN
dpc-6010	38	20	,	,	PUNCT
dpc-6010	38	21	brodalumab	brodalumab	NOUN
dpc-6010	38	22	could	could	AUX
dpc-6010	38	23	block	block	VERB
dpc-6010	38	24	il-17a	il-17a	PROPN
dpc-6010	38	25	,	,	PUNCT
dpc-6010	38	26	il-17f	il-17f	PROPN
dpc-6010	38	27	,	,	PUNCT
dpc-6010	38	28	il-17a	il-17a	PROPN
dpc-6010	38	29	/	/	SYM
dpc-6010	38	30	f	f	PROPN
dpc-6010	38	31	,	,	PUNCT
dpc-6010	38	32	and	and	CCONJ
dpc-6010	38	33	il-17e	il-17e	NOUN
dpc-6010	38	34	isotypes	isotype	NOUN
dpc-6010	38	35	,	,	PUNCT
dpc-6010	38	36	providing	provide	VERB
dpc-6010	38	37	deeper	deep	ADJ
dpc-6010	38	38	cytokine	cytokine	NOUN
dpc-6010	38	39	inhibition	inhibition	NOUN
dpc-6010	38	40	and	and	CCONJ
dpc-6010	38	41	faster	fast	ADJ
dpc-6010	38	42	anti	anti	ADJ
dpc-6010	38	43	inflammatory	inflammatory	ADJ
dpc-6010	38	44	activity	activity	NOUN
dpc-6010	38	45	than	than	ADP
dpc-6010	38	46	other	other	ADJ
dpc-6010	38	47	drugs	drug	NOUN
dpc-6010	38	48	of	of	ADP
dpc-6010	38	49	the	the	DET
dpc-6010	38	50	same	same	ADJ
dpc-6010	38	51	class	class	NOUN
dpc-6010	39	1	[	[	X
dpc-6010	39	2	6	6	NUM
dpc-6010	39	3	]	]	PUNCT
dpc-6010	39	4	.	.	PUNCT
dpc-6010	40	1	results	result	NOUN
dpc-6010	40	2	from	from	ADP
dpc-6010	40	3	the	the	DET
dpc-6010	40	4	amagine	amagine	ADJ
dpc-6010	40	5	1	1	NUM
dpc-6010	40	6	-	-	SYM
dpc-6010	40	7	2	2	NUM
dpc-6010	40	8	-	-	SYM
dpc-6010	40	9	3	3	NUM
dpc-6010	40	10	randomized	randomize	VERB
dpc-6010	40	11	controlled	control	VERB
dpc-6010	40	12	trials	trial	NOUN
dpc-6010	40	13	(	(	PUNCT
dpc-6010	40	14	rcts	rct	NOUN
dpc-6010	40	15	)	)	PUNCT
dpc-6010	40	16	showed	show	VERB
dpc-6010	40	17	that	that	SCONJ
dpc-6010	40	18	51	51	NUM
dpc-6010	40	19	%	%	NOUN
dpc-6010	40	20	of	of	ADP
dpc-6010	40	21	patients	patient	NOUN
dpc-6010	40	22	achieved	achieve	VERB
dpc-6010	40	23	complete	complete	ADJ
dpc-6010	40	24	skin	skin	NOUN
dpc-6010	40	25	clearance	clearance	NOUN
dpc-6010	40	26	(	(	PUNCT
dpc-6010	40	27	pasi	pasi	NOUN
dpc-6010	40	28	100	100	NUM
dpc-6010	40	29	)	)	PUNCT
dpc-6010	40	30	after	after	ADP
dpc-6010	40	31	52	52	NUM
dpc-6010	40	32	weeks	week	NOUN
dpc-6010	40	33	of	of	ADP
dpc-6010	40	34	treatment	treatment	NOUN
dpc-6010	40	35	.	.	PUNCT
dpc-6010	41	1	efficacy	efficacy	NOUN
dpc-6010	41	2	was	be	AUX
dpc-6010	41	3	sustained	sustain	VERB
dpc-6010	41	4	over	over	ADP
dpc-6010	41	5	a	a	DET
dpc-6010	41	6	long	long	ADJ
dpc-6010	41	7	period	period	NOUN
dpc-6010	41	8	,	,	PUNCT
dpc-6010	41	9	with	with	ADP
dpc-6010	41	10	more	more	ADJ
dpc-6010	41	11	than	than	ADP
dpc-6010	41	12	half	half	NOUN
dpc-6010	41	13	of	of	ADP
dpc-6010	41	14	patients	patient	NOUN
dpc-6010	41	15	maintaining	maintain	VERB
dpc-6010	41	16	pasi	pasi	NOUN
dpc-6010	41	17	100	100	NUM
dpc-6010	41	18	and	and	CCONJ
dpc-6010	41	19	more	more	ADJ
dpc-6010	41	20	than	than	ADP
dpc-6010	41	21	75	75	NUM
dpc-6010	41	22	%	%	NOUN
dpc-6010	41	23	of	of	ADP
dpc-6010	41	24	patients	patient	NOUN
dpc-6010	41	25	maintaining	maintain	VERB
dpc-6010	41	26	almost	almost	ADV
dpc-6010	41	27	clear	clear	ADJ
dpc-6010	41	28	skin	skin	NOUN
dpc-6010	41	29	(	(	PUNCT
dpc-6010	41	30	pasi	pasi	NOUN
dpc-6010	41	31	90	90	NUM
dpc-6010	41	32	)	)	PUNCT
dpc-6010	41	33	up	up	ADP
dpc-6010	41	34	to	to	PART
dpc-6010	41	35	120	120	NUM
dpc-6010	41	36	weeks	week	NOUN
dpc-6010	42	1	[	[	X
dpc-6010	42	2	7	7	NUM
dpc-6010	42	3	-	-	SYM
dpc-6010	42	4	9	9	NUM
dpc-6010	42	5	]	]	PUNCT
dpc-6010	42	6	.	.	PUNCT
dpc-6010	43	1	objectives	objective	NOUN
dpc-6010	43	2	we	we	PRON
dpc-6010	43	3	performed	perform	VERB
dpc-6010	43	4	a	a	DET
dpc-6010	43	5	real	real	ADJ
dpc-6010	43	6	-	-	PUNCT
dpc-6010	43	7	life	life	NOUN
dpc-6010	43	8	retrospective	retrospective	ADJ
dpc-6010	43	9	study	study	NOUN
dpc-6010	43	10	to	to	PART
dpc-6010	43	11	evaluate	evaluate	VERB
dpc-6010	43	12	the	the	DET
dpc-6010	43	13	safety	safety	NOUN
dpc-6010	43	14	and	and	CCONJ
dpc-6010	43	15	the	the	DET
dpc-6010	43	16	efficacy	efficacy	NOUN
dpc-6010	43	17	of	of	ADP
dpc-6010	43	18	brodalumab	brodalumab	NOUN
dpc-6010	43	19	in	in	ADP
dpc-6010	43	20	a	a	DET
dpc-6010	43	21	subgroup	subgroup	NOUN
dpc-6010	43	22	of	of	ADP
dpc-6010	43	23	psoriasis	psoriasis	NOUN
dpc-6010	43	24	patients	patient	NOUN
dpc-6010	43	25	who	who	PRON
dpc-6010	43	26	already	already	ADV
dpc-6010	43	27	failed	fail	VERB
dpc-6010	43	28	anti	anti	ADJ
dpc-6010	43	29	-	-	ADJ
dpc-6010	43	30	il23	il23	ADJ
dpc-6010	43	31	or	or	CCONJ
dpc-6010	43	32	anti	anti	ADJ
dpc-6010	43	33	-	-	ADJ
dpc-6010	43	34	il12/23	il12/23	ADJ
dpc-6010	43	35	treatment	treatment	NOUN
dpc-6010	43	36	.	.	PUNCT
dpc-6010	44	1	patients	patient	NOUN
dpc-6010	44	2	and	and	CCONJ
dpc-6010	44	3	methods	method	NOUN
dpc-6010	44	4	we	we	PRON
dpc-6010	44	5	retrospectively	retrospectively	ADV
dpc-6010	44	6	evaluated	evaluate	VERB
dpc-6010	44	7	over	over	ADP
dpc-6010	44	8	a	a	DET
dpc-6010	44	9	follow	follow	NOUN
dpc-6010	44	10	-	-	PUNCT
dpc-6010	44	11	up	up	NOUN
dpc-6010	44	12	period	period	NOUN
dpc-6010	44	13	of	of	ADP
dpc-6010	44	14	52	52	NUM
dpc-6010	44	15	weeks	week	NOUN
dpc-6010	44	16	a	a	DET
dpc-6010	44	17	cohort	cohort	NOUN
dpc-6010	44	18	of	of	ADP
dpc-6010	44	19	23	23	NUM
dpc-6010	44	20	psoriasis	psoriasis	NOUN
dpc-6010	44	21	patients	patient	NOUN
dpc-6010	44	22	who	who	PRON
dpc-6010	44	23	underwent	undergo	VERB
dpc-6010	44	24	a	a	DET
dpc-6010	44	25	medical	medical	ADJ
dpc-6010	44	26	switch	switch	NOUN
dpc-6010	44	27	to	to	PART
dpc-6010	44	28	brodalumab	brodalumab	VERB
dpc-6010	44	29	exclusively	exclusively	ADV
dpc-6010	44	30	following	follow	VERB
dpc-6010	44	31	primary	primary	ADJ
dpc-6010	44	32	or	or	CCONJ
dpc-6010	44	33	secondary	secondary	ADJ
dpc-6010	44	34	therapeutic	therapeutic	ADJ
dpc-6010	44	35	failure	failure	NOUN
dpc-6010	44	36	of	of	ADP
dpc-6010	44	37	anti	anti	ADJ
dpc-6010	44	38	-	-	ADJ
dpc-6010	44	39	il-23	il-23	NOUN
dpc-6010	44	40	or	or	CCONJ
dpc-6010	44	41	anti-12/23	anti-12/23	NOUN
dpc-6010	44	42	drugs	drug	NOUN
dpc-6010	44	43	.	.	PUNCT
dpc-6010	45	1	patients	patient	NOUN
dpc-6010	45	2	who	who	PRON
dpc-6010	45	3	transitioned	transition	VERB
dpc-6010	45	4	for	for	ADP
dpc-6010	45	5	adverse	adverse	ADJ
dpc-6010	45	6	effects	effect	NOUN
dpc-6010	45	7	or	or	CCONJ
dpc-6010	45	8	because	because	SCONJ
dpc-6010	45	9	of	of	ADP
dpc-6010	45	10	any	any	DET
dpc-6010	45	11	reason	reason	NOUN
dpc-6010	45	12	other	other	ADJ
dpc-6010	45	13	than	than	ADP
dpc-6010	45	14	anti	anti	ADJ
dpc-6010	45	15	-	-	ADJ
dpc-6010	45	16	il23	il23	ADJ
dpc-6010	45	17	or	or	CCONJ
dpc-6010	45	18	anti-12/23	anti-12/23	NOUN
dpc-6010	45	19	failure	failure	NOUN
dpc-6010	45	20	were	be	AUX
dpc-6010	45	21	excluded	exclude	VERB
dpc-6010	45	22	from	from	ADP
dpc-6010	45	23	the	the	DET
dpc-6010	45	24	study	study	NOUN
dpc-6010	45	25	.	.	PUNCT
dpc-6010	46	1	clinical	clinical	ADJ
dpc-6010	46	2	and	and	CCONJ
dpc-6010	46	3	quality	quality	NOUN
dpc-6010	46	4	-	-	PUNCT
dpc-6010	46	5	of	of	ADP
dpc-6010	46	6	-	-	PUNCT
dpc-6010	46	7	life	life	NOUN
dpc-6010	46	8	parameters	parameter	NOUN
dpc-6010	46	9	collected	collect	VERB
dpc-6010	46	10	at	at	ADP
dpc-6010	46	11	baseline	baseline	NOUN
dpc-6010	46	12	(	(	PUNCT
dpc-6010	46	13	start	start	NOUN
dpc-6010	46	14	of	of	ADP
dpc-6010	46	15	brodalumab	brodalumab	NOUN
dpc-6010	46	16	treatment	treatment	NOUN
dpc-6010	46	17	)	)	PUNCT
dpc-6010	46	18	and	and	CCONJ
dpc-6010	46	19	at	at	ADP
dpc-6010	46	20	four	four	NUM
dpc-6010	46	21	predefined	predefine	VERB
dpc-6010	46	22	timepoints	timepoint	NOUN
dpc-6010	46	23	(	(	PUNCT
dpc-6010	46	24	4	4	NUM
dpc-6010	46	25	,	,	PUNCT
dpc-6010	46	26	16	16	NUM
dpc-6010	46	27	,	,	PUNCT
dpc-6010	46	28	36	36	NUM
dpc-6010	46	29	,	,	PUNCT
dpc-6010	46	30	52	52	NUM
dpc-6010	46	31	weeks	week	NOUN
dpc-6010	46	32	of	of	ADP
dpc-6010	46	33	continuous	continuous	ADJ
dpc-6010	46	34	brodalumab	brodalumab	NOUN
dpc-6010	46	35	treatment	treatment	NOUN
dpc-6010	46	36	)	)	PUNCT
dpc-6010	46	37	were	be	AUX
dpc-6010	46	38	included	include	VERB
dpc-6010	46	39	for	for	ADP
dpc-6010	46	40	the	the	DET
dpc-6010	46	41	purposes	purpose	NOUN
dpc-6010	46	42	of	of	ADP
dpc-6010	46	43	this	this	DET
dpc-6010	46	44	study	study	NOUN
dpc-6010	46	45	.	.	PUNCT
dpc-6010	47	1	the	the	DET
dpc-6010	47	2	following	follow	VERB
dpc-6010	47	3	parameters	parameter	NOUN
dpc-6010	47	4	were	be	AUX
dpc-6010	47	5	used	use	VERB
dpc-6010	47	6	for	for	ADP
dpc-6010	47	7	statistical	statistical	ADJ
dpc-6010	47	8	comparisons	comparison	NOUN
dpc-6010	47	9	:	:	PUNCT
dpc-6010	47	10	psoriasi	psoriasi	NOUN
dpc-6010	47	11	area	area	NOUN
dpc-6010	47	12	and	and	CCONJ
dpc-6010	47	13	severity	severity	NOUN
dpc-6010	47	14	index	index	NOUN
dpc-6010	47	15	(	(	PUNCT
dpc-6010	47	16	pasi	pasi	NOUN
dpc-6010	47	17	)	)	PUNCT
dpc-6010	47	18	,	,	PUNCT
dpc-6010	47	19	dermatology	dermatology	NOUN
dpc-6010	47	20	life	life	NOUN
dpc-6010	47	21	quality	quality	NOUN
dpc-6010	47	22	index	index	NOUN
dpc-6010	47	23	(	(	PUNCT
dpc-6010	47	24	dlqi	dlqi	PROPN
dpc-6010	47	25	)	)	PUNCT
dpc-6010	47	26	,	,	PUNCT
dpc-6010	47	27	presence/	presence/	NUM
dpc-6010	47	28	absence	absence	NOUN
dpc-6010	47	29	of	of	ADP
dpc-6010	47	30	active	active	ADJ
dpc-6010	47	31	psoriatic	psoriatic	ADJ
dpc-6010	47	32	arthritis	arthritis	NOUN
dpc-6010	47	33	,	,	PUNCT
dpc-6010	47	34	presence	presence	NOUN
dpc-6010	47	35	/	/	SYM
dpc-6010	47	36	absence	absence	NOUN
dpc-6010	47	37	of	of	ADP
dpc-6010	47	38	adverse	adverse	ADJ
dpc-6010	47	39	events	event	NOUN
dpc-6010	47	40	.	.	PUNCT
dpc-6010	48	1	data	datum	NOUN
dpc-6010	48	2	were	be	AUX
dpc-6010	48	3	summarized	summarize	VERB
dpc-6010	48	4	by	by	ADP
dpc-6010	48	5	means	mean	NOUN
dpc-6010	48	6	of	of	ADP
dpc-6010	48	7	descriptive	descriptive	ADJ
dpc-6010	48	8	analysis	analysis	NOUN
dpc-6010	48	9	.	.	PUNCT
dpc-6010	49	1	means	mean	NOUN
dpc-6010	49	2	and	and	CCONJ
dpc-6010	49	3	standard	standard	ADJ
dpc-6010	49	4	deviations	deviation	NOUN
dpc-6010	49	5	(	(	PUNCT
dpc-6010	49	6	sds	sds	NOUN
dpc-6010	49	7	)	)	PUNCT
dpc-6010	49	8	were	be	AUX
dpc-6010	49	9	introduction	introduction	NOUN
dpc-6010	49	10	:	:	PUNCT
dpc-6010	49	11	the	the	DET
dpc-6010	49	12	use	use	NOUN
dpc-6010	49	13	of	of	ADP
dpc-6010	49	14	brodalumab	brodalumab	NOUN
dpc-6010	49	15	in	in	ADP
dpc-6010	49	16	patients	patient	NOUN
dpc-6010	49	17	with	with	ADP
dpc-6010	49	18	psoriasis	psoriasis	NOUN
dpc-6010	49	19	who	who	PRON
dpc-6010	49	20	have	have	AUX
dpc-6010	49	21	failed	fail	VERB
dpc-6010	49	22	other	other	ADJ
dpc-6010	49	23	biologic	biologic	NOUN
dpc-6010	49	24	drugs	drug	NOUN
dpc-6010	49	25	is	be	AUX
dpc-6010	49	26	an	an	DET
dpc-6010	49	27	underexplored	underexplored	ADJ
dpc-6010	49	28	topic	topic	NOUN
dpc-6010	49	29	.	.	PUNCT
dpc-6010	50	1	objectives	objective	NOUN
dpc-6010	50	2	:	:	PUNCT
dpc-6010	50	3	to	to	PART
dpc-6010	50	4	evaluate	evaluate	VERB
dpc-6010	50	5	the	the	DET
dpc-6010	50	6	safety	safety	NOUN
dpc-6010	50	7	and	and	CCONJ
dpc-6010	50	8	the	the	DET
dpc-6010	50	9	efficacy	efficacy	NOUN
dpc-6010	50	10	of	of	ADP
dpc-6010	50	11	brodalumab	brodalumab	NOUN
dpc-6010	50	12	in	in	ADP
dpc-6010	50	13	a	a	DET
dpc-6010	50	14	subgroup	subgroup	NOUN
dpc-6010	50	15	of	of	ADP
dpc-6010	50	16	psoriasis	psoriasis	NOUN
dpc-6010	50	17	patients	patient	NOUN
dpc-6010	50	18	who	who	PRON
dpc-6010	50	19	already	already	ADV
dpc-6010	50	20	failed	fail	VERB
dpc-6010	50	21	anti	anti	ADJ
dpc-6010	50	22	-	-	ADJ
dpc-6010	50	23	il23	il23	ADJ
dpc-6010	50	24	or	or	CCONJ
dpc-6010	50	25	anti	anti	ADJ
dpc-6010	50	26	-	-	ADJ
dpc-6010	50	27	il12/23	il12/23	ADJ
dpc-6010	50	28	treatment	treatment	NOUN
dpc-6010	50	29	.	.	PUNCT
dpc-6010	51	1	methods	method	NOUN
dpc-6010	51	2	:	:	PUNCT
dpc-6010	51	3	using	use	VERB
dpc-6010	51	4	the	the	DET
dpc-6010	51	5	psoriasis	psoriasis	NOUN
dpc-6010	51	6	area	area	NOUN
dpc-6010	51	7	and	and	CCONJ
dpc-6010	51	8	severity	severity	NOUN
dpc-6010	51	9	index	index	NOUN
dpc-6010	51	10	(	(	PUNCT
dpc-6010	51	11	pasi	pasi	NOUN
dpc-6010	51	12	)	)	PUNCT
dpc-6010	51	13	and	and	CCONJ
dpc-6010	51	14	dermatology	dermatology	NOUN
dpc-6010	51	15	life	life	NOUN
dpc-6010	51	16	quality	quality	NOUN
dpc-6010	51	17	index	index	NOUN
dpc-6010	51	18	(	(	PUNCT
dpc-6010	51	19	dlqi	dlqi	PROPN
dpc-6010	51	20	)	)	PUNCT
dpc-6010	51	21	,	,	PUNCT
dpc-6010	51	22	we	we	PRON
dpc-6010	51	23	retrospectively	retrospectively	ADV
dpc-6010	51	24	evaluated	evaluate	VERB
dpc-6010	51	25	a	a	DET
dpc-6010	51	26	cohort	cohort	NOUN
dpc-6010	51	27	of	of	ADP
dpc-6010	51	28	23	23	NUM
dpc-6010	51	29	patients	patient	NOUN
dpc-6010	51	30	with	with	ADP
dpc-6010	51	31	psoriasis	psoriasis	NOUN
dpc-6010	51	32	who	who	PRON
dpc-6010	51	33	underwent	undergo	VERB
dpc-6010	51	34	a	a	DET
dpc-6010	51	35	change	change	NOUN
dpc-6010	51	36	in	in	ADP
dpc-6010	51	37	therapy	therapy	NOUN
dpc-6010	51	38	with	with	ADP
dpc-6010	51	39	brodalumab	brodalumab	NOUN
dpc-6010	51	40	exclusively	exclusively	ADV
dpc-6010	51	41	following	follow	VERB
dpc-6010	51	42	primary	primary	ADJ
dpc-6010	51	43	or	or	CCONJ
dpc-6010	51	44	secondary	secondary	ADJ
dpc-6010	51	45	therapeutic	therapeutic	ADJ
dpc-6010	51	46	failure	failure	NOUN
dpc-6010	51	47	of	of	ADP
dpc-6010	51	48	anti	anti	ADJ
dpc-6010	51	49	-	-	ADJ
dpc-6010	51	50	il-23	il-23	NOUN
dpc-6010	51	51	or	or	CCONJ
dpc-6010	51	52	anti-12/23	anti-12/23	NOUN
dpc-6010	51	53	drugs	drug	NOUN
dpc-6010	51	54	.	.	PUNCT
dpc-6010	52	1	results	result	NOUN
dpc-6010	52	2	:	:	PUNCT
dpc-6010	52	3	the	the	DET
dpc-6010	52	4	mean	mean	ADJ
dpc-6010	52	5	pasi	pasi	NOUN
dpc-6010	52	6	decreased	decrease	VERB
dpc-6010	52	7	significantly	significantly	ADV
dpc-6010	52	8	following	follow	VERB
dpc-6010	52	9	the	the	DET
dpc-6010	52	10	introduction	introduction	NOUN
dpc-6010	52	11	of	of	ADP
dpc-6010	52	12	brodalumab	brodalumab	NOUN
dpc-6010	52	13	after	after	ADP
dpc-6010	52	14	four	four	NUM
dpc-6010	52	15	weeks	week	NOUN
dpc-6010	52	16	of	of	ADP
dpc-6010	52	17	treatment	treatment	NOUN
dpc-6010	52	18	,	,	PUNCT
dpc-6010	52	19	continuing	continue	VERB
dpc-6010	52	20	to	to	PART
dpc-6010	52	21	decrease	decrease	VERB
dpc-6010	52	22	at	at	ADP
dpc-6010	52	23	16	16	NUM
dpc-6010	52	24	and	and	CCONJ
dpc-6010	52	25	36	36	NUM
dpc-6010	52	26	weeks	week	NOUN
dpc-6010	52	27	,	,	PUNCT
dpc-6010	52	28	reaching	reach	VERB
dpc-6010	52	29	the	the	DET
dpc-6010	52	30	nadir	nadir	NOUN
dpc-6010	52	31	at	at	ADP
dpc-6010	52	32	52	52	NUM
dpc-6010	52	33	weeks	week	NOUN
dpc-6010	52	34	(	(	PUNCT
dpc-6010	52	35	baseline	baseline	PROPN
dpc-6010	52	36	pasi	pasi	PROPN
dpc-6010	52	37	baseline	baseline	PROPN
dpc-6010	52	38	:	:	PUNCT
dpc-6010	52	39	14.6	14.6	NUM
dpc-6010	52	40	±	±	NUM
dpc-6010	52	41	9.2	9.2	NUM
dpc-6010	52	42	vs.	vs.	ADP
dpc-6010	52	43	52	52	NUM
dpc-6010	52	44	weeks	week	NOUN
dpc-6010	52	45	pasi	pasi	NOUN
dpc-6010	52	46	:	:	PUNCT
dpc-6010	52	47	1.1	1.1	NUM
dpc-6010	52	48	±	±	NUM
dpc-6010	52	49	1.8	1.8	NUM
dpc-6010	52	50	;	;	PUNCT
dpc-6010	52	51	p<0.001	p<0.001	X
dpc-6010	52	52	)	)	PUNCT
dpc-6010	52	53	.	.	PUNCT
dpc-6010	53	1	sixty	sixty	NUM
dpc-6010	53	2	-	-	PUNCT
dpc-6010	53	3	three	three	NUM
dpc-6010	53	4	point	point	NOUN
dpc-6010	53	5	six	six	NUM
dpc-6010	53	6	percent	percent	NOUN
dpc-6010	53	7	of	of	ADP
dpc-6010	53	8	patients	patient	NOUN
dpc-6010	53	9	reached	reach	VERB
dpc-6010	53	10	pasi	pasi	NOUN
dpc-6010	53	11	100	100	NUM
dpc-6010	53	12	just	just	ADV
dpc-6010	53	13	after	after	ADP
dpc-6010	53	14	16	16	NUM
dpc-6010	53	15	weeks	week	NOUN
dpc-6010	53	16	.	.	PUNCT
dpc-6010	54	1	the	the	DET
dpc-6010	54	2	same	same	ADJ
dpc-6010	54	3	trend	trend	NOUN
dpc-6010	54	4	of	of	ADP
dpc-6010	54	5	improvement	improvement	NOUN
dpc-6010	54	6	was	be	AUX
dpc-6010	54	7	also	also	ADV
dpc-6010	54	8	observed	observe	VERB
dpc-6010	54	9	for	for	ADP
dpc-6010	54	10	the	the	DET
dpc-6010	54	11	dlqi	dlqi	NOUN
dpc-6010	54	12	.	.	PUNCT
dpc-6010	55	1	the	the	DET
dpc-6010	55	2	adverse	adverse	ADJ
dpc-6010	55	3	effects	effect	NOUN
dpc-6010	55	4	observed	observe	VERB
dpc-6010	55	5	in	in	ADP
dpc-6010	55	6	our	our	PRON
dpc-6010	55	7	study	study	NOUN
dpc-6010	55	8	population	population	NOUN
dpc-6010	55	9	were	be	AUX
dpc-6010	55	10	generally	generally	ADV
dpc-6010	55	11	mild	mild	ADJ
dpc-6010	55	12	.	.	PUNCT
dpc-6010	56	1	conclusions	conclusion	NOUN
dpc-6010	56	2	:	:	PUNCT
dpc-6010	56	3	our	our	PRON
dpc-6010	56	4	results	result	NOUN
dpc-6010	56	5	are	be	AUX
dpc-6010	56	6	in	in	ADP
dpc-6010	56	7	line	line	NOUN
dpc-6010	56	8	with	with	ADP
dpc-6010	56	9	the	the	DET
dpc-6010	56	10	current	current	ADJ
dpc-6010	56	11	literature	literature	NOUN
dpc-6010	56	12	and	and	CCONJ
dpc-6010	56	13	suggest	suggest	VERB
dpc-6010	56	14	that	that	SCONJ
dpc-6010	56	15	patients	patient	NOUN
dpc-6010	56	16	who	who	PRON
dpc-6010	56	17	have	have	AUX
dpc-6010	56	18	failed	fail	VERB
dpc-6010	56	19	therapy	therapy	NOUN
dpc-6010	56	20	with	with	ADP
dpc-6010	56	21	il-23	il-23	NOUN
dpc-6010	56	22	or	or	CCONJ
dpc-6010	56	23	il-12/23	il-12/23	ADJ
dpc-6010	56	24	inhibitors	inhibitor	NOUN
dpc-6010	56	25	may	may	AUX
dpc-6010	56	26	benefit	benefit	VERB
dpc-6010	56	27	from	from	ADP
dpc-6010	56	28	switching	switch	VERB
dpc-6010	56	29	to	to	ADP
dpc-6010	56	30	brodalumab	brodalumab	NOUN
dpc-6010	56	31	,	,	PUNCT
dpc-6010	56	32	which	which	PRON
dpc-6010	56	33	could	could	AUX
dpc-6010	56	34	be	be	AUX
dpc-6010	56	35	considered	consider	VERB
dpc-6010	56	36	a	a	DET
dpc-6010	56	37	good	good	ADJ
dpc-6010	56	38	choice	choice	NOUN
dpc-6010	56	39	for	for	ADP
dpc-6010	56	40	patients	patient	NOUN
dpc-6010	56	41	who	who	PRON
dpc-6010	56	42	need	need	VERB
dpc-6010	56	43	a	a	DET
dpc-6010	56	44	rapid	rapid	ADJ
dpc-6010	56	45	resolution	resolution	NOUN
dpc-6010	56	46	of	of	ADP
dpc-6010	56	47	the	the	DET
dpc-6010	56	48	inflammatory	inflammatory	ADJ
dpc-6010	56	49	skin	skin	NOUN
dpc-6010	56	50	condition	condition	NOUN
dpc-6010	56	51	.	.	PUNCT
dpc-6010	57	1	abstract	abstract	ADJ
dpc-6010	57	2	4	4	NUM
dpc-6010	57	3	original	original	ADJ
dpc-6010	57	4	article	article	NOUN
dpc-6010	57	5	|	|	ADV
dpc-6010	57	6	dermatol	dermatol	ADJ
dpc-6010	57	7	pract	pract	NOUN
dpc-6010	57	8	concept	concept	NOUN
dpc-6010	57	9	.	.	PUNCT
dpc-6010	58	1	2025;15(4):6010	2025;15(4):6010	NUM
dpc-6010	58	2	remaining	remain	VERB
dpc-6010	58	3	were	be	AUX
dpc-6010	58	4	overweight	overweight	ADJ
dpc-6010	58	5	or	or	CCONJ
dpc-6010	58	6	obese	obese	ADJ
dpc-6010	58	7	(	(	PUNCT
dpc-6010	58	8	mean	mean	INTJ
dpc-6010	58	9	bmi=	bmi=	PROPN
dpc-6010	58	10	28.8	28.8	NUM
dpc-6010	58	11	±	±	NUM
dpc-6010	58	12	5.9	5.9	NUM
dpc-6010	58	13	)	)	PUNCT
dpc-6010	58	14	.	.	PUNCT
dpc-6010	59	1	the	the	DET
dpc-6010	59	2	mean	mean	ADJ
dpc-6010	59	3	pasi	pasi	NOUN
dpc-6010	59	4	at	at	ADP
dpc-6010	59	5	baseline	baseline	PROPN
dpc-6010	59	6	was	be	AUX
dpc-6010	59	7	14.4	14.4	NUM
dpc-6010	59	8	±	±	NUM
dpc-6010	59	9	9.1	9.1	NUM
dpc-6010	59	10	,	,	PUNCT
dpc-6010	59	11	and	and	CCONJ
dpc-6010	59	12	100	100	NUM
dpc-6010	59	13	%	%	NOUN
dpc-6010	59	14	of	of	ADP
dpc-6010	59	15	participants	participant	NOUN
dpc-6010	59	16	had	have	VERB
dpc-6010	59	17	at	at	ADV
dpc-6010	59	18	least	least	ADJ
dpc-6010	59	19	one	one	NUM
dpc-6010	59	20	difficult	difficult	ADJ
dpc-6010	59	21	-	-	PUNCT
dpc-6010	59	22	to	to	ADP
dpc-6010	59	23	-	-	PUNCT
dpc-6010	59	24	treat	treat	NOUN
dpc-6010	59	25	area	area	NOUN
dpc-6010	59	26	involved	involve	VERB
dpc-6010	59	27	.	.	PUNCT
dpc-6010	60	1	almost	almost	ADV
dpc-6010	60	2	13	13	NUM
dpc-6010	60	3	%	%	NOUN
dpc-6010	60	4	(	(	PUNCT
dpc-6010	60	5	3/23	3/23	NUM
dpc-6010	60	6	)	)	PUNCT
dpc-6010	60	7	of	of	ADP
dpc-6010	60	8	patients	patient	NOUN
dpc-6010	60	9	had	have	AUX
dpc-6010	60	10	been	be	AUX
dpc-6010	60	11	diagnosed	diagnose	VERB
dpc-6010	60	12	with	with	ADP
dpc-6010	60	13	oligoarticular	oligoarticular	ADJ
dpc-6010	60	14	psoriatic	psoriatic	ADJ
dpc-6010	60	15	arthritis	arthritis	NOUN
dpc-6010	60	16	(	(	PUNCT
dpc-6010	60	17	psa	psa	NOUN
dpc-6010	60	18	)	)	PUNCT
dpc-6010	60	19	yet	yet	ADV
dpc-6010	60	20	were	be	AUX
dpc-6010	60	21	in	in	ADP
dpc-6010	60	22	complete	complete	ADJ
dpc-6010	60	23	and	and	CCONJ
dpc-6010	60	24	stable	stable	ADJ
dpc-6010	60	25	remission	remission	NOUN
dpc-6010	60	26	at	at	ADP
dpc-6010	60	27	the	the	DET
dpc-6010	60	28	time	time	NOUN
dpc-6010	60	29	of	of	ADP
dpc-6010	60	30	brodalumab	brodalumab	NOUN
dpc-6010	60	31	prescription	prescription	NOUN
dpc-6010	60	32	.	.	PUNCT
dpc-6010	61	1	baseline	baseline	PROPN
dpc-6010	61	2	demographic	demographic	ADJ
dpc-6010	61	3	characteristics	characteristic	NOUN
dpc-6010	61	4	were	be	AUX
dpc-6010	61	5	summarized	summarize	VERB
dpc-6010	61	6	in	in	ADP
dpc-6010	61	7	table	table	NOUN
dpc-6010	61	8	1	1	NUM
dpc-6010	61	9	.	.	PUNCT
dpc-6010	62	1	all	all	DET
dpc-6010	62	2	patients	patient	NOUN
dpc-6010	62	3	involved	involve	VERB
dpc-6010	62	4	in	in	ADP
dpc-6010	62	5	the	the	DET
dpc-6010	62	6	study	study	NOUN
dpc-6010	62	7	(	(	PUNCT
dpc-6010	62	8	n=23	n=23	PROPN
dpc-6010	62	9	)	)	PUNCT
dpc-6010	62	10	had	have	AUX
dpc-6010	62	11	previously	previously	ADV
dpc-6010	62	12	received	receive	VERB
dpc-6010	62	13	unsuccessful	unsuccessful	ADJ
dpc-6010	62	14	treatment	treatment	NOUN
dpc-6010	62	15	with	with	ADP
dpc-6010	62	16	traditional	traditional	ADJ
dpc-6010	62	17	dmards	dmard	NOUN
dpc-6010	62	18	and	and	CCONJ
dpc-6010	62	19	were	be	AUX
dpc-6010	62	20	receiving	receive	VERB
dpc-6010	62	21	,	,	PUNCT
dpc-6010	62	22	at	at	ADP
dpc-6010	62	23	the	the	DET
dpc-6010	62	24	time	time	NOUN
dpc-6010	62	25	of	of	ADP
dpc-6010	62	26	enrollment	enrollment	NOUN
dpc-6010	62	27	,	,	PUNCT
dpc-6010	62	28	one	one	NUM
dpc-6010	62	29	of	of	ADP
dpc-6010	62	30	the	the	DET
dpc-6010	62	31	following	follow	VERB
dpc-6010	62	32	anti	anti	NOUN
dpc-6010	62	33	-	-	NOUN
dpc-6010	62	34	il-23	il-23	NOUN
dpc-6010	62	35	or	or	CCONJ
dpc-6010	62	36	12/23	12/23	NUM
dpc-6010	62	37	inhibitors	inhibitor	NOUN
dpc-6010	62	38	–	–	PUNCT
dpc-6010	62	39	guselkumab	guselkumab	NOUN
dpc-6010	62	40	,	,	PUNCT
dpc-6010	62	41	tildrakizumab	tildrakizumab	NOUN
dpc-6010	62	42	,	,	PUNCT
dpc-6010	62	43	risankizumab	risankizumab	NOUN
dpc-6010	62	44	,	,	PUNCT
dpc-6010	62	45	or	or	CCONJ
dpc-6010	62	46	ustekinumab	ustekinumab	NOUN
dpc-6010	62	47	–	–	PUNCT
dpc-6010	62	48	as	as	ADP
dpc-6010	62	49	their	their	PRON
dpc-6010	62	50	first	first	ADJ
dpc-6010	62	51	biological	biological	ADJ
dpc-6010	62	52	treatment	treatment	NOUN
dpc-6010	62	53	.	.	PUNCT
dpc-6010	63	1	most	most	ADJ
dpc-6010	63	2	participants	participant	NOUN
dpc-6010	63	3	(	(	PUNCT
dpc-6010	63	4	14	14	NUM
dpc-6010	63	5	,	,	PUNCT
dpc-6010	63	6	60.8	60.8	NUM
dpc-6010	63	7	%	%	NOUN
dpc-6010	63	8	)	)	PUNCT
dpc-6010	63	9	were	be	AUX
dpc-6010	63	10	on	on	ADP
dpc-6010	63	11	anti	anti	ADJ
dpc-6010	63	12	-	-	ADJ
dpc-6010	63	13	il23	il23	ADJ
dpc-6010	63	14	treatment	treatment	NOUN
dpc-6010	63	15	at	at	ADP
dpc-6010	63	16	the	the	DET
dpc-6010	63	17	time	time	NOUN
dpc-6010	63	18	of	of	ADP
dpc-6010	63	19	switching	switch	VERB
dpc-6010	63	20	to	to	AUX
dpc-6010	63	21	brodalumab	brodalumab	VERB
dpc-6010	63	22	,	,	PUNCT
dpc-6010	63	23	while	while	SCONJ
dpc-6010	63	24	nine	nine	NUM
dpc-6010	63	25	patients	patient	NOUN
dpc-6010	63	26	(	(	PUNCT
dpc-6010	63	27	39.1	39.1	NUM
dpc-6010	63	28	%	%	NOUN
dpc-6010	63	29	)	)	PUNCT
dpc-6010	63	30	were	be	AUX
dpc-6010	63	31	on	on	ADP
dpc-6010	63	32	ustekinumab	ustekinumab	NOUN
dpc-6010	63	33	(	(	PUNCT
dpc-6010	63	34	anti	anti	ADJ
dpc-6010	63	35	-	-	NOUN
dpc-6010	63	36	il12/23	il12/23	NOUN
dpc-6010	63	37	)	)	PUNCT
dpc-6010	63	38	.	.	PUNCT
dpc-6010	64	1	previous	previous	ADJ
dpc-6010	64	2	biological	biological	ADJ
dpc-6010	64	3	treatments	treatment	NOUN
dpc-6010	64	4	used	use	VERB
dpc-6010	64	5	by	by	ADP
dpc-6010	64	6	the	the	DET
dpc-6010	64	7	study	study	NOUN
dpc-6010	64	8	population	population	NOUN
dpc-6010	64	9	are	be	AUX
dpc-6010	64	10	summarized	summarize	VERB
dpc-6010	64	11	in	in	ADP
dpc-6010	64	12	table	table	NOUN
dpc-6010	64	13	2	2	NUM
dpc-6010	64	14	.	.	PUNCT
dpc-6010	65	1	the	the	DET
dpc-6010	65	2	mean	mean	ADJ
dpc-6010	65	3	pasi	pasi	NOUN
dpc-6010	65	4	decreased	decrease	VERB
dpc-6010	65	5	significantly	significantly	ADV
dpc-6010	65	6	after	after	ADP
dpc-6010	65	7	the	the	DET
dpc-6010	65	8	introduction	introduction	NOUN
dpc-6010	65	9	of	of	ADP
dpc-6010	65	10	brodalumab	brodalumab	NOUN
dpc-6010	65	11	as	as	ADV
dpc-6010	65	12	early	early	ADV
dpc-6010	65	13	as	as	ADP
dpc-6010	65	14	week	week	NOUN
dpc-6010	65	15	4	4	NUM
dpc-6010	65	16	of	of	ADP
dpc-6010	65	17	treatment	treatment	NOUN
dpc-6010	65	18	,	,	PUNCT
dpc-6010	65	19	from	from	ADP
dpc-6010	65	20	a	a	DET
dpc-6010	65	21	mean	mean	ADJ
dpc-6010	65	22	value	value	NOUN
dpc-6010	65	23	of	of	ADP
dpc-6010	65	24	14.6	14.6	NUM
dpc-6010	65	25	±	±	NUM
dpc-6010	65	26	9.2	9.2	NUM
dpc-6010	65	27	to	to	ADP
dpc-6010	65	28	6.0	6.0	NUM
dpc-6010	65	29	±	±	NUM
dpc-6010	65	30	7.1	7.1	NUM
dpc-6010	65	31	(	(	PUNCT
dpc-6010	65	32	p<0.001	p<0.001	PROPN
dpc-6010	65	33	)	)	PUNCT
dpc-6010	65	34	.	.	PUNCT
dpc-6010	66	1	the	the	DET
dpc-6010	66	2	trend	trend	NOUN
dpc-6010	66	3	of	of	ADP
dpc-6010	66	4	pasi	pasi	NOUN
dpc-6010	66	5	improvement	improvement	NOUN
dpc-6010	66	6	persisted	persist	VERB
dpc-6010	66	7	during	during	ADP
dpc-6010	66	8	follow	follow	NOUN
dpc-6010	66	9	-	-	PUNCT
dpc-6010	66	10	up	up	ADP
dpc-6010	66	11	assessments	assessment	NOUN
dpc-6010	66	12	performed	perform	VERB
dpc-6010	66	13	at	at	ADP
dpc-6010	66	14	16	16	NUM
dpc-6010	66	15	and	and	CCONJ
dpc-6010	66	16	36	36	NUM
dpc-6010	66	17	weeks	week	NOUN
dpc-6010	66	18	,	,	PUNCT
dpc-6010	66	19	reaching	reach	VERB
dpc-6010	66	20	the	the	DET
dpc-6010	66	21	nadir	nadir	NOUN
dpc-6010	66	22	at	at	ADP
dpc-6010	66	23	52	52	NUM
dpc-6010	66	24	weeks	week	NOUN
dpc-6010	66	25	(	(	PUNCT
dpc-6010	66	26	pasi	pasi	NOUN
dpc-6010	66	27	:	:	PUNCT
dpc-6010	66	28	1.1	1.1	NUM
dpc-6010	66	29	±	±	NUM
dpc-6010	66	30	1.8	1.8	NUM
dpc-6010	66	31	;	;	PUNCT
dpc-6010	66	32	p<0.001	p<0.001	X
dpc-6010	66	33	)	)	PUNCT
dpc-6010	66	34	(	(	PUNCT
dpc-6010	66	35	table	table	NOUN
dpc-6010	66	36	3	3	NUM
dpc-6010	66	37	,	,	PUNCT
dpc-6010	66	38	figure	figure	NOUN
dpc-6010	66	39	  	  	SPACE
dpc-6010	66	40	1	1	NUM
dpc-6010	66	41	)	)	PUNCT
dpc-6010	66	42	.	.	PUNCT
dpc-6010	67	1	the	the	DET
dpc-6010	67	2	percentages	percentage	NOUN
dpc-6010	67	3	of	of	ADP
dpc-6010	67	4	patients	patient	NOUN
dpc-6010	67	5	who	who	PRON
dpc-6010	67	6	progressively	progressively	ADV
dpc-6010	67	7	achieved	achieve	VERB
dpc-6010	67	8	the	the	DET
dpc-6010	67	9	pasi	pasi	NOUN
dpc-6010	67	10	75	75	NUM
dpc-6010	67	11	,	,	PUNCT
dpc-6010	67	12	90	90	NUM
dpc-6010	67	13	,	,	PUNCT
dpc-6010	67	14	and	and	CCONJ
dpc-6010	67	15	100	100	NUM
dpc-6010	67	16	clinical	clinical	ADJ
dpc-6010	67	17	responses	response	NOUN
dpc-6010	67	18	on	on	ADP
dpc-6010	67	19	assessments	assessment	NOUN
dpc-6010	67	20	performed	perform	VERB
dpc-6010	67	21	at	at	ADP
dpc-6010	67	22	the	the	DET
dpc-6010	67	23	scheduled	schedule	VERB
dpc-6010	67	24	timepoints	timepoint	NOUN
dpc-6010	67	25	are	be	AUX
dpc-6010	67	26	shown	show	VERB
dpc-6010	67	27	in	in	ADP
dpc-6010	67	28	table	table	NOUN
dpc-6010	67	29	4	4	NUM
dpc-6010	67	30	and	and	CCONJ
dpc-6010	67	31	depicted	depict	VERB
dpc-6010	67	32	graphically	graphically	ADV
dpc-6010	67	33	in	in	ADP
dpc-6010	67	34	figure	figure	NOUN
dpc-6010	67	35	2	2	NUM
dpc-6010	67	36	.	.	PUNCT
dpc-6010	67	37	mirroring	mirror	VERB
dpc-6010	67	38	the	the	DET
dpc-6010	67	39	results	result	NOUN
dpc-6010	67	40	obtained	obtain	VERB
dpc-6010	67	41	on	on	ADP
dpc-6010	67	42	disease	disease	NOUN
dpc-6010	67	43	severity	severity	NOUN
dpc-6010	67	44	,	,	PUNCT
dpc-6010	67	45	the	the	DET
dpc-6010	67	46	dlqi	dlqi	NOUN
dpc-6010	67	47	also	also	ADV
dpc-6010	67	48	improved	improve	VERB
dpc-6010	67	49	significantly	significantly	ADV
dpc-6010	67	50	in	in	ADP
dpc-6010	67	51	our	our	PRON
dpc-6010	67	52	study	study	NOUN
dpc-6010	67	53	population	population	NOUN
dpc-6010	67	54	,	,	PUNCT
dpc-6010	67	55	dropping	drop	VERB
dpc-6010	67	56	to	to	ADP
dpc-6010	67	57	1/3	1/3	NUM
dpc-6010	67	58	of	of	ADP
dpc-6010	67	59	the	the	DET
dpc-6010	67	60	baseline	baseline	NOUN
dpc-6010	67	61	level	level	NOUN
dpc-6010	67	62	after	after	ADP
dpc-6010	67	63	just	just	ADV
dpc-6010	67	64	four	four	NUM
dpc-6010	67	65	weeks	week	NOUN
dpc-6010	67	66	of	of	ADP
dpc-6010	67	67	treatment	treatment	NOUN
dpc-6010	67	68	with	with	ADP
dpc-6010	67	69	brodalumab	brodalumab	NOUN
dpc-6010	67	70	(	(	PUNCT
dpc-6010	67	71	baseline	baseline	NOUN
dpc-6010	67	72	:	:	PUNCT
dpc-6010	67	73	16.9	16.9	NUM
dpc-6010	67	74	±	±	NUM
dpc-6010	67	75	7.6	7.6	NUM
dpc-6010	67	76	vs.	vs.	ADP
dpc-6010	67	77	4	4	NUM
dpc-6010	67	78	weeks	week	NOUN
dpc-6010	67	79	:	:	PUNCT
dpc-6010	67	80	5.1	5.1	NUM
dpc-6010	67	81	±	±	NUM
dpc-6010	67	82	7.0	7.0	NUM
dpc-6010	67	83	;	;	PUNCT
dpc-6010	67	84	p<0.001	p<0.001	X
dpc-6010	67	85	)	)	PUNCT
dpc-6010	67	86	and	and	CCONJ
dpc-6010	67	87	reaching	reach	VERB
dpc-6010	67	88	the	the	DET
dpc-6010	67	89	lowest	low	ADJ
dpc-6010	67	90	value	value	NOUN
dpc-6010	67	91	after	after	ADP
dpc-6010	67	92	52	52	NUM
dpc-6010	67	93	weeks	week	NOUN
dpc-6010	67	94	of	of	ADP
dpc-6010	67	95	treatment	treatment	NOUN
dpc-6010	67	96	(	(	PUNCT
dpc-6010	67	97	1.8	1.8	NUM
dpc-6010	67	98	±	±	NUM
dpc-6010	67	99	3.8	3.8	NUM
dpc-6010	67	100	;	;	PUNCT
dpc-6010	67	101	p<0.001	p<0.001	X
dpc-6010	67	102	)	)	PUNCT
dpc-6010	67	103	.	.	PUNCT
dpc-6010	68	1	the	the	DET
dpc-6010	68	2	trend	trend	NOUN
dpc-6010	68	3	of	of	ADP
dpc-6010	68	4	the	the	DET
dpc-6010	68	5	dlqi	dlqi	NOUN
dpc-6010	68	6	across	across	ADP
dpc-6010	68	7	all	all	DET
dpc-6010	68	8	assessments	assessment	NOUN
dpc-6010	68	9	is	be	AUX
dpc-6010	68	10	summarized	summarize	VERB
dpc-6010	68	11	in	in	ADP
dpc-6010	68	12	table	table	NOUN
dpc-6010	68	13	5	5	NUM
dpc-6010	68	14	and	and	CCONJ
dpc-6010	68	15	graphically	graphically	ADV
dpc-6010	68	16	represented	represent	VERB
dpc-6010	68	17	in	in	ADP
dpc-6010	68	18	figure	figure	NOUN
dpc-6010	68	19	3	3	NUM
dpc-6010	68	20	.	.	PUNCT
dpc-6010	68	21	of	of	ADP
dpc-6010	68	22	note	note	NOUN
dpc-6010	68	23	,	,	PUNCT
dpc-6010	68	24	two	two	NUM
dpc-6010	68	25	patients	patient	NOUN
dpc-6010	68	26	(	(	PUNCT
dpc-6010	68	27	8.7	8.7	NUM
dpc-6010	68	28	%	%	NOUN
dpc-6010	68	29	)	)	PUNCT
dpc-6010	68	30	calculated	calculate	VERB
dpc-6010	68	31	for	for	ADP
dpc-6010	68	32	continuous	continuous	ADJ
dpc-6010	68	33	variables	variable	NOUN
dpc-6010	68	34	,	,	PUNCT
dpc-6010	68	35	while	while	SCONJ
dpc-6010	68	36	absolute	absolute	ADJ
dpc-6010	68	37	values	value	NOUN
dpc-6010	68	38	and	and	CCONJ
dpc-6010	68	39	frequency	frequency	NOUN
dpc-6010	68	40	(	(	PUNCT
dpc-6010	68	41	%	%	INTJ
dpc-6010	68	42	)	)	PUNCT
dpc-6010	68	43	were	be	AUX
dpc-6010	68	44	calculated	calculate	VERB
dpc-6010	68	45	for	for	ADP
dpc-6010	68	46	categorical	categorical	ADJ
dpc-6010	68	47	variables	variable	NOUN
dpc-6010	68	48	.	.	PUNCT
dpc-6010	69	1	a	a	DET
dpc-6010	69	2	t	t	NOUN
dpc-6010	69	3	-	-	PUNCT
dpc-6010	69	4	test	test	NOUN
dpc-6010	69	5	or	or	CCONJ
dpc-6010	69	6	analysis	analysis	NOUN
dpc-6010	69	7	of	of	ADP
dpc-6010	69	8	variance	variance	NOUN
dpc-6010	69	9	was	be	AUX
dpc-6010	69	10	performed	perform	VERB
dpc-6010	69	11	to	to	PART
dpc-6010	69	12	compare	compare	VERB
dpc-6010	69	13	mean	mean	ADJ
dpc-6010	69	14	values	value	NOUN
dpc-6010	69	15	,	,	PUNCT
dpc-6010	69	16	while	while	SCONJ
dpc-6010	69	17	a	a	DET
dpc-6010	69	18	paired	pair	VERB
dpc-6010	69	19	t	t	NOUN
dpc-6010	69	20	-	-	PUNCT
dpc-6010	69	21	test	test	NOUN
dpc-6010	69	22	compared	compare	VERB
dpc-6010	69	23	mean	mean	ADJ
dpc-6010	69	24	values	value	NOUN
dpc-6010	69	25	at	at	ADP
dpc-6010	69	26	different	different	ADJ
dpc-6010	69	27	timepoints	timepoint	NOUN
dpc-6010	69	28	.	.	PUNCT
dpc-6010	70	1	the	the	DET
dpc-6010	70	2	chi	chi	NOUN
dpc-6010	70	3	-	-	PUNCT
dpc-6010	70	4	squared	square	VERB
dpc-6010	70	5	test	test	NOUN
dpc-6010	70	6	was	be	AUX
dpc-6010	70	7	used	use	VERB
dpc-6010	70	8	to	to	PART
dpc-6010	70	9	compare	compare	VERB
dpc-6010	70	10	frequencies	frequency	NOUN
dpc-6010	70	11	.	.	PUNCT
dpc-6010	71	1	the	the	DET
dpc-6010	71	2	statistical	statistical	ADJ
dpc-6010	71	3	significance	significance	NOUN
dpc-6010	71	4	was	be	AUX
dpc-6010	71	5	defined	define	VERB
dpc-6010	71	6	as	as	ADP
dpc-6010	71	7	p<0.05	p<0.05	NOUN
dpc-6010	71	8	.	.	PUNCT
dpc-6010	72	1	all	all	DET
dpc-6010	72	2	analyses	analysis	NOUN
dpc-6010	72	3	were	be	AUX
dpc-6010	72	4	performed	perform	VERB
dpc-6010	72	5	with	with	ADP
dpc-6010	72	6	ibm	ibm	PROPN
dpc-6010	72	7	spss	spss	PROPN
dpc-6010	72	8	statistics	statistic	NOUN
dpc-6010	72	9	for	for	ADP
dpc-6010	72	10	windows	window	NOUN
dpc-6010	72	11	,	,	PUNCT
dpc-6010	72	12	version	version	NOUN
dpc-6010	72	13	26.0	26.0	NUM
dpc-6010	72	14	.	.	PUNCT
dpc-6010	73	1	results	result	VERB
dpc-6010	73	2	the	the	DET
dpc-6010	73	3	mean	mean	ADJ
dpc-6010	73	4	age	age	NOUN
dpc-6010	73	5	of	of	ADP
dpc-6010	73	6	the	the	DET
dpc-6010	73	7	patients	patient	NOUN
dpc-6010	73	8	enrolled	enrol	VERB
dpc-6010	73	9	was	be	AUX
dpc-6010	73	10	56.7	56.7	NUM
dpc-6010	73	11	±	±	NUM
dpc-6010	73	12	13.9	13.9	NUM
dpc-6010	73	13	years	year	NOUN
dpc-6010	73	14	.	.	PUNCT
dpc-6010	74	1	only	only	ADV
dpc-6010	74	2	4/23	4/23	NUM
dpc-6010	74	3	(	(	PUNCT
dpc-6010	74	4	17.4	17.4	NUM
dpc-6010	74	5	%	%	NOUN
dpc-6010	74	6	)	)	PUNCT
dpc-6010	74	7	patients	patient	NOUN
dpc-6010	74	8	were	be	AUX
dpc-6010	74	9	normal	normal	ADJ
dpc-6010	74	10	weight	weight	NOUN
dpc-6010	74	11	,	,	PUNCT
dpc-6010	74	12	while	while	SCONJ
dpc-6010	74	13	the	the	DET
dpc-6010	74	14	table	table	NOUN
dpc-6010	74	15	1	1	NUM
dpc-6010	74	16	.	.	PUNCT
dpc-6010	75	1	clinical	clinical	ADJ
dpc-6010	75	2	and	and	CCONJ
dpc-6010	75	3	demographic	demographic	ADJ
dpc-6010	75	4	characteristics	characteristic	NOUN
dpc-6010	75	5	of	of	ADP
dpc-6010	75	6	our	our	PRON
dpc-6010	75	7	population	population	NOUN
dpc-6010	75	8	at	at	ADP
dpc-6010	75	9	baseline	baseline	NOUN
dpc-6010	75	10	visit	visit	NOUN
dpc-6010	75	11	.	.	PUNCT
dpc-6010	76	1	demography	demography	NOUN
dpc-6010	76	2	n=23	n=23	PROPN
dpc-6010	76	3	male	male	PROPN
dpc-6010	76	4	,	,	PUNCT
dpc-6010	76	5	n	n	PROPN
dpc-6010	76	6	(	(	PUNCT
dpc-6010	76	7	%	%	INTJ
dpc-6010	76	8	)	)	PUNCT
dpc-6010	76	9	age	age	NOUN
dpc-6010	76	10	(	(	PUNCT
dpc-6010	76	11	years	year	NOUN
dpc-6010	76	12	)	)	PUNCT
dpc-6010	76	13	,	,	PUNCT
dpc-6010	76	14	mean	mean	VERB
dpc-6010	76	15	±	±	NUM
dpc-6010	76	16	sd	sd	ADP
dpc-6010	76	17	disease	disease	NOUN
dpc-6010	76	18	duration	duration	NOUN
dpc-6010	76	19	(	(	PUNCT
dpc-6010	76	20	years	year	NOUN
dpc-6010	76	21	)	)	PUNCT
dpc-6010	76	22	,	,	PUNCT
dpc-6010	76	23	mean	mean	VERB
dpc-6010	76	24	±	±	NUM
dpc-6010	76	25	sd	sd	ADP
dpc-6010	76	26	bmi	bmi	NOUN
dpc-6010	76	27	,	,	PUNCT
dpc-6010	76	28	mean	mean	VERB
dpc-6010	76	29	±	±	NUM
dpc-6010	76	30	sd	sd	ADP
dpc-6010	76	31	obese	obese	NOUN
dpc-6010	76	32	,	,	PUNCT
dpc-6010	76	33	n	n	CCONJ
dpc-6010	76	34	(	(	PUNCT
dpc-6010	76	35	%	%	INTJ
dpc-6010	76	36	)	)	PUNCT
dpc-6010	76	37	overweight	overweight	NOUN
dpc-6010	76	38	,	,	PUNCT
dpc-6010	76	39	n	n	CCONJ
dpc-6010	76	40	(	(	PUNCT
dpc-6010	76	41	%	%	INTJ
dpc-6010	76	42	)	)	PUNCT
dpc-6010	76	43	normal	normal	ADJ
dpc-6010	76	44	weight	weight	NOUN
dpc-6010	76	45	,	,	PUNCT
dpc-6010	76	46	n	n	CCONJ
dpc-6010	76	47	(	(	PUNCT
dpc-6010	76	48	%	%	INTJ
dpc-6010	76	49	)	)	PUNCT
dpc-6010	76	50	diabetes	diabetes	NOUN
dpc-6010	76	51	,	,	PUNCT
dpc-6010	76	52	n	n	CCONJ
dpc-6010	76	53	(	(	PUNCT
dpc-6010	76	54	%	%	INTJ
dpc-6010	76	55	)	)	PUNCT
dpc-6010	76	56	hypertension	hypertension	NOUN
dpc-6010	76	57	,	,	PUNCT
dpc-6010	76	58	n	n	CCONJ
dpc-6010	76	59	(	(	PUNCT
dpc-6010	76	60	%	%	INTJ
dpc-6010	76	61	)	)	PUNCT
dpc-6010	76	62	hyperlipidemia	hyperlipidemia	NOUN
dpc-6010	76	63	,	,	PUNCT
dpc-6010	76	64	n	n	PROPN
dpc-6010	76	65	(	(	PUNCT
dpc-6010	76	66	%	%	INTJ
dpc-6010	76	67	)	)	PUNCT
dpc-6010	76	68	thyroid	thyroid	NOUN
dpc-6010	76	69	disease	disease	NOUN
dpc-6010	76	70	,	,	PUNCT
dpc-6010	76	71	n	n	CCONJ
dpc-6010	76	72	(	(	PUNCT
dpc-6010	76	73	%	%	INTJ
dpc-6010	76	74	)	)	PUNCT
dpc-6010	76	75	cardiopathy	cardiopathy	ADJ
dpc-6010	76	76	,	,	PUNCT
dpc-6010	76	77	n	n	CCONJ
dpc-6010	76	78	(	(	PUNCT
dpc-6010	76	79	%	%	INTJ
dpc-6010	76	80	)	)	PUNCT
dpc-6010	76	81	other	other	ADJ
dpc-6010	76	82	,	,	PUNCT
dpc-6010	76	83	n	n	PROPN
dpc-6010	76	84	(	(	PUNCT
dpc-6010	76	85	%	%	INTJ
dpc-6010	76	86	)	)	PUNCT
dpc-6010	76	87	psa	psa	NOUN
dpc-6010	76	88	,	,	PUNCT
dpc-6010	76	89	n	n	CCONJ
dpc-6010	76	90	(	(	PUNCT
dpc-6010	76	91	%	%	INTJ
dpc-6010	76	92	)	)	PUNCT
dpc-6010	76	93	≥	≥	NOUN
dpc-6010	76	94	1	1	NUM
dpc-6010	76	95	difficult	difficult	ADJ
dpc-6010	76	96	-	-	PUNCT
dpc-6010	76	97	to	to	ADP
dpc-6010	76	98	-	-	PUNCT
dpc-6010	76	99	treat	treat	NOUN
dpc-6010	76	100	areas	area	NOUN
dpc-6010	76	101	,	,	PUNCT
dpc-6010	76	102	n	n	CCONJ
dpc-6010	76	103	(	(	PUNCT
dpc-6010	76	104	%	%	INTJ
dpc-6010	76	105	)	)	PUNCT
dpc-6010	76	106	pasi	pasi	PROPN
dpc-6010	76	107	baseline	baseline	PROPN
dpc-6010	76	108	,	,	PUNCT
dpc-6010	76	109	mean	mean	VERB
dpc-6010	76	110	±	±	NUM
dpc-6010	76	111	sd	sd	ADP
dpc-6010	76	112	naïve	naïve	ADJ
dpc-6010	76	113	for	for	ADP
dpc-6010	76	114	systemic	systemic	ADJ
dpc-6010	76	115	therapies	therapy	NOUN
dpc-6010	76	116	,	,	PUNCT
dpc-6010	76	117	n	n	PROPN
dpc-6010	76	118	(	(	PUNCT
dpc-6010	76	119	%	%	INTJ
dpc-6010	76	120	)	)	PUNCT
dpc-6010	76	121	18	18	NUM
dpc-6010	76	122	(	(	PUNCT
dpc-6010	76	123	78.3	78.3	NUM
dpc-6010	76	124	%	%	NOUN
dpc-6010	76	125	)	)	PUNCT
dpc-6010	76	126	56.7	56.7	NUM
dpc-6010	76	127	(	(	PUNCT
dpc-6010	76	128	±	±	NOUN
dpc-6010	76	129	13.9	13.9	NUM
dpc-6010	76	130	)	)	PUNCT
dpc-6010	76	131	20.4	20.4	NUM
dpc-6010	76	132	(	(	PUNCT
dpc-6010	76	133	±	±	NUM
dpc-6010	76	134	9.7	9.7	NUM
dpc-6010	76	135	)	)	PUNCT
dpc-6010	76	136	28.8	28.8	NUM
dpc-6010	76	137	(	(	PUNCT
dpc-6010	76	138	±	±	NUM
dpc-6010	76	139	5.9	5.9	NUM
dpc-6010	76	140	)	)	PUNCT
dpc-6010	76	141	7	7	NUM
dpc-6010	76	142	(	(	PUNCT
dpc-6010	76	143	30.4	30.4	NUM
dpc-6010	76	144	%	%	NOUN
dpc-6010	76	145	)	)	PUNCT
dpc-6010	76	146	19	19	NUM
dpc-6010	76	147	(	(	PUNCT
dpc-6010	76	148	82.6	82.6	NUM
dpc-6010	76	149	%	%	NOUN
dpc-6010	76	150	)	)	PUNCT
dpc-6010	76	151	4	4	NUM
dpc-6010	76	152	(	(	PUNCT
dpc-6010	76	153	17.4	17.4	NUM
dpc-6010	76	154	%	%	NOUN
dpc-6010	76	155	)	)	PUNCT
dpc-6010	76	156	2	2	NUM
dpc-6010	76	157	(	(	PUNCT
dpc-6010	76	158	2.9	2.9	NUM
dpc-6010	76	159	%	%	NOUN
dpc-6010	76	160	)	)	PUNCT
dpc-6010	76	161	10	10	NUM
dpc-6010	76	162	(	(	PUNCT
dpc-6010	76	163	43.5	43.5	NUM
dpc-6010	76	164	%	%	NOUN
dpc-6010	76	165	)	)	PUNCT
dpc-6010	76	166	8	8	NUM
dpc-6010	76	167	(	(	PUNCT
dpc-6010	76	168	34.8	34.8	NUM
dpc-6010	76	169	%	%	NOUN
dpc-6010	76	170	)	)	PUNCT
dpc-6010	76	171	1	1	NUM
dpc-6010	76	172	(	(	PUNCT
dpc-6010	76	173	4.3	4.3	NUM
dpc-6010	76	174	%	%	NOUN
dpc-6010	76	175	)	)	PUNCT
dpc-6010	76	176	3	3	NUM
dpc-6010	76	177	(	(	PUNCT
dpc-6010	76	178	13.0	13.0	NUM
dpc-6010	76	179	%	%	NOUN
dpc-6010	76	180	)	)	PUNCT
dpc-6010	76	181	3	3	NUM
dpc-6010	76	182	(	(	PUNCT
dpc-6010	76	183	13.0	13.0	NUM
dpc-6010	76	184	%	%	NOUN
dpc-6010	76	185	)	)	PUNCT
dpc-6010	76	186	3	3	NUM
dpc-6010	76	187	(	(	PUNCT
dpc-6010	76	188	13.0	13.0	NUM
dpc-6010	76	189	%	%	NOUN
dpc-6010	76	190	)	)	PUNCT
dpc-6010	76	191	23	23	NUM
dpc-6010	76	192	(	(	PUNCT
dpc-6010	76	193	100	100	NUM
dpc-6010	76	194	%	%	NOUN
dpc-6010	76	195	)	)	PUNCT
dpc-6010	76	196	14.4	14.4	NUM
dpc-6010	76	197	(	(	PUNCT
dpc-6010	76	198	±	±	NUM
dpc-6010	76	199	9.1	9.1	NUM
dpc-6010	76	200	)	)	PUNCT
dpc-6010	76	201	0	0	NUM
dpc-6010	76	202	table	table	NOUN
dpc-6010	76	203	2	2	NUM
dpc-6010	76	204	.	.	PUNCT
dpc-6010	77	1	last	last	ADJ
dpc-6010	77	2	previous	previous	ADJ
dpc-6010	77	3	biological	biological	ADJ
dpc-6010	77	4	therapies	therapy	NOUN
dpc-6010	77	5	.	.	PUNCT
dpc-6010	78	1	last	last	ADJ
dpc-6010	78	2	previous	previous	ADJ
dpc-6010	78	3	biological	biological	ADJ
dpc-6010	78	4	therapy	therapy	NOUN
dpc-6010	78	5	  	  	SPACE
dpc-6010	78	6	n=23	n=23	PROPN
dpc-6010	78	7	  	  	SPACE
dpc-6010	78	8	reason	reason	NOUN
dpc-6010	78	9	for	for	ADP
dpc-6010	78	10	discontinuation	discontinuation	NOUN
dpc-6010	78	11	guselkumab	guselkumab	NOUN
dpc-6010	78	12	  	  	SPACE
dpc-6010	78	13	6	6	NUM
dpc-6010	78	14	(	(	PUNCT
dpc-6010	78	15	26.1	26.1	NUM
dpc-6010	78	16	%	%	NOUN
dpc-6010	78	17	)	)	PUNCT
dpc-6010	78	18	  	  	SPACE
dpc-6010	78	19	primary	primary	ADJ
dpc-6010	78	20	inefficacy	inefficacy	NOUN
dpc-6010	78	21	(	(	PUNCT
dpc-6010	78	22	1	1	NUM
dpc-6010	78	23	,	,	PUNCT
dpc-6010	78	24	16.7	16.7	NUM
dpc-6010	78	25	%	%	NOUN
dpc-6010	78	26	)	)	PUNCT
dpc-6010	78	27	loss	loss	NOUN
dpc-6010	78	28	of	of	ADP
dpc-6010	78	29	efficacy	efficacy	NOUN
dpc-6010	78	30	(	(	PUNCT
dpc-6010	78	31	5	5	NUM
dpc-6010	78	32	,	,	PUNCT
dpc-6010	78	33	83.3	83.3	NUM
dpc-6010	78	34	%	%	NOUN
dpc-6010	78	35	)	)	PUNCT
dpc-6010	78	36	risankizumab	risankizumab	VERB
dpc-6010	78	37	3	3	NUM
dpc-6010	78	38	(	(	PUNCT
dpc-6010	78	39	13.0	13.0	NUM
dpc-6010	78	40	%	%	NOUN
dpc-6010	78	41	)	)	PUNCT
dpc-6010	78	42	primary	primary	ADJ
dpc-6010	78	43	inefficacy	inefficacy	NOUN
dpc-6010	78	44	(	(	PUNCT
dpc-6010	78	45	1	1	NUM
dpc-6010	78	46	,	,	PUNCT
dpc-6010	78	47	33.3	33.3	NUM
dpc-6010	78	48	%	%	NOUN
dpc-6010	78	49	)	)	PUNCT
dpc-6010	78	50	loss	loss	NOUN
dpc-6010	78	51	of	of	ADP
dpc-6010	78	52	efficacy	efficacy	NOUN
dpc-6010	78	53	(	(	PUNCT
dpc-6010	78	54	1	1	NUM
dpc-6010	78	55	,	,	PUNCT
dpc-6010	78	56	33.3	33.3	NUM
dpc-6010	78	57	%	%	NOUN
dpc-6010	78	58	)	)	PUNCT
dpc-6010	78	59	other	other	ADJ
dpc-6010	78	60	(	(	PUNCT
dpc-6010	78	61	1	1	NUM
dpc-6010	78	62	,	,	PUNCT
dpc-6010	78	63	33.3	33.3	NUM
dpc-6010	78	64	%	%	NOUN
dpc-6010	78	65	)	)	PUNCT
dpc-6010	78	66	tildrakizumab	tildrakizumab	NOUN
dpc-6010	78	67	5	5	NUM
dpc-6010	78	68	(	(	PUNCT
dpc-6010	78	69	21.7	21.7	NUM
dpc-6010	78	70	%	%	NOUN
dpc-6010	78	71	)	)	PUNCT
dpc-6010	78	72	  	  	SPACE
dpc-6010	78	73	primary	primary	ADJ
dpc-6010	78	74	inefficacy	inefficacy	NOUN
dpc-6010	78	75	(	(	PUNCT
dpc-6010	78	76	1	1	NUM
dpc-6010	78	77	,	,	PUNCT
dpc-6010	78	78	20.0	20.0	NUM
dpc-6010	78	79	%	%	NOUN
dpc-6010	78	80	)	)	PUNCT
dpc-6010	78	81	loss	loss	NOUN
dpc-6010	78	82	of	of	ADP
dpc-6010	78	83	efficacy	efficacy	NOUN
dpc-6010	78	84	(	(	PUNCT
dpc-6010	78	85	4	4	NUM
dpc-6010	78	86	,	,	PUNCT
dpc-6010	78	87	80.0	80.0	NUM
dpc-6010	78	88	%	%	NOUN
dpc-6010	78	89	)	)	PUNCT
dpc-6010	78	90	ustekinumab	ustekinumab	NOUN
dpc-6010	78	91	9	9	NUM
dpc-6010	78	92	(	(	PUNCT
dpc-6010	78	93	39.1	39.1	NUM
dpc-6010	78	94	%	%	NOUN
dpc-6010	78	95	)	)	PUNCT
dpc-6010	78	96	primary	primary	ADJ
dpc-6010	78	97	inefficacy	inefficacy	NOUN
dpc-6010	78	98	(	(	PUNCT
dpc-6010	78	99	1	1	NUM
dpc-6010	78	100	,	,	PUNCT
dpc-6010	78	101	11.1	11.1	NUM
dpc-6010	78	102	%	%	NOUN
dpc-6010	78	103	)	)	PUNCT
dpc-6010	78	104	loss	loss	NOUN
dpc-6010	78	105	of	of	ADP
dpc-6010	78	106	efficacy	efficacy	NOUN
dpc-6010	78	107	(	(	PUNCT
dpc-6010	78	108	7	7	NUM
dpc-6010	78	109	,	,	PUNCT
dpc-6010	78	110	77.8	77.8	NUM
dpc-6010	78	111	%	%	NOUN
dpc-6010	78	112	)	)	PUNCT
dpc-6010	78	113	other	other	ADJ
dpc-6010	78	114	(	(	PUNCT
dpc-6010	78	115	1	1	NUM
dpc-6010	78	116	,	,	PUNCT
dpc-6010	78	117	11.1	11.1	NUM
dpc-6010	78	118	%	%	NOUN
dpc-6010	78	119	)	)	PUNCT
dpc-6010	79	1	12/23	12/23	NUM
dpc-6010	79	2	(	(	PUNCT
dpc-6010	79	3	52.2	52.2	NUM
dpc-6010	79	4	%	%	NOUN
dpc-6010	79	5	)	)	PUNCT
dpc-6010	79	6	patients	patient	NOUN
dpc-6010	79	7	have	have	AUX
dpc-6010	79	8	taken	take	VERB
dpc-6010	79	9	more	more	ADJ
dpc-6010	79	10	than	than	ADP
dpc-6010	79	11	one	one	NUM
dpc-6010	79	12	previous	previous	ADJ
dpc-6010	79	13	biologic	biologic	NOUN
dpc-6010	79	14	drug	drug	NOUN
dpc-6010	79	15	.	.	PUNCT
dpc-6010	80	1	original	original	ADJ
dpc-6010	80	2	article	article	NOUN
dpc-6010	80	3	|	|	ADV
dpc-6010	80	4	dermatol	dermatol	ADJ
dpc-6010	80	5	pract	pract	NOUN
dpc-6010	80	6	concept	concept	NOUN
dpc-6010	80	7	.	.	PUNCT
dpc-6010	81	1	2025;15(4):6010	2025;15(4):6010	NUM
dpc-6010	81	2	5	5	NUM
dpc-6010	81	3	table	table	NOUN
dpc-6010	81	4	3	3	NUM
dpc-6010	81	5	.	.	PUNCT
dpc-6010	81	6	mean	mean	PROPN
dpc-6010	81	7	pasi	pasi	NOUN
dpc-6010	81	8	by	by	ADP
dpc-6010	81	9	visit	visit	NOUN
dpc-6010	81	10	.	.	PUNCT
dpc-6010	82	1	visit	visit	NOUN
dpc-6010	82	2	mean	mean	NOUN
dpc-6010	82	3	pasi	pasi	NOUN
dpc-6010	82	4	(	(	PUNCT
dpc-6010	82	5	sd	sd	NOUN
dpc-6010	82	6	)	)	PUNCT
dpc-6010	82	7	mpasi	mpasi	NOUN
dpc-6010	82	8	decrease	decrease	NOUN
dpc-6010	82	9	paired	pair	VERB
dpc-6010	82	10	t	t	PROPN
dpc-6010	82	11	-	-	PUNCT
dpc-6010	82	12	test	test	NOUN
dpc-6010	82	13	baseline	baseline	NOUN
dpc-6010	82	14	(	(	PUNCT
dpc-6010	82	15	n=22	n=22	PROPN
dpc-6010	82	16	)	)	PUNCT
dpc-6010	82	17	14.6	14.6	NUM
dpc-6010	82	18	(	(	PUNCT
dpc-6010	82	19	±	±	NOUN
dpc-6010	82	20	9.2	9.2	NUM
dpc-6010	82	21	)	)	PUNCT
dpc-6010	82	22	4	4	NUM
dpc-6010	82	23	weeks	week	NOUN
dpc-6010	82	24	(	(	PUNCT
dpc-6010	82	25	n=22	n=22	PROPN
dpc-6010	82	26	)	)	PUNCT
dpc-6010	82	27	6.0	6.0	NUM
dpc-6010	82	28	(	(	PUNCT
dpc-6010	82	29	±	±	NUM
dpc-6010	82	30	7.1	7.1	NUM
dpc-6010	82	31	)	)	PUNCT
dpc-6010	82	32	-8.6	-8.6	PROPN
dpc-6010	82	33	(	(	PUNCT
dpc-6010	82	34	±	±	NOUN
dpc-6010	82	35	6.0	6.0	NUM
dpc-6010	82	36	)	)	PUNCT
dpc-6010	82	37	<	<	X
dpc-6010	82	38	0.001	0.001	NUM
dpc-6010	82	39	16	16	NUM
dpc-6010	82	40	weeks	week	NOUN
dpc-6010	82	41	(	(	PUNCT
dpc-6010	82	42	n=22	n=22	PROPN
dpc-6010	82	43	)	)	PUNCT
dpc-6010	82	44	2.6	2.6	NUM
dpc-6010	82	45	(	(	PUNCT
dpc-6010	82	46	±	±	NUM
dpc-6010	82	47	5.7	5.7	NUM
dpc-6010	82	48	)	)	PUNCT
dpc-6010	82	49	-11.9	-11.9	NOUN
dpc-6010	82	50	(	(	PUNCT
dpc-6010	82	51	±6.8	±6.8	NOUN
dpc-6010	82	52	)	)	PUNCT
dpc-6010	82	53	<	<	X
dpc-6010	82	54	0.001	0.001	NUM
dpc-6010	82	55	36	36	NUM
dpc-6010	82	56	weeks	week	NOUN
dpc-6010	82	57	(	(	PUNCT
dpc-6010	82	58	n=22	n=22	PROPN
dpc-6010	82	59	)	)	PUNCT
dpc-6010	82	60	1.7	1.7	NUM
dpc-6010	82	61	(	(	PUNCT
dpc-6010	82	62	±	±	NOUN
dpc-6010	82	63	3.4	3.4	NUM
dpc-6010	82	64	)	)	PUNCT
dpc-6010	82	65	-12.9	-12.9	INTJ
dpc-6010	82	66	(	(	PUNCT
dpc-6010	82	67	±6.9	±6.9	PROPN
dpc-6010	82	68	)	)	PUNCT
dpc-6010	82	69	<	<	NOUN
dpc-6010	82	70	0.001	0.001	NUM
dpc-6010	82	71	1	1	NUM
dpc-6010	82	72	year	year	NOUN
dpc-6010	82	73	(	(	PUNCT
dpc-6010	82	74	n=21	n=21	NOUN
dpc-6010	82	75	)	)	PUNCT
dpc-6010	82	76	1.1	1.1	NUM
dpc-6010	82	77	(	(	PUNCT
dpc-6010	82	78	±	±	NUM
dpc-6010	82	79	1.8	1.8	NUM
dpc-6010	82	80	)	)	PUNCT
dpc-6010	82	81	-12.0	-12.0	X
dpc-6010	82	82	(	(	PUNCT
dpc-6010	82	83	±	±	NOUN
dpc-6010	82	84	6.0	6.0	NUM
dpc-6010	82	85	)	)	PUNCT
dpc-6010	82	86	<	<	X
dpc-6010	82	87	0.001	0.001	NUM
dpc-6010	82	88	figure	figure	NOUN
dpc-6010	82	89	1	1	NUM
dpc-6010	82	90	.	.	PUNCT
dpc-6010	82	91	mpasi	mpasi	NOUN
dpc-6010	82	92	by	by	ADP
dpc-6010	82	93	visit	visit	NOUN
dpc-6010	82	94	.	.	PUNCT
dpc-6010	83	1	figure	figure	NOUN
dpc-6010	83	2	2	2	NUM
dpc-6010	83	3	.	.	PUNCT
dpc-6010	83	4	relative	relative	ADJ
dpc-6010	83	5	pasi	pasi	NOUN
dpc-6010	83	6	over	over	ADP
dpc-6010	83	7	one	one	NUM
dpc-6010	83	8	year	year	NOUN
dpc-6010	83	9	.	.	PUNCT
dpc-6010	84	1	experienced	experience	VERB
dpc-6010	84	2	a	a	DET
dpc-6010	84	3	primary	primary	ADJ
dpc-6010	84	4	non	non	NOUN
dpc-6010	84	5	-	-	NOUN
dpc-6010	84	6	response	response	NOUN
dpc-6010	84	7	to	to	AUX
dpc-6010	84	8	brodalumab	brodalumab	NOUN
dpc-6010	84	9	treatment	treatment	NOUN
dpc-6010	84	10	(	(	PUNCT
dpc-6010	84	11	median	median	ADJ
dpc-6010	84	12	pasi	pasi	NOUN
dpc-6010	84	13	at	at	ADP
dpc-6010	84	14	baseline	baseline	NOUN
dpc-6010	84	15	:	:	PUNCT
dpc-6010	84	16	9.3	9.3	NUM
dpc-6010	84	17	vs	vs	ADP
dpc-6010	84	18	median	median	ADJ
dpc-6010	84	19	pasi	pasi	NOUN
dpc-6010	84	20	at	at	ADP
dpc-6010	84	21	16	16	NUM
dpc-6010	84	22	weeks	week	NOUN
dpc-6010	84	23	:	:	PUNCT
dpc-6010	84	24	7.8	7.8	NUM
dpc-6010	84	25	;	;	PUNCT
dpc-6010	84	26	p=	p=	NOUN
dpc-6010	84	27	0.3	0.3	NUM
dpc-6010	84	28	)	)	PUNCT
dpc-6010	84	29	.	.	PUNCT
dpc-6010	85	1	both	both	DET
dpc-6010	85	2	subjects	subject	NOUN
dpc-6010	85	3	discontinued	discontinue	VERB
dpc-6010	85	4	therapy	therapy	NOUN
dpc-6010	85	5	after	after	SCONJ
dpc-6010	85	6	the	the	DET
dpc-6010	85	7	assessment	assessment	NOUN
dpc-6010	85	8	performed	perform	VERB
dpc-6010	85	9	at	at	ADP
dpc-6010	85	10	16	16	NUM
dpc-6010	85	11	weeks	week	NOUN
dpc-6010	85	12	of	of	ADP
dpc-6010	85	13	treatment	treatment	NOUN
dpc-6010	85	14	and	and	CCONJ
dpc-6010	85	15	were	be	AUX
dpc-6010	85	16	further	far	ADV
dpc-6010	85	17	switched	switch	VERB
dpc-6010	85	18	to	to	ADP
dpc-6010	85	19	a	a	DET
dpc-6010	85	20	biologic	biologic	NOUN
dpc-6010	85	21	of	of	ADP
dpc-6010	85	22	a	a	DET
dpc-6010	85	23	different	different	ADJ
dpc-6010	85	24	class	class	NOUN
dpc-6010	85	25	.	.	PUNCT
dpc-6010	86	1	all	all	DET
dpc-6010	86	2	three	three	NUM
dpc-6010	86	3	psa	psa	NOUN
dpc-6010	86	4	patients	patient	NOUN
dpc-6010	86	5	maintained	maintain	VERB
dpc-6010	86	6	clinical	clinical	ADJ
dpc-6010	86	7	remission	remission	NOUN
dpc-6010	86	8	;	;	PUNCT
dpc-6010	86	9	however	however	ADV
dpc-6010	86	10	,	,	PUNCT
dpc-6010	86	11	none	none	NOUN
dpc-6010	86	12	of	of	ADP
dpc-6010	86	13	them	they	PRON
dpc-6010	86	14	underwent	undergo	VERB
dpc-6010	86	15	ultrasound	ultrasound	NOUN
dpc-6010	86	16	assessment	assessment	NOUN
dpc-6010	86	17	for	for	ADP
dpc-6010	86	18	subclinical	subclinical	ADJ
dpc-6010	86	19	disease	disease	NOUN
dpc-6010	86	20	detection	detection	NOUN
dpc-6010	86	21	.	.	PUNCT
dpc-6010	87	1	we	we	PRON
dpc-6010	87	2	found	find	VERB
dpc-6010	87	3	no	no	DET
dpc-6010	87	4	significant	significant	ADJ
dpc-6010	87	5	difference	difference	NOUN
dpc-6010	87	6	in	in	ADP
dpc-6010	87	7	clinical	clinical	ADJ
dpc-6010	87	8	response	response	NOUN
dpc-6010	87	9	to	to	PART
dpc-6010	87	10	brodalumab	brodalumab	VERB
dpc-6010	87	11	among	among	ADP
dpc-6010	87	12	the	the	DET
dpc-6010	87	13	previous	previous	ADJ
dpc-6010	87	14	failed	fail	VERB
dpc-6010	87	15	anti	anti	ADJ
dpc-6010	87	16	-	-	ADJ
dpc-6010	87	17	il23	il23	ADJ
dpc-6010	87	18	or	or	CCONJ
dpc-6010	87	19	anti	anti	ADJ
dpc-6010	87	20	-	-	NOUN
dpc-6010	87	21	il12/23	il12/23	NOUN
dpc-6010	87	22	.	.	PUNCT
dpc-6010	88	1	none	none	NOUN
dpc-6010	88	2	of	of	ADP
dpc-6010	88	3	patients	patient	NOUN
dpc-6010	88	4	included	include	VERB
dpc-6010	88	5	in	in	ADP
dpc-6010	88	6	the	the	DET
dpc-6010	88	7	study	study	NOUN
dpc-6010	88	8	experienced	experience	VERB
dpc-6010	88	9	any	any	DET
dpc-6010	88	10	major	major	ADJ
dpc-6010	88	11	adverse	adverse	ADJ
dpc-6010	88	12	effect	effect	NOUN
dpc-6010	88	13	,	,	PUNCT
dpc-6010	88	14	while	while	SCONJ
dpc-6010	88	15	9/23	9/23	NUM
dpc-6010	88	16	patients	patient	NOUN
dpc-6010	88	17	(	(	PUNCT
dpc-6010	88	18	39.1	39.1	NUM
dpc-6010	88	19	%	%	NOUN
dpc-6010	88	20	)	)	PUNCT
dpc-6010	88	21	reported	report	VERB
dpc-6010	88	22	mild	mild	ADJ
dpc-6010	88	23	adverse	adverse	ADJ
dpc-6010	88	24	events	event	NOUN
dpc-6010	88	25	mainly	mainly	ADV
dpc-6010	88	26	related	relate	VERB
dpc-6010	88	27	to	to	ADP
dpc-6010	88	28	an	an	DET
dpc-6010	88	29	increased	increase	VERB
dpc-6010	88	30	susceptibility	susceptibility	NOUN
dpc-6010	88	31	to	to	PART
dpc-6010	88	32	transient	transient	VERB
dpc-6010	88	33	rhinopharyngeal	rhinopharyngeal	ADJ
dpc-6010	88	34	infections	infection	NOUN
dpc-6010	88	35	and	and	CCONJ
dpc-6010	88	36	oral	oral	ADJ
dpc-6010	88	37	candidiasis	candidiasis	NOUN
dpc-6010	88	38	.	.	PUNCT
dpc-6010	89	1	furthermore	furthermore	ADV
dpc-6010	89	2	,	,	PUNCT
dpc-6010	89	3	no	no	DET
dpc-6010	89	4	significant	significant	ADJ
dpc-6010	89	5	depressive	depressive	ADJ
dpc-6010	89	6	symptom	symptom	NOUN
dpc-6010	89	7	was	be	AUX
dpc-6010	89	8	reported	report	VERB
dpc-6010	89	9	by	by	ADP
dpc-6010	89	10	patients	patient	NOUN
dpc-6010	89	11	enrolled	enrol	VERB
dpc-6010	89	12	during	during	ADP
dpc-6010	89	13	the	the	DET
dpc-6010	89	14	scheduled	schedule	VERB
dpc-6010	89	15	follow	follow	NOUN
dpc-6010	89	16	-	-	PUNCT
dpc-6010	89	17	up	up	NOUN
dpc-6010	89	18	period	period	NOUN
dpc-6010	89	19	.	.	PUNCT
dpc-6010	89	20	  	  	SPACE
dpc-6010	90	1	6	6	NUM
dpc-6010	90	2	original	original	ADJ
dpc-6010	90	3	article	article	NOUN
dpc-6010	90	4	|	|	ADV
dpc-6010	90	5	dermatol	dermatol	ADJ
dpc-6010	90	6	pract	pract	NOUN
dpc-6010	90	7	concept	concept	NOUN
dpc-6010	90	8	.	.	PUNCT
dpc-6010	91	1	2025;15(4):6010	2025;15(4):6010	NUM
dpc-6010	91	2	16	16	NUM
dpc-6010	91	3	weeks	week	NOUN
dpc-6010	91	4	of	of	ADP
dpc-6010	91	5	treatment	treatment	NOUN
dpc-6010	91	6	with	with	ADP
dpc-6010	91	7	brodalumab	brodalumab	NOUN
dpc-6010	91	8	and	and	CCONJ
dpc-6010	91	9	in	in	ADP
dpc-6010	91	10	45.5	45.5	NUM
dpc-6010	91	11	%	%	NOUN
dpc-6010	91	12	of	of	ADP
dpc-6010	91	13	patients	patient	NOUN
dpc-6010	91	14	after	after	ADP
dpc-6010	91	15	26	26	NUM
dpc-6010	91	16	weeks	week	NOUN
dpc-6010	91	17	[	[	X
dpc-6010	91	18	15	15	NUM
dpc-6010	91	19	]	]	PUNCT
dpc-6010	91	20	.	.	PUNCT
dpc-6010	92	1	as	as	SCONJ
dpc-6010	92	2	shown	show	VERB
dpc-6010	92	3	in	in	ADP
dpc-6010	92	4	table	table	NOUN
dpc-6010	92	5	4	4	NUM
dpc-6010	92	6	,	,	PUNCT
dpc-6010	92	7	the	the	DET
dpc-6010	92	8	percentage	percentage	NOUN
dpc-6010	92	9	of	of	ADP
dpc-6010	92	10	our	our	PRON
dpc-6010	92	11	patients	patient	NOUN
dpc-6010	92	12	who	who	PRON
dpc-6010	92	13	achieved	achieve	VERB
dpc-6010	92	14	pasi	pasi	NOUN
dpc-6010	92	15	100	100	NUM
dpc-6010	92	16	just	just	ADV
dpc-6010	92	17	after	after	ADP
dpc-6010	92	18	16	16	NUM
dpc-6010	92	19	weeks	week	NOUN
dpc-6010	92	20	of	of	ADP
dpc-6010	92	21	treatment	treatment	NOUN
dpc-6010	92	22	was	be	AUX
dpc-6010	92	23	63.6	63.6	NUM
dpc-6010	92	24	%	%	NOUN
dpc-6010	92	25	,	,	PUNCT
dpc-6010	92	26	a	a	DET
dpc-6010	92	27	significantly	significantly	ADV
dpc-6010	92	28	higher	high	ADJ
dpc-6010	92	29	proportion	proportion	NOUN
dpc-6010	92	30	compared	compare	VERB
dpc-6010	92	31	to	to	ADP
dpc-6010	92	32	the	the	DET
dpc-6010	92	33	results	result	NOUN
dpc-6010	92	34	obtained	obtain	VERB
dpc-6010	92	35	by	by	ADP
dpc-6010	92	36	papp	papp	PROPN
dpc-6010	92	37	et	et	PROPN
dpc-6010	92	38	al	al	PROPN
dpc-6010	92	39	.	.	PROPN
dpc-6010	92	40	discussion	discussion	NOUN
dpc-6010	92	41	a	a	DET
dpc-6010	92	42	critical	critical	ADJ
dpc-6010	92	43	question	question	NOUN
dpc-6010	92	44	in	in	ADP
dpc-6010	92	45	the	the	DET
dpc-6010	92	46	clinical	clinical	ADJ
dpc-6010	92	47	management	management	NOUN
dpc-6010	92	48	of	of	ADP
dpc-6010	92	49	psoriasis	psoriasis	NOUN
dpc-6010	92	50	,	,	PUNCT
dpc-6010	92	51	and	and	CCONJ
dpc-6010	92	52	particularly	particularly	ADV
dpc-6010	92	53	in	in	ADP
dpc-6010	92	54	the	the	DET
dpc-6010	92	55	case	case	NOUN
dpc-6010	92	56	of	of	ADP
dpc-6010	92	57	therapeutic	therapeutic	ADJ
dpc-6010	92	58	failure	failure	NOUN
dpc-6010	92	59	of	of	ADP
dpc-6010	92	60	a	a	DET
dpc-6010	92	61	biologic	biologic	NOUN
dpc-6010	92	62	drug	drug	NOUN
dpc-6010	92	63	,	,	PUNCT
dpc-6010	92	64	is	be	AUX
dpc-6010	92	65	whether	whether	SCONJ
dpc-6010	92	66	it	it	PRON
dpc-6010	92	67	is	be	AUX
dpc-6010	92	68	more	more	ADV
dpc-6010	92	69	appropriate	appropriate	ADJ
dpc-6010	92	70	to	to	PART
dpc-6010	92	71	use	use	VERB
dpc-6010	92	72	a	a	DET
dpc-6010	92	73	drug	drug	NOUN
dpc-6010	92	74	of	of	ADP
dpc-6010	92	75	the	the	DET
dpc-6010	92	76	same	same	ADJ
dpc-6010	92	77	class	class	NOUN
dpc-6010	92	78	or	or	CCONJ
dpc-6010	92	79	to	to	PART
dpc-6010	92	80	switch	switch	VERB
dpc-6010	92	81	to	to	ADP
dpc-6010	92	82	another	another	DET
dpc-6010	92	83	class	class	NOUN
dpc-6010	92	84	.	.	PUNCT
dpc-6010	93	1	some	some	DET
dpc-6010	93	2	real	real	ADJ
dpc-6010	93	3	-	-	PUNCT
dpc-6010	93	4	world	world	NOUN
dpc-6010	93	5	evidence	evidence	NOUN
dpc-6010	93	6	has	have	AUX
dpc-6010	93	7	shown	show	VERB
dpc-6010	93	8	that	that	DET
dpc-6010	93	9	failure	failure	NOUN
dpc-6010	93	10	of	of	ADP
dpc-6010	93	11	a	a	DET
dpc-6010	93	12	specific	specific	ADJ
dpc-6010	93	13	cytokinedirected	cytokinedirecte	VERB
dpc-6010	93	14	treatment	treatment	NOUN
dpc-6010	93	15	does	do	AUX
dpc-6010	93	16	not	not	PART
dpc-6010	93	17	preclude	preclude	VERB
dpc-6010	93	18	the	the	DET
dpc-6010	93	19	use	use	NOUN
dpc-6010	93	20	of	of	ADP
dpc-6010	93	21	biologics	biologic	NOUN
dpc-6010	93	22	from	from	ADP
dpc-6010	93	23	other	other	ADJ
dpc-6010	93	24	classes	class	NOUN
dpc-6010	93	25	or	or	CCONJ
dpc-6010	93	26	from	from	ADP
dpc-6010	93	27	the	the	DET
dpc-6010	93	28	same	same	ADJ
dpc-6010	93	29	class	class	NOUN
dpc-6010	93	30	,	,	PUNCT
dpc-6010	93	31	making	make	VERB
dpc-6010	93	32	this	this	PRON
dpc-6010	93	33	an	an	DET
dpc-6010	93	34	interesting	interesting	ADJ
dpc-6010	93	35	research	research	NOUN
dpc-6010	93	36	topic	topic	NOUN
dpc-6010	93	37	regarding	regard	VERB
dpc-6010	93	38	the	the	DET
dpc-6010	93	39	long	long	ADJ
dpc-6010	93	40	-	-	PUNCT
dpc-6010	93	41	term	term	NOUN
dpc-6010	93	42	management	management	NOUN
dpc-6010	93	43	of	of	ADP
dpc-6010	93	44	psoriasis	psoriasis	NOUN
dpc-6010	93	45	[	[	X
dpc-6010	93	46	10	10	NUM
dpc-6010	93	47	-	-	SYM
dpc-6010	93	48	12	12	NUM
dpc-6010	93	49	]	]	PUNCT
dpc-6010	93	50	.	.	PUNCT
dpc-6010	94	1	unfortunately	unfortunately	ADV
dpc-6010	94	2	,	,	PUNCT
dpc-6010	94	3	to	to	ADP
dpc-6010	94	4	date	date	NOUN
dpc-6010	94	5	there	there	PRON
dpc-6010	94	6	is	be	VERB
dpc-6010	94	7	a	a	DET
dpc-6010	94	8	lack	lack	NOUN
dpc-6010	94	9	of	of	ADP
dpc-6010	94	10	biomarkers	biomarker	NOUN
dpc-6010	94	11	to	to	PART
dpc-6010	94	12	guide	guide	VERB
dpc-6010	94	13	treatment	treatment	NOUN
dpc-6010	94	14	changes	change	NOUN
dpc-6010	94	15	.	.	PUNCT
dpc-6010	95	1	therefore	therefore	ADV
dpc-6010	95	2	,	,	PUNCT
dpc-6010	95	3	intraor	intraor	NOUN
dpc-6010	95	4	interclass	interclass	NOUN
dpc-6010	95	5	switching	switching	NOUN
dpc-6010	95	6	in	in	ADP
dpc-6010	95	7	the	the	DET
dpc-6010	95	8	treatment	treatment	NOUN
dpc-6010	95	9	of	of	ADP
dpc-6010	95	10	psoriasis	psoriasis	NOUN
dpc-6010	95	11	is	be	AUX
dpc-6010	95	12	currently	currently	ADV
dpc-6010	95	13	based	base	VERB
dpc-6010	95	14	on	on	ADP
dpc-6010	95	15	the	the	DET
dpc-6010	95	16	dermatologist	dermatologist	NOUN
dpc-6010	95	17	’s	’s	PART
dpc-6010	95	18	experience	experience	NOUN
dpc-6010	95	19	,	,	PUNCT
dpc-6010	95	20	the	the	DET
dpc-6010	95	21	severity	severity	NOUN
dpc-6010	95	22	of	of	ADP
dpc-6010	95	23	the	the	DET
dpc-6010	95	24	disease	disease	NOUN
dpc-6010	95	25	,	,	PUNCT
dpc-6010	95	26	the	the	DET
dpc-6010	95	27	skin	skin	NOUN
dpc-6010	95	28	areas	area	NOUN
dpc-6010	95	29	involved	involve	VERB
dpc-6010	95	30	,	,	PUNCT
dpc-6010	95	31	and	and	CCONJ
dpc-6010	95	32	the	the	DET
dpc-6010	95	33	patient	patient	NOUN
dpc-6010	95	34	’s	’s	PART
dpc-6010	95	35	comorbidities	comorbiditie	NOUN
dpc-6010	95	36	.	.	PUNCT
dpc-6010	96	1	in	in	ADP
dpc-6010	96	2	this	this	DET
dpc-6010	96	3	context	context	NOUN
dpc-6010	96	4	,	,	PUNCT
dpc-6010	96	5	real	real	ADJ
dpc-6010	96	6	-	-	PUNCT
dpc-6010	96	7	world	world	NOUN
dpc-6010	96	8	data	datum	NOUN
dpc-6010	96	9	supporting	support	VERB
dpc-6010	96	10	the	the	DET
dpc-6010	96	11	availability	availability	NOUN
dpc-6010	96	12	and	and	CCONJ
dpc-6010	96	13	the	the	DET
dpc-6010	96	14	rate	rate	NOUN
dpc-6010	96	15	of	of	ADP
dpc-6010	96	16	efficacy	efficacy	NOUN
dpc-6010	96	17	and	and	CCONJ
dpc-6010	96	18	safety	safety	NOUN
dpc-6010	96	19	of	of	ADP
dpc-6010	96	20	these	these	DET
dpc-6010	96	21	treatment	treatment	NOUN
dpc-6010	96	22	changes	change	NOUN
dpc-6010	96	23	are	be	AUX
dpc-6010	96	24	highly	highly	ADV
dpc-6010	96	25	needed	need	VERB
dpc-6010	96	26	.	.	PUNCT
dpc-6010	97	1	a	a	DET
dpc-6010	97	2	recent	recent	ADJ
dpc-6010	97	3	study	study	NOUN
dpc-6010	97	4	showed	show	VERB
dpc-6010	97	5	brodalumab	brodalumab	NOUN
dpc-6010	97	6	to	to	PART
dpc-6010	97	7	be	be	AUX
dpc-6010	97	8	one	one	NUM
dpc-6010	97	9	of	of	ADP
dpc-6010	97	10	the	the	DET
dpc-6010	97	11	biologic	biologic	NOUN
dpc-6010	97	12	drugs	drug	NOUN
dpc-6010	97	13	with	with	ADP
dpc-6010	97	14	lowest	low	ADJ
dpc-6010	97	15	anti	anti	ADJ
dpc-6010	97	16	-	-	ADJ
dpc-6010	97	17	drug	drug	ADJ
dpc-6010	97	18	-	-	PUNCT
dpc-6010	97	19	antibody	antibody	NOUN
dpc-6010	97	20	(	(	PUNCT
dpc-6010	97	21	adas	adas	PROPN
dpc-6010	97	22	)	)	PUNCT
dpc-6010	97	23	formation	formation	NOUN
dpc-6010	97	24	rates	rate	NOUN
dpc-6010	97	25	.	.	PUNCT
dpc-6010	98	1	this	this	DET
dpc-6010	98	2	finding	finding	NOUN
dpc-6010	98	3	supports	support	VERB
dpc-6010	98	4	this	this	DET
dpc-6010	98	5	biologic	biologic	NOUN
dpc-6010	98	6	agent	agent	NOUN
dpc-6010	98	7	as	as	ADP
dpc-6010	98	8	a	a	DET
dpc-6010	98	9	suitable	suitable	ADJ
dpc-6010	98	10	drug	drug	NOUN
dpc-6010	98	11	for	for	ADP
dpc-6010	98	12	patients	patient	NOUN
dpc-6010	98	13	who	who	PRON
dpc-6010	98	14	have	have	AUX
dpc-6010	98	15	experienced	experience	VERB
dpc-6010	98	16	therapeutic	therapeutic	ADJ
dpc-6010	98	17	failures	failure	NOUN
dpc-6010	98	18	potentially	potentially	ADV
dpc-6010	98	19	due	due	ADJ
dpc-6010	98	20	to	to	ADP
dpc-6010	98	21	the	the	DET
dpc-6010	98	22	presence	presence	NOUN
dpc-6010	98	23	of	of	ADP
dpc-6010	98	24	adas	adas	PROPN
dpc-6010	98	25	[	[	X
dpc-6010	98	26	13	13	NUM
dpc-6010	98	27	]	]	PUNCT
dpc-6010	98	28	.	.	PUNCT
dpc-6010	99	1	a	a	DET
dpc-6010	99	2	recent	recent	ADJ
dpc-6010	99	3	trial	trial	NOUN
dpc-6010	99	4	on	on	ADP
dpc-6010	99	5	psoriatic	psoriatic	ADJ
dpc-6010	99	6	patients	patient	NOUN
dpc-6010	99	7	experiencing	experience	VERB
dpc-6010	99	8	a	a	DET
dpc-6010	99	9	failure	failure	NOUN
dpc-6010	99	10	of	of	ADP
dpc-6010	99	11	ustekinumab	ustekinumab	NOUN
dpc-6010	99	12	showed	show	VERB
dpc-6010	99	13	a	a	DET
dpc-6010	99	14	favorable	favorable	ADJ
dpc-6010	99	15	and	and	CCONJ
dpc-6010	99	16	earlier	early	ADJ
dpc-6010	99	17	effect	effect	NOUN
dpc-6010	99	18	of	of	ADP
dpc-6010	99	19	brodalumab	brodalumab	NOUN
dpc-6010	99	20	as	as	SCONJ
dpc-6010	99	21	compared	compare	VERB
dpc-6010	99	22	to	to	ADP
dpc-6010	99	23	guselkumab	guselkumab	NOUN
dpc-6010	99	24	,	,	PUNCT
dpc-6010	99	25	thus	thus	ADV
dpc-6010	99	26	providing	provide	VERB
dpc-6010	99	27	important	important	ADJ
dpc-6010	99	28	information	information	NOUN
dpc-6010	99	29	to	to	PART
dpc-6010	99	30	help	help	VERB
dpc-6010	99	31	physicians	physician	NOUN
dpc-6010	99	32	in	in	ADP
dpc-6010	99	33	the	the	DET
dpc-6010	99	34	choice	choice	NOUN
dpc-6010	99	35	of	of	ADP
dpc-6010	99	36	therapy	therapy	NOUN
dpc-6010	99	37	for	for	ADP
dpc-6010	99	38	this	this	DET
dpc-6010	99	39	subgroup	subgroup	NOUN
dpc-6010	99	40	of	of	ADP
dpc-6010	99	41	patients	patient	NOUN
dpc-6010	99	42	[	[	X
dpc-6010	99	43	14	14	NUM
dpc-6010	99	44	]	]	PUNCT
dpc-6010	99	45	.	.	PUNCT
dpc-6010	100	1	recently	recently	ADV
dpc-6010	100	2	,	,	PUNCT
dpc-6010	100	3	papp	papp	PROPN
dpc-6010	100	4	et	et	PROPN
dpc-6010	100	5	al	al	PROPN
dpc-6010	100	6	.	.	PROPN
dpc-6010	100	7	conducted	conduct	VERB
dpc-6010	100	8	an	an	DET
dpc-6010	100	9	open	open	ADJ
dpc-6010	100	10	-	-	PUNCT
dpc-6010	100	11	label	label	NOUN
dpc-6010	100	12	study	study	NOUN
dpc-6010	100	13	on	on	ADP
dpc-6010	100	14	a	a	DET
dpc-6010	100	15	large	large	ADJ
dpc-6010	100	16	cohort	cohort	NOUN
dpc-6010	100	17	of	of	ADP
dpc-6010	100	18	patients	patient	NOUN
dpc-6010	100	19	with	with	ADP
dpc-6010	100	20	psoriasis	psoriasis	NOUN
dpc-6010	100	21	that	that	PRON
dpc-6010	100	22	demonstrated	demonstrate	VERB
dpc-6010	100	23	how	how	SCONJ
dpc-6010	100	24	brodalumab	brodalumab	NOUN
dpc-6010	100	25	can	can	AUX
dpc-6010	100	26	be	be	AUX
dpc-6010	100	27	useful	useful	ADJ
dpc-6010	100	28	in	in	ADP
dpc-6010	100	29	patients	patient	NOUN
dpc-6010	100	30	who	who	PRON
dpc-6010	100	31	do	do	AUX
dpc-6010	100	32	not	not	PART
dpc-6010	100	33	respond	respond	VERB
dpc-6010	100	34	to	to	ADP
dpc-6010	100	35	tnf	tnf	PROPN
dpc-6010	100	36	-	-	PUNCT
dpc-6010	100	37	α	α	PROPN
dpc-6010	100	38	,	,	PUNCT
dpc-6010	100	39	il-12/23	il-12/23	PROPN
dpc-6010	100	40	,	,	PUNCT
dpc-6010	100	41	or	or	CCONJ
dpc-6010	100	42	il-17	il-17	ADV
dpc-6010	100	43	inhibitors	inhibitor	NOUN
dpc-6010	100	44	.	.	PUNCT
dpc-6010	101	1	these	these	DET
dpc-6010	101	2	authors	author	NOUN
dpc-6010	101	3	found	find	VERB
dpc-6010	101	4	a	a	DET
dpc-6010	101	5	pasi	pasi	NOUN
dpc-6010	101	6	100	100	NUM
dpc-6010	101	7	response	response	NOUN
dpc-6010	101	8	in	in	ADP
dpc-6010	101	9	40.3	40.3	NUM
dpc-6010	101	10	%	%	NOUN
dpc-6010	101	11	of	of	ADP
dpc-6010	101	12	patients	patient	NOUN
dpc-6010	101	13	after	after	ADP
dpc-6010	101	14	figure	figure	NOUN
dpc-6010	101	15	3	3	NUM
dpc-6010	101	16	.	.	PUNCT
dpc-6010	101	17	mean	mean	VERB
dpc-6010	101	18	dlqi	dlqi	VERB
dpc-6010	101	19	by	by	ADP
dpc-6010	101	20	visit	visit	NOUN
dpc-6010	101	21	.	.	PUNCT
dpc-6010	102	1	table	table	NOUN
dpc-6010	102	2	4	4	NUM
dpc-6010	102	3	.	.	PUNCT
dpc-6010	102	4	percentage	percentage	NOUN
dpc-6010	102	5	of	of	ADP
dpc-6010	102	6	patients	patient	NOUN
dpc-6010	102	7	with	with	ADP
dpc-6010	102	8	pasi	pasi	NOUN
dpc-6010	102	9	score	score	NOUN
dpc-6010	102	10	reduction	reduction	NOUN
dpc-6010	102	11	of	of	ADP
dpc-6010	102	12	75	75	NUM
dpc-6010	102	13	,	,	PUNCT
dpc-6010	102	14	90	90	NUM
dpc-6010	102	15	,	,	PUNCT
dpc-6010	102	16	and	and	CCONJ
dpc-6010	102	17	100	100	NUM
dpc-6010	102	18	,	,	PUNCT
dpc-6010	102	19	by	by	ADP
dpc-6010	102	20	visit	visit	NOUN
dpc-6010	102	21	.	.	PUNCT
dpc-6010	103	1	pasi	pasi	NOUN
dpc-6010	103	2	75	75	NUM
dpc-6010	103	3	visit	visit	NOUN
dpc-6010	103	4	n	n	DET
dpc-6010	103	5	%	%	NOUN
dpc-6010	103	6	4	4	NUM
dpc-6010	103	7	weeks	week	NOUN
dpc-6010	103	8	16	16	NUM
dpc-6010	103	9	weeks	week	NOUN
dpc-6010	103	10	36	36	NUM
dpc-6010	103	11	weeks	week	NOUN
dpc-6010	103	12	1	1	NUM
dpc-6010	103	13	year	year	NOUN
dpc-6010	103	14	9/22	9/22	NUM
dpc-6010	103	15	16/22	16/22	NUM
dpc-6010	103	16	17/22	17/22	NUM
dpc-6010	103	17	17/21	17/21	NUM
dpc-6010	103	18	40.9	40.9	NUM
dpc-6010	103	19	72.7	72.7	NUM
dpc-6010	103	20	77.3	77.3	NUM
dpc-6010	103	21	81.0	81.0	NUM
dpc-6010	103	22	pasi	pasi	NOUN
dpc-6010	103	23	90	90	NUM
dpc-6010	103	24	visit	visit	NOUN
dpc-6010	103	25	n	n	DET
dpc-6010	103	26	%	%	NOUN
dpc-6010	103	27	4	4	NUM
dpc-6010	103	28	weeks	week	NOUN
dpc-6010	103	29	16	16	NUM
dpc-6010	103	30	weeks	week	NOUN
dpc-6010	103	31	36	36	NUM
dpc-6010	103	32	weeks	week	NOUN
dpc-6010	103	33	1	1	NUM
dpc-6010	103	34	year	year	NOUN
dpc-6010	103	35	6/22	6/22	NUM
dpc-6010	103	36	14/22	14/22	NUM
dpc-6010	103	37	15/22	15/22	NUM
dpc-6010	103	38	13/21	13/21	NUM
dpc-6010	103	39	27.3	27.3	NUM
dpc-6010	103	40	63.6	63.6	NUM
dpc-6010	103	41	68.2	68.2	NUM
dpc-6010	103	42	61.9	61.9	NUM
dpc-6010	103	43	pasi	pasi	NOUN
dpc-6010	103	44	100	100	NUM
dpc-6010	103	45	visit	visit	NOUN
dpc-6010	103	46	n	n	DET
dpc-6010	103	47	%	%	NOUN
dpc-6010	103	48	4	4	NUM
dpc-6010	103	49	weeks	week	NOUN
dpc-6010	103	50	16	16	NUM
dpc-6010	103	51	weeks	week	NOUN
dpc-6010	103	52	36	36	NUM
dpc-6010	103	53	weeks	week	NOUN
dpc-6010	103	54	1	1	NUM
dpc-6010	103	55	year	year	NOUN
dpc-6010	103	56	5/22	5/22	NUM
dpc-6010	103	57	14/22	14/22	NUM
dpc-6010	103	58	14/22	14/22	NUM
dpc-6010	103	59	13/21	13/21	NUM
dpc-6010	103	60	22.7	22.7	NUM
dpc-6010	103	61	63.6	63.6	NUM
dpc-6010	103	62	63.6	63.6	NUM
dpc-6010	103	63	61.9	61.9	NUM
dpc-6010	103	64	pasi	pasi	NOUN
dpc-6010	103	65	<	<	X
dpc-6010	103	66	2	2	NUM
dpc-6010	103	67	visit	visit	NOUN
dpc-6010	103	68	n	n	DET
dpc-6010	103	69	%	%	NOUN
dpc-6010	103	70	4	4	NUM
dpc-6010	103	71	weeks	week	NOUN
dpc-6010	103	72	16	16	NUM
dpc-6010	103	73	weeks	week	NOUN
dpc-6010	103	74	36	36	NUM
dpc-6010	103	75	weeks	week	NOUN
dpc-6010	103	76	1	1	NUM
dpc-6010	103	77	year	year	NOUN
dpc-6010	103	78	8/22	8/22	NUM
dpc-6010	103	79	15/22	15/22	NUM
dpc-6010	103	80	17/22	17/22	NUM
dpc-6010	103	81	17/21	17/21	NUM
dpc-6010	103	82	36.4	36.4	NUM
dpc-6010	103	83	68.2	68.2	NUM
dpc-6010	103	84	77.3	77.3	NUM
dpc-6010	103	85	81.0	81.0	NUM
dpc-6010	103	86	original	original	ADJ
dpc-6010	103	87	article	article	NOUN
dpc-6010	103	88	|	|	ADV
dpc-6010	103	89	dermatol	dermatol	ADJ
dpc-6010	103	90	pract	pract	NOUN
dpc-6010	103	91	concept	concept	NOUN
dpc-6010	103	92	.	.	PUNCT
dpc-6010	104	1	2025;15(4):6010	2025;15(4):6010	NUM
dpc-6010	104	2	7	7	NUM
dpc-6010	104	3	ethics	ethic	NOUN
dpc-6010	104	4	approval	approval	NOUN
dpc-6010	104	5	:	:	PUNCT
dpc-6010	105	1	institutional	institutional	ADJ
dpc-6010	105	2	review	review	NOUN
dpc-6010	105	3	board	board	NOUN
dpc-6010	105	4	approval	approval	NOUN
dpc-6010	105	5	was	be	AUX
dpc-6010	105	6	exempted	exempt	VERB
dpc-6010	105	7	for	for	ADP
dpc-6010	105	8	this	this	DET
dpc-6010	105	9	study	study	NOUN
dpc-6010	105	10	as	as	SCONJ
dpc-6010	105	11	its	its	PRON
dpc-6010	105	12	procedure	procedure	NOUN
dpc-6010	105	13	did	do	AUX
dpc-6010	105	14	not	not	PART
dpc-6010	105	15	deviate	deviate	VERB
dpc-6010	105	16	from	from	ADP
dpc-6010	105	17	good	good	ADJ
dpc-6010	105	18	routine	routine	ADJ
dpc-6010	105	19	clinical	clinical	ADJ
dpc-6010	105	20	practice	practice	NOUN
dpc-6010	105	21	.	.	PUNCT
dpc-6010	106	1	the	the	DET
dpc-6010	106	2	study	study	NOUN
dpc-6010	106	3	was	be	AUX
dpc-6010	106	4	conducted	conduct	VERB
dpc-6010	106	5	in	in	ADP
dpc-6010	106	6	accordance	accordance	NOUN
dpc-6010	106	7	with	with	ADP
dpc-6010	106	8	the	the	DET
dpc-6010	106	9	helsinki	helsinki	PROPN
dpc-6010	106	10	declaration	declaration	NOUN
dpc-6010	106	11	of	of	ADP
dpc-6010	106	12	1964	1964	NUM
dpc-6010	106	13	and	and	CCONJ
dpc-6010	106	14	its	its	PRON
dpc-6010	106	15	later	later	ADJ
dpc-6010	106	16	amendments	amendment	NOUN
dpc-6010	106	17	.	.	PUNCT
dpc-6010	107	1	consent	consent	NOUN
dpc-6010	107	2	to	to	PART
dpc-6010	107	3	participate	participate	VERB
dpc-6010	107	4	:	:	PUNCT
dpc-6010	107	5	all	all	DET
dpc-6010	107	6	patients	patient	NOUN
dpc-6010	107	7	gave	gave	AUX
dpc-6010	107	8	written	write	VERB
dpc-6010	107	9	informed	informed	ADJ
dpc-6010	107	10	consent	consent	NOUN
dpc-6010	107	11	for	for	ADP
dpc-6010	107	12	the	the	DET
dpc-6010	107	13	retrospective	retrospective	ADJ
dpc-6010	107	14	retrieval	retrieval	NOUN
dpc-6010	107	15	of	of	ADP
dpc-6010	107	16	anonymized	anonymize	VERB
dpc-6010	107	17	data	datum	NOUN
dpc-6010	107	18	.	.	PUNCT
dpc-6010	108	1	consent	consent	NOUN
dpc-6010	108	2	for	for	ADP
dpc-6010	108	3	publication	publication	NOUN
dpc-6010	108	4	:	:	PUNCT
dpc-6010	108	5	all	all	DET
dpc-6010	108	6	patients	patient	NOUN
dpc-6010	108	7	gave	gave	AUX
dpc-6010	108	8	written	write	VERB
dpc-6010	108	9	informed	informed	ADJ
dpc-6010	108	10	consent	consent	NOUN
dpc-6010	108	11	for	for	ADP
dpc-6010	108	12	the	the	DET
dpc-6010	108	13	publication	publication	NOUN
dpc-6010	108	14	of	of	ADP
dpc-6010	108	15	anonymized	anonymize	VERB
dpc-6010	108	16	data	datum	NOUN
dpc-6010	108	17	.	.	PUNCT
dpc-6010	109	1	references	reference	NOUN
dpc-6010	109	2	1	1	NUM
dpc-6010	109	3	.	.	PUNCT
dpc-6010	110	1	egeberg	egeberg	PROPN
dpc-6010	110	2	a	a	PROPN
dpc-6010	110	3	,	,	PUNCT
dpc-6010	110	4	andersen	andersen	PROPN
dpc-6010	110	5	ymf	ymf	PROPN
dpc-6010	110	6	,	,	PUNCT
dpc-6010	110	7	halling	halling	NOUN
dpc-6010	110	8	-	-	PUNCT
dpc-6010	110	9	overgaard	overgaard	NOUN
dpc-6010	110	10	as	as	ADP
dpc-6010	110	11	et	et	PROPN
dpc-6010	110	12	al	al	PROPN
dpc-6010	110	13	.	.	PUNCT
dpc-6010	111	1	corrigendum	corrigendum	NOUN
dpc-6010	111	2	:	:	PUNCT
dpc-6010	111	3	systematic	systematic	ADJ
dpc-6010	111	4	review	review	NOUN
dpc-6010	111	5	on	on	ADP
dpc-6010	111	6	rapidity	rapidity	NOUN
dpc-6010	111	7	of	of	ADP
dpc-6010	111	8	onset	onset	NOUN
dpc-6010	111	9	of	of	ADP
dpc-6010	111	10	action	action	NOUN
dpc-6010	111	11	for	for	ADP
dpc-6010	111	12	interleukin-17	interleukin-17	PROPN
dpc-6010	111	13	and	and	CCONJ
dpc-6010	111	14	interleukin-23	interleukin-23	VERB
dpc-6010	111	15	inhibitors	inhibitor	NOUN
dpc-6010	111	16	for	for	ADP
dpc-6010	111	17	psoriasis	psoriasis	NOUN
dpc-6010	111	18	.	.	PUNCT
dpc-6010	112	1	j	j	PROPN
dpc-6010	112	2	eur	eur	PROPN
dpc-6010	112	3	acad	acad	PROPN
dpc-6010	112	4	dermatol	dermatol	NOUN
dpc-6010	112	5	venereol	venereol	NOUN
dpc-6010	112	6	.	.	PUNCT
dpc-6010	113	1	2020	2020	NUM
dpc-6010	114	1	sep;34(9):2156	sep;34(9):2156	PROPN
dpc-6010	114	2	.	.	PUNCT
dpc-6010	114	3	doi	doi	PROPN
dpc-6010	114	4	:	:	PUNCT
dpc-6010	114	5	10.1111	10.1111	NUM
dpc-6010	114	6	/jdv.16827	/jdv.16827	PROPN
dpc-6010	114	7	.	.	PUNCT
dpc-6010	115	1	erratum	erratum	PROPN
dpc-6010	115	2	for	for	ADP
dpc-6010	115	3	:	:	PUNCT
dpc-6010	115	4	j	j	PROPN
dpc-6010	115	5	eur	eur	PROPN
dpc-6010	115	6	acad	acad	PROPN
dpc-6010	115	7	dermatol	dermatol	NOUN
dpc-6010	115	8	venereol	venereol	NOUN
dpc-6010	115	9	.	.	PUNCT
dpc-6010	116	1	2020	2020	NUM
dpc-6010	117	1	jan;34(1):39	jan;34(1):39	PROPN
dpc-6010	117	2	-	-	PUNCT
dpc-6010	117	3	46	46	NUM
dpc-6010	117	4	.	.	PUNCT
dpc-6010	118	1	doi	doi	NOUN
dpc-6010	118	2	:	:	PUNCT
dpc-6010	118	3	10.1111	10.1111	NUM
dpc-6010	118	4	/	/	SYM
dpc-6010	118	5	jdv.15920	jdv.15920	NOUN
dpc-6010	118	6	.	.	PUNCT
dpc-6010	119	1	pmid	pmid	NOUN
dpc-6010	119	2	:	:	PUNCT
dpc-6010	119	3	33448477	33448477	NUM
dpc-6010	119	4	.	.	PUNCT
dpc-6010	120	1	2	2	X
dpc-6010	120	2	.	.	X
dpc-6010	120	3	dapavo	dapavo	VERB
dpc-6010	120	4	p	p	NOUN
dpc-6010	120	5	,	,	PUNCT
dpc-6010	120	6	siliquini	siliquini	PROPN
dpc-6010	120	7	n	n	CCONJ
dpc-6010	120	8	,	,	PUNCT
dpc-6010	120	9	mastorino	mastorino	PROPN
dpc-6010	120	10	l	l	PROPN
dpc-6010	120	11	et	et	PROPN
dpc-6010	120	12	al	al	PROPN
dpc-6010	120	13	.	.	PROPN
dpc-6010	120	14	efficacy	efficacy	PROPN
dpc-6010	120	15	,	,	PUNCT
dpc-6010	120	16	safety	safety	NOUN
dpc-6010	120	17	,	,	PUNCT
dpc-6010	120	18	and	and	CCONJ
dpc-6010	120	19	drug	drug	NOUN
dpc-6010	120	20	survival	survival	NOUN
dpc-6010	120	21	of	of	ADP
dpc-6010	120	22	il-23	il-23	NOUN
dpc-6010	120	23	,	,	PUNCT
dpc-6010	120	24	il-17	il-17	X
dpc-6010	120	25	,	,	PUNCT
dpc-6010	120	26	and	and	CCONJ
dpc-6010	120	27	tnf	tnf	PROPN
dpc-6010	120	28	-	-	PUNCT
dpc-6010	120	29	alpha	alpha	NOUN
dpc-6010	120	30	inhibitors	inhibitor	NOUN
dpc-6010	120	31	for	for	ADP
dpc-6010	120	32	psoriasis	psoriasis	NOUN
dpc-6010	120	33	treatment	treatment	NOUN
dpc-6010	120	34	:	:	PUNCT
dpc-6010	120	35	a	a	DET
dpc-6010	120	36	retrospective	retrospective	ADJ
dpc-6010	120	37	study	study	NOUN
dpc-6010	120	38	.	.	PUNCT
dpc-6010	121	1	j	j	PROPN
dpc-6010	121	2	dermatolog	dermatolog	PROPN
dpc-6010	121	3	treat	treat	NOUN
dpc-6010	121	4	.	.	PUNCT
dpc-6010	122	1	2022	2022	NUM
dpc-6010	122	2	jun;33(4):2352	jun;33(4):2352	NOUN
dpc-6010	122	3	-	-	PUNCT
dpc-6010	122	4	2357	2357	NUM
dpc-6010	122	5	.	.	PUNCT
dpc-6010	123	1	doi	doi	NOUN
dpc-6010	123	2	:	:	PUNCT
dpc-6010	123	3	10.1080/09546634.2021.1961998	10.1080/09546634.2021.1961998	NUM
dpc-6010	123	4	.	.	PUNCT
dpc-6010	124	1	pmid	pmid	NOUN
dpc-6010	124	2	:	:	PUNCT
dpc-6010	124	3	34315331	34315331	NUM
dpc-6010	124	4	.	.	PUNCT
dpc-6010	125	1	3	3	X
dpc-6010	125	2	.	.	NOUN
dpc-6010	125	3	mastorino	mastorino	PROPN
dpc-6010	125	4	l	l	PROPN
dpc-6010	125	5	,	,	PUNCT
dpc-6010	125	6	susca	susca	PROPN
dpc-6010	125	7	s	s	NOUN
dpc-6010	125	8	,	,	PUNCT
dpc-6010	125	9	cariti	cariti	PROPN
dpc-6010	125	10	c	c	PROPN
dpc-6010	125	11	et	et	PROPN
dpc-6010	125	12	al	al	PROPN
dpc-6010	125	13	.	.	PROPN
dpc-6010	125	14	efficacy	efficacy	NOUN
dpc-6010	125	15	of	of	ADP
dpc-6010	125	16	anti	anti	ADJ
dpc-6010	125	17	-	-	NOUN
dpc-6010	125	18	il-23	il-23	ADJ
dpc-6010	125	19	and	and	CCONJ
dpc-6010	125	20	anti	anti	ADJ
dpc-6010	125	21	-	-	ADJ
dpc-6010	125	22	il-17	il-17	ADJ
dpc-6010	125	23	after	after	ADP
dpc-6010	125	24	adalimumab	adalimumab	NOUN
dpc-6010	125	25	failure	failure	NOUN
dpc-6010	125	26	in	in	ADP
dpc-6010	125	27	psoriatic	psoriatic	ADJ
dpc-6010	125	28	patients	patient	NOUN
dpc-6010	125	29	.	.	PUNCT
dpc-6010	126	1	j	j	PROPN
dpc-6010	126	2	eur	eur	PROPN
dpc-6010	126	3	acad	acad	PROPN
dpc-6010	126	4	dermatol	dermatol	NOUN
dpc-6010	126	5	venereol	venereol	NOUN
dpc-6010	126	6	.	.	PUNCT
dpc-6010	127	1	2023	2023	NUM
dpc-6010	127	2	sep;37(9):1848	sep;37(9):1848	PROPN
dpc-6010	127	3	-	-	PUNCT
dpc-6010	127	4	1853	1853	PROPN
dpc-6010	127	5	.	.	PUNCT
dpc-6010	128	1	doi	doi	NOUN
dpc-6010	128	2	:	:	PUNCT
dpc-6010	128	3	10.1111	10.1111	NUM
dpc-6010	128	4	/	/	SYM
dpc-6010	128	5	jdv.19135	jdv.19135	PROPN
dpc-6010	128	6	.	.	PUNCT
dpc-6010	129	1	pmid	pmid	NOUN
dpc-6010	129	2	:	:	PUNCT
dpc-6010	129	3	37113043	37113043	NUM
dpc-6010	129	4	.	.	PUNCT
dpc-6010	130	1	4	4	NUM
dpc-6010	130	2	.	.	NOUN
dpc-6010	130	3	chiricozzi	chiricozzi	PROPN
dpc-6010	130	4	a	a	PROPN
dpc-6010	130	5	,	,	PUNCT
dpc-6010	130	6	conti	conti	PROPN
dpc-6010	130	7	a	a	X
dpc-6010	130	8	,	,	PUNCT
dpc-6010	130	9	burlando	burlando	PROPN
dpc-6010	130	10	m	m	PROPN
dpc-6010	130	11	et	et	PROPN
dpc-6010	130	12	al	al	PROPN
dpc-6010	130	13	.	.	PUNCT
dpc-6010	131	1	switching	switch	VERB
dpc-6010	131	2	from	from	ADP
dpc-6010	131	3	secukinumab	secukinumab	NOUN
dpc-6010	131	4	to	to	ADP
dpc-6010	131	5	ustekinumab	ustekinumab	NOUN
dpc-6010	131	6	in	in	ADP
dpc-6010	131	7	psoriasis	psoriasis	NOUN
dpc-6010	131	8	patients	patient	NOUN
dpc-6010	131	9	:	:	PUNCT
dpc-6010	131	10	results	result	VERB
dpc-6010	131	11	from	from	ADP
dpc-6010	131	12	a	a	DET
dpc-6010	131	13	multicenter	multicenter	ADJ
dpc-6010	131	14	experience	experience	NOUN
dpc-6010	131	15	.	.	PUNCT
dpc-6010	132	1	dermatology	dermatology	NOUN
dpc-6010	132	2	.	.	PUNCT
dpc-6010	133	1	2019;235(3):213	2019;235(3):213	NUM
dpc-6010	133	2	-	-	SYM
dpc-6010	133	3	218	218	NUM
dpc-6010	133	4	.	.	PUNCT
dpc-6010	134	1	doi	doi	NOUN
dpc-6010	134	2	:	:	PUNCT
dpc-6010	134	3	10.1159/000497274	10.1159/000497274	NUM
dpc-6010	134	4	.	.	PUNCT
dpc-6010	135	1	pmid	pmid	NOUN
dpc-6010	135	2	:	:	PUNCT
dpc-6010	135	3	30928971	30928971	NUM
dpc-6010	135	4	.	.	PUNCT
dpc-6010	136	1	5	5	X
dpc-6010	136	2	.	.	X
dpc-6010	136	3	damiani	damiani	PROPN
dpc-6010	136	4	g	g	PROPN
dpc-6010	136	5	,	,	PUNCT
dpc-6010	136	6	conic	conic	ADJ
dpc-6010	136	7	rrz	rrz	X
dpc-6010	136	8	,	,	PUNCT
dpc-6010	136	9	de	de	X
dpc-6010	136	10	vita	vita	X
dpc-6010	136	11	et	et	PROPN
dpc-6010	136	12	al	al	PROPN
dpc-6010	136	13	.	.	PROPN
dpc-6010	137	1	when	when	SCONJ
dpc-6010	137	2	il-17	il-17	NUM
dpc-6010	137	3	inhibitors	inhibitor	NOUN
dpc-6010	137	4	fail	fail	VERB
dpc-6010	137	5	:	:	PUNCT
dpc-6010	137	6	real	real	ADJ
dpc-6010	137	7	-	-	PUNCT
dpc-6010	137	8	life	life	NOUN
dpc-6010	137	9	evidence	evidence	NOUN
dpc-6010	137	10	to	to	PART
dpc-6010	137	11	switch	switch	VERB
dpc-6010	137	12	from	from	ADP
dpc-6010	137	13	secukinumab	secukinumab	NOUN
dpc-6010	137	14	to	to	ADP
dpc-6010	137	15	adalimumab	adalimumab	NOUN
dpc-6010	137	16	or	or	CCONJ
dpc-6010	137	17	ustekinumab	ustekinumab	NOUN
dpc-6010	137	18	.	.	PUNCT
dpc-6010	138	1	dermatol	dermatol	NOUN
dpc-6010	138	2	ther	ther	ADV
dpc-6010	138	3	.	.	PUNCT
dpc-6010	139	1	2019	2019	NUM
dpc-6010	139	2	mar;32(2	mar;32(2	NOUN
dpc-6010	139	3	):	):	PUNCT
dpc-6010	139	4	e12793	e12793	NOUN
dpc-6010	139	5	.	.	PUNCT
dpc-6010	139	6	doi	doi	NOUN
dpc-6010	139	7	:	:	PUNCT
dpc-6010	140	1	10.1111	10.1111	NUM
dpc-6010	140	2	/	/	SYM
dpc-6010	140	3	dth.12793	dth.12793	NOUN
dpc-6010	140	4	.	.	PUNCT
dpc-6010	141	1	pmid	pmid	NOUN
dpc-6010	141	2	:	:	PUNCT
dpc-6010	141	3	30515970	30515970	NUM
dpc-6010	141	4	;	;	PUNCT
dpc-6010	141	5	pmcid	pmcid	ADJ
dpc-6010	141	6	:	:	PUNCT
dpc-6010	141	7	pmc6445726	pmc6445726	NOUN
dpc-6010	141	8	.	.	PUNCT
dpc-6010	142	1	6	6	X
dpc-6010	142	2	.	.	X
dpc-6010	142	3	fargnoli	fargnoli	PROPN
dpc-6010	142	4	mc	mc	PROPN
dpc-6010	142	5	,	,	PUNCT
dpc-6010	142	6	bardazzi	bardazzi	PROPN
dpc-6010	142	7	f	f	PROPN
dpc-6010	142	8	,	,	PUNCT
dpc-6010	142	9	bianchi	bianchi	PROPN
dpc-6010	142	10	l	l	PROPN
dpc-6010	142	11	et	et	PROPN
dpc-6010	142	12	al	al	PROPN
dpc-6010	142	13	.	.	PROPN
dpc-6010	142	14	brodalumab	brodalumab	PROPN
dpc-6010	142	15	for	for	ADP
dpc-6010	142	16	the	the	DET
dpc-6010	142	17	treatment	treatment	NOUN
dpc-6010	142	18	of	of	ADP
dpc-6010	142	19	moderate	moderate	ADJ
dpc-6010	142	20	-	-	PUNCT
dpc-6010	142	21	to	to	ADP
dpc-6010	142	22	-	-	PUNCT
dpc-6010	142	23	severe	severe	ADJ
dpc-6010	142	24	psoriasis	psoriasis	NOUN
dpc-6010	142	25	:	:	PUNCT
dpc-6010	142	26	an	an	DET
dpc-6010	142	27	expert	expert	ADJ
dpc-6010	142	28	delphi	delphi	NOUN
dpc-6010	142	29	consensus	consensus	NOUN
dpc-6010	142	30	statement	statement	NOUN
dpc-6010	142	31	.	.	PUNCT
dpc-6010	143	1	j	j	PROPN
dpc-6010	143	2	clin	clin	PROPN
dpc-6010	143	3	med	med	PROPN
dpc-6010	143	4	.	.	PUNCT
dpc-6010	144	1	2023	2023	NUM
dpc-6010	144	2	may	may	AUX
dpc-6010	144	3	18;12(10):3545	18;12(10):3545	NUM
dpc-6010	144	4	.	.	PUNCT
dpc-6010	145	1	doi	doi	NOUN
dpc-6010	145	2	:	:	PUNCT
dpc-6010	145	3	10.3390	10.3390	NUM
dpc-6010	145	4	/jcm12103545	/jcm12103545	PUNCT
dpc-6010	145	5	.	.	PUNCT
dpc-6010	146	1	pmid	pmid	NOUN
dpc-6010	146	2	:	:	PUNCT
dpc-6010	146	3	37240650	37240650	NUM
dpc-6010	146	4	;	;	PUNCT
dpc-6010	146	5	pmcid	pmcid	ADJ
dpc-6010	146	6	:	:	PUNCT
dpc-6010	146	7	pmc10219103	pmc10219103	ADJ
dpc-6010	146	8	.	.	PUNCT
dpc-6010	147	1	7	7	X
dpc-6010	147	2	.	.	X
dpc-6010	147	3	papp	papp	PROPN
dpc-6010	147	4	ka	ka	PROPN
dpc-6010	147	5	,	,	PUNCT
dpc-6010	147	6	reich	reich	PROPN
dpc-6010	147	7	k	k	PROPN
dpc-6010	147	8	,	,	PUNCT
dpc-6010	147	9	paul	paul	PROPN
dpc-6010	147	10	c	c	PROPN
dpc-6010	147	11	et	et	PROPN
dpc-6010	147	12	al	al	PROPN
dpc-6010	147	13	.	.	PUNCT
dpc-6010	148	1	a	a	DET
dpc-6010	148	2	prospective	prospective	ADJ
dpc-6010	148	3	phase	phase	NOUN
dpc-6010	148	4	iii	iii	NOUN
dpc-6010	148	5	,	,	PUNCT
dpc-6010	148	6	randomized	randomize	VERB
dpc-6010	148	7	,	,	PUNCT
dpc-6010	148	8	double	double	ADJ
dpc-6010	148	9	-	-	PUNCT
dpc-6010	148	10	blind	blind	ADJ
dpc-6010	148	11	,	,	PUNCT
dpc-6010	148	12	placebo	placebo	NOUN
dpc-6010	148	13	-	-	PUNCT
dpc-6010	148	14	controlled	control	VERB
dpc-6010	148	15	study	study	NOUN
dpc-6010	148	16	of	of	ADP
dpc-6010	148	17	brodalumab	brodalumab	NOUN
dpc-6010	148	18	in	in	ADP
dpc-6010	148	19	patients	patient	NOUN
dpc-6010	148	20	with	with	ADP
dpc-6010	148	21	moderate	moderate	ADJ
dpc-6010	148	22	-	-	PUNCT
dpc-6010	148	23	to	to	ADP
dpc-6010	148	24	-	-	PUNCT
dpc-6010	148	25	severe	severe	ADJ
dpc-6010	148	26	plaque	plaque	NOUN
dpc-6010	148	27	psoriasis	psoriasis	NOUN
dpc-6010	148	28	.	.	PUNCT
dpc-6010	149	1	additional	additional	ADJ
dpc-6010	149	2	data	datum	NOUN
dpc-6010	149	3	on	on	ADP
dpc-6010	149	4	brodalumab	brodalumab	NOUN
dpc-6010	149	5	efficacy	efficacy	NOUN
dpc-6010	149	6	after	after	ADP
dpc-6010	149	7	anti	anti	ADJ
dpc-6010	149	8	-	-	ADJ
dpc-6010	149	9	il	il	ADJ
dpc-6010	149	10	23	23	NUM
dpc-6010	149	11	failure	failure	NOUN
dpc-6010	149	12	are	be	AUX
dpc-6010	149	13	lacking	lack	VERB
dpc-6010	149	14	.	.	PUNCT
dpc-6010	150	1	in	in	ADP
dpc-6010	150	2	this	this	DET
dpc-6010	150	3	context	context	NOUN
dpc-6010	150	4	,	,	PUNCT
dpc-6010	150	5	our	our	PRON
dpc-6010	150	6	real	real	ADJ
dpc-6010	150	7	-	-	PUNCT
dpc-6010	150	8	life	life	NOUN
dpc-6010	150	9	52	52	NUM
dpc-6010	150	10	-	-	PUNCT
dpc-6010	150	11	week	week	NOUN
dpc-6010	150	12	retrospective	retrospective	ADJ
dpc-6010	150	13	study	study	NOUN
dpc-6010	150	14	demonstrates	demonstrate	VERB
dpc-6010	150	15	good	good	ADJ
dpc-6010	150	16	efficacy	efficacy	NOUN
dpc-6010	150	17	,	,	PUNCT
dpc-6010	150	18	speed	speed	NOUN
dpc-6010	150	19	of	of	ADP
dpc-6010	150	20	action	action	NOUN
dpc-6010	150	21	,	,	PUNCT
dpc-6010	150	22	and	and	CCONJ
dpc-6010	150	23	safety	safety	NOUN
dpc-6010	150	24	of	of	ADP
dpc-6010	150	25	brodalumab	brodalumab	NOUN
dpc-6010	150	26	in	in	ADP
dpc-6010	150	27	psoriasis	psoriasis	NOUN
dpc-6010	150	28	patients	patient	NOUN
dpc-6010	150	29	with	with	ADP
dpc-6010	150	30	previous	previous	ADJ
dpc-6010	150	31	exposure	exposure	NOUN
dpc-6010	150	32	to	to	ADP
dpc-6010	150	33	il-23	il-23	NOUN
dpc-6010	150	34	and	and	CCONJ
dpc-6010	150	35	12/23	12/23	NUM
dpc-6010	150	36	inhibitors	inhibitor	NOUN
dpc-6010	150	37	with	with	ADP
dpc-6010	150	38	performances	performance	NOUN
dpc-6010	150	39	similar	similar	ADJ
dpc-6010	150	40	or	or	CCONJ
dpc-6010	150	41	superior	superior	ADJ
dpc-6010	150	42	to	to	ADP
dpc-6010	150	43	those	those	PRON
dpc-6010	150	44	shown	show	VERB
dpc-6010	150	45	in	in	ADP
dpc-6010	150	46	rcts	rct	NOUN
dpc-6010	150	47	.	.	PUNCT
dpc-6010	151	1	the	the	DET
dpc-6010	151	2	excellent	excellent	ADJ
dpc-6010	151	3	results	result	NOUN
dpc-6010	151	4	obtained	obtain	VERB
dpc-6010	151	5	in	in	ADP
dpc-6010	151	6	our	our	PRON
dpc-6010	151	7	group	group	NOUN
dpc-6010	151	8	of	of	ADP
dpc-6010	151	9	patients	patient	NOUN
dpc-6010	151	10	unresponsive	unresponsive	ADJ
dpc-6010	151	11	to	to	ADP
dpc-6010	151	12	il-23	il-23	VERB
dpc-6010	151	13	inhibitors	inhibitor	NOUN
dpc-6010	151	14	could	could	AUX
dpc-6010	151	15	be	be	AUX
dpc-6010	151	16	explained	explain	VERB
dpc-6010	151	17	by	by	ADP
dpc-6010	151	18	a	a	DET
dpc-6010	151	19	more	more	ADV
dpc-6010	151	20	extensive	extensive	ADJ
dpc-6010	151	21	suppressive	suppressive	ADJ
dpc-6010	151	22	effect	effect	NOUN
dpc-6010	151	23	exerted	exert	VERB
dpc-6010	151	24	by	by	ADP
dpc-6010	151	25	this	this	DET
dpc-6010	151	26	drug	drug	NOUN
dpc-6010	151	27	on	on	ADP
dpc-6010	151	28	the	the	DET
dpc-6010	151	29	th-17	th-17	NUM
dpc-6010	151	30	pathway	pathway	NOUN
dpc-6010	151	31	.	.	PUNCT
dpc-6010	152	1	interestingly	interestingly	ADV
dpc-6010	152	2	,	,	PUNCT
dpc-6010	152	3	this	this	DET
dpc-6010	152	4	feature	feature	NOUN
dpc-6010	152	5	was	be	AUX
dpc-6010	152	6	not	not	PART
dpc-6010	152	7	associated	associate	VERB
dpc-6010	152	8	in	in	ADP
dpc-6010	152	9	our	our	PRON
dpc-6010	152	10	study	study	NOUN
dpc-6010	152	11	population	population	NOUN
dpc-6010	152	12	with	with	ADP
dpc-6010	152	13	a	a	DET
dpc-6010	152	14	higher	high	ADJ
dpc-6010	152	15	incidence	incidence	NOUN
dpc-6010	152	16	of	of	ADP
dpc-6010	152	17	infectious	infectious	ADJ
dpc-6010	152	18	events	event	NOUN
dpc-6010	152	19	or	or	CCONJ
dpc-6010	152	20	the	the	DET
dpc-6010	152	21	occurrence	occurrence	NOUN
dpc-6010	152	22	of	of	ADP
dpc-6010	152	23	inflammatory	inflammatory	ADJ
dpc-6010	152	24	bowel	bowel	NOUN
dpc-6010	152	25	disease	disease	NOUN
dpc-6010	152	26	.	.	PUNCT
dpc-6010	153	1	limitations	limitation	NOUN
dpc-6010	153	2	of	of	ADP
dpc-6010	153	3	the	the	DET
dpc-6010	153	4	study	study	NOUN
dpc-6010	153	5	the	the	DET
dpc-6010	153	6	main	main	ADJ
dpc-6010	153	7	limitations	limitation	NOUN
dpc-6010	153	8	of	of	ADP
dpc-6010	153	9	our	our	PRON
dpc-6010	153	10	study	study	NOUN
dpc-6010	153	11	include	include	VERB
dpc-6010	153	12	its	its	PRON
dpc-6010	153	13	retrospective	retrospective	ADJ
dpc-6010	153	14	design	design	NOUN
dpc-6010	153	15	and	and	CCONJ
dpc-6010	153	16	the	the	DET
dpc-6010	153	17	relatively	relatively	ADV
dpc-6010	153	18	small	small	ADJ
dpc-6010	153	19	number	number	NOUN
dpc-6010	153	20	of	of	ADP
dpc-6010	153	21	patients	patient	NOUN
dpc-6010	153	22	involved	involve	VERB
dpc-6010	153	23	.	.	PUNCT
dpc-6010	154	1	however	however	ADV
dpc-6010	154	2	,	,	PUNCT
dpc-6010	154	3	it	it	PRON
dpc-6010	154	4	should	should	AUX
dpc-6010	154	5	be	be	AUX
dpc-6010	154	6	noted	note	VERB
dpc-6010	154	7	that	that	SCONJ
dpc-6010	154	8	il-23	il-23	NOUN
dpc-6010	154	9	inhibitors	inhibitor	NOUN
dpc-6010	154	10	have	have	VERB
dpc-6010	154	11	very	very	ADV
dpc-6010	154	12	high	high	ADJ
dpc-6010	154	13	response	response	NOUN
dpc-6010	154	14	rates	rate	NOUN
dpc-6010	154	15	and	and	CCONJ
dpc-6010	154	16	a	a	DET
dpc-6010	154	17	consequently	consequently	ADV
dpc-6010	154	18	limited	limited	ADJ
dpc-6010	154	19	number	number	NOUN
dpc-6010	154	20	of	of	ADP
dpc-6010	154	21	treatment	treatment	NOUN
dpc-6010	154	22	failures	failure	NOUN
dpc-6010	154	23	.	.	PUNCT
dpc-6010	155	1	another	another	DET
dpc-6010	155	2	limitation	limitation	NOUN
dpc-6010	155	3	of	of	ADP
dpc-6010	155	4	our	our	PRON
dpc-6010	155	5	study	study	NOUN
dpc-6010	155	6	was	be	AUX
dpc-6010	155	7	the	the	DET
dpc-6010	155	8	inability	inability	NOUN
dpc-6010	155	9	to	to	PART
dpc-6010	155	10	demonstrate	demonstrate	VERB
dpc-6010	155	11	whether	whether	SCONJ
dpc-6010	155	12	main	main	ADJ
dpc-6010	155	13	clinical	clinical	ADJ
dpc-6010	155	14	and	and	CCONJ
dpc-6010	155	15	anamnestic	anamnestic	ADJ
dpc-6010	155	16	variables	variable	NOUN
dpc-6010	155	17	could	could	AUX
dpc-6010	155	18	influence	influence	VERB
dpc-6010	155	19	the	the	DET
dpc-6010	155	20	therapeutic	therapeutic	ADJ
dpc-6010	155	21	performance	performance	NOUN
dpc-6010	155	22	of	of	ADP
dpc-6010	155	23	brodalumab	brodalumab	NOUN
dpc-6010	155	24	.	.	PUNCT
dpc-6010	156	1	despite	despite	SCONJ
dpc-6010	156	2	the	the	DET
dpc-6010	156	3	implementation	implementation	NOUN
dpc-6010	156	4	of	of	ADP
dpc-6010	156	5	a	a	DET
dpc-6010	156	6	cox	cox	PROPN
dpc-6010	156	7	regression	regression	NOUN
dpc-6010	156	8	model	model	NOUN
dpc-6010	156	9	,	,	PUNCT
dpc-6010	156	10	the	the	DET
dpc-6010	156	11	small	small	ADJ
dpc-6010	156	12	sample	sample	NOUN
dpc-6010	156	13	size	size	NOUN
dpc-6010	156	14	,	,	PUNCT
dpc-6010	156	15	and	and	CCONJ
dpc-6010	156	16	high	high	ADJ
dpc-6010	156	17	remission	remission	NOUN
dpc-6010	156	18	rate	rate	NOUN
dpc-6010	156	19	achieved	achieve	VERB
dpc-6010	156	20	in	in	ADP
dpc-6010	156	21	patients	patient	NOUN
dpc-6010	156	22	(	(	PUNCT
dpc-6010	156	23	only	only	ADV
dpc-6010	156	24	two	two	NUM
dpc-6010	156	25	primary	primary	ADJ
dpc-6010	156	26	failures	failure	NOUN
dpc-6010	156	27	)	)	PUNCT
dpc-6010	156	28	probably	probably	ADV
dpc-6010	156	29	precluded	preclude	VERB
dpc-6010	156	30	us	we	PRON
dpc-6010	156	31	from	from	ADP
dpc-6010	156	32	identifying	identify	VERB
dpc-6010	156	33	any	any	DET
dpc-6010	156	34	variable	variable	NOUN
dpc-6010	156	35	that	that	PRON
dpc-6010	156	36	could	could	AUX
dpc-6010	156	37	affect	affect	VERB
dpc-6010	156	38	the	the	DET
dpc-6010	156	39	key	key	ADJ
dpc-6010	156	40	endpoint	endpoint	NOUN
dpc-6010	156	41	of	of	ADP
dpc-6010	156	42	the	the	DET
dpc-6010	156	43	study	study	NOUN
dpc-6010	156	44	.	.	PUNCT
dpc-6010	157	1	conclusions	conclusion	NOUN
dpc-6010	157	2	in	in	ADP
dpc-6010	157	3	conclusion	conclusion	NOUN
dpc-6010	157	4	,	,	PUNCT
dpc-6010	157	5	our	our	PRON
dpc-6010	157	6	results	result	NOUN
dpc-6010	157	7	suggest	suggest	VERB
dpc-6010	157	8	that	that	SCONJ
dpc-6010	157	9	patients	patient	NOUN
dpc-6010	157	10	who	who	PRON
dpc-6010	157	11	had	have	AUX
dpc-6010	157	12	previously	previously	ADV
dpc-6010	157	13	failed	fail	VERB
dpc-6010	157	14	therapy	therapy	NOUN
dpc-6010	157	15	with	with	ADP
dpc-6010	157	16	il-23	il-23	NOUN
dpc-6010	157	17	or	or	CCONJ
dpc-6010	157	18	il12/23	il12/23	NOUN
dpc-6010	157	19	blockers	blocker	NOUN
dpc-6010	157	20	may	may	AUX
dpc-6010	157	21	respond	respond	VERB
dpc-6010	157	22	to	to	ADP
dpc-6010	157	23	medical	medical	ADJ
dpc-6010	157	24	switch	switch	NOUN
dpc-6010	157	25	to	to	ADP
dpc-6010	157	26	another	another	DET
dpc-6010	157	27	class	class	NOUN
dpc-6010	157	28	of	of	ADP
dpc-6010	157	29	biologics	biologic	NOUN
dpc-6010	157	30	.	.	PUNCT
dpc-6010	158	1	in	in	ADP
dpc-6010	158	2	particular	particular	ADJ
dpc-6010	158	3	,	,	PUNCT
dpc-6010	158	4	brodalumab	brodalumab	NOUN
dpc-6010	158	5	could	could	AUX
dpc-6010	158	6	be	be	AUX
dpc-6010	158	7	considered	consider	VERB
dpc-6010	158	8	a	a	DET
dpc-6010	158	9	good	good	ADJ
dpc-6010	158	10	choice	choice	NOUN
dpc-6010	158	11	for	for	ADP
dpc-6010	158	12	this	this	DET
dpc-6010	158	13	group	group	NOUN
dpc-6010	158	14	of	of	ADP
dpc-6010	158	15	difficult	difficult	ADJ
dpc-6010	158	16	-	-	PUNCT
dpc-6010	158	17	to	to	ADP
dpc-6010	158	18	-	-	PUNCT
dpc-6010	158	19	treat	treat	VERB
dpc-6010	158	20	patients	patient	NOUN
dpc-6010	158	21	because	because	SCONJ
dpc-6010	158	22	,	,	PUNCT
dpc-6010	158	23	burdened	burden	VERB
dpc-6010	158	24	by	by	ADP
dpc-6010	158	25	several	several	ADJ
dpc-6010	158	26	therapeutic	therapeutic	ADJ
dpc-6010	158	27	failures	failure	NOUN
dpc-6010	158	28	,	,	PUNCT
dpc-6010	158	29	they	they	PRON
dpc-6010	158	30	could	could	AUX
dpc-6010	158	31	be	be	AUX
dpc-6010	158	32	considered	consider	VERB
dpc-6010	158	33	high	high	ADJ
dpc-6010	158	34	-	-	PUNCT
dpc-6010	158	35	need	need	NOUN
dpc-6010	158	36	of	of	ADP
dpc-6010	158	37	an	an	DET
dpc-6010	158	38	effective	effective	ADJ
dpc-6010	158	39	and	and	CCONJ
dpc-6010	158	40	fast	fast	ADV
dpc-6010	158	41	-	-	PUNCT
dpc-6010	158	42	acting	act	VERB
dpc-6010	158	43	drug	drug	NOUN
dpc-6010	158	44	which	which	PRON
dpc-6010	158	45	also	also	ADV
dpc-6010	158	46	shows	show	VERB
dpc-6010	158	47	a	a	DET
dpc-6010	158	48	very	very	ADV
dpc-6010	158	49	low	low	ADJ
dpc-6010	158	50	immunogenicity	immunogenicity	NOUN
dpc-6010	158	51	risk	risk	NOUN
dpc-6010	158	52	.	.	PUNCT
dpc-6010	159	1	however	however	ADV
dpc-6010	159	2	,	,	PUNCT
dpc-6010	159	3	more	more	ADJ
dpc-6010	159	4	data	datum	NOUN
dpc-6010	159	5	are	be	AUX
dpc-6010	159	6	needed	need	VERB
dpc-6010	159	7	to	to	PART
dpc-6010	159	8	further	far	ADV
dpc-6010	159	9	explore	explore	VERB
dpc-6010	159	10	the	the	DET
dpc-6010	159	11	possibility	possibility	NOUN
dpc-6010	159	12	of	of	ADP
dpc-6010	159	13	switching	switch	VERB
dpc-6010	159	14	therapy	therapy	NOUN
dpc-6010	159	15	among	among	ADP
dpc-6010	159	16	different	different	ADJ
dpc-6010	159	17	classes	class	NOUN
dpc-6010	159	18	of	of	ADP
dpc-6010	159	19	biologics	biologic	NOUN
dpc-6010	159	20	for	for	ADP
dpc-6010	159	21	the	the	DET
dpc-6010	159	22	treatment	treatment	NOUN
dpc-6010	159	23	of	of	ADP
dpc-6010	159	24	psoriasis	psoriasis	NOUN
dpc-6010	159	25	.	.	PUNCT
dpc-6010	160	1	table	table	NOUN
dpc-6010	160	2	5	5	NUM
dpc-6010	160	3	.	.	PUNCT
dpc-6010	161	1	mean	mean	VERB
dpc-6010	161	2	dlqi	dlqi	VERB
dpc-6010	161	3	by	by	ADP
dpc-6010	161	4	visit	visit	NOUN
dpc-6010	161	5	.	.	PUNCT
dpc-6010	162	1	visit	visit	VERB
dpc-6010	162	2	meandlqi	meandlqi	PROPN
dpc-6010	162	3	(	(	PUNCT
dpc-6010	162	4	sd	sd	NOUN
dpc-6010	162	5	)	)	PUNCT
dpc-6010	162	6	mdlqi	mdlqi	NOUN
dpc-6010	162	7	decrease	decrease	NOUN
dpc-6010	162	8	paired	pair	VERB
dpc-6010	162	9	t	t	PROPN
dpc-6010	162	10	-	-	PUNCT
dpc-6010	162	11	test	test	NOUN
dpc-6010	162	12	baseline	baseline	NOUN
dpc-6010	162	13	(	(	PUNCT
dpc-6010	162	14	n=22	n=22	PROPN
dpc-6010	162	15	)	)	PUNCT
dpc-6010	162	16	16.9	16.9	NUM
dpc-6010	162	17	(	(	PUNCT
dpc-6010	162	18	±	±	NOUN
dpc-6010	162	19	7.6	7.6	NUM
dpc-6010	162	20	)	)	PUNCT
dpc-6010	162	21	4	4	NUM
dpc-6010	162	22	weeks	week	NOUN
dpc-6010	162	23	(	(	PUNCT
dpc-6010	162	24	n=22	n=22	PROPN
dpc-6010	162	25	)	)	PUNCT
dpc-6010	162	26	5.1	5.1	NUM
dpc-6010	162	27	(	(	PUNCT
dpc-6010	162	28	±	±	NOUN
dpc-6010	162	29	7.0	7.0	NUM
dpc-6010	162	30	)	)	PUNCT
dpc-6010	162	31	-11.9	-11.9	PROPN
dpc-6010	162	32	(	(	PUNCT
dpc-6010	162	33	±	±	NOUN
dpc-6010	162	34	9.2	9.2	NUM
dpc-6010	162	35	)	)	PUNCT
dpc-6010	162	36	<	<	X
dpc-6010	162	37	0.001	0.001	NUM
dpc-6010	162	38	16	16	NUM
dpc-6010	162	39	weeks	week	NOUN
dpc-6010	162	40	(	(	PUNCT
dpc-6010	162	41	n=22	n=22	PROPN
dpc-6010	162	42	)	)	PUNCT
dpc-6010	162	43	2.9	2.9	NUM
dpc-6010	162	44	(	(	PUNCT
dpc-6010	162	45	±	±	NUM
dpc-6010	162	46	5.5	5.5	NUM
dpc-6010	162	47	)	)	PUNCT
dpc-6010	162	48	-14.0	-14.0	PUNCT
dpc-6010	163	1	(	(	PUNCT
dpc-6010	163	2	±	±	NOUN
dpc-6010	163	3	8.4	8.4	NUM
dpc-6010	163	4	)	)	PUNCT
dpc-6010	163	5	<	<	X
dpc-6010	163	6	0.001	0.001	NUM
dpc-6010	163	7	36	36	NUM
dpc-6010	163	8	weeks	week	NOUN
dpc-6010	163	9	(	(	PUNCT
dpc-6010	163	10	n=22	n=22	PROPN
dpc-6010	163	11	)	)	PUNCT
dpc-6010	163	12	2.6	2.6	NUM
dpc-6010	163	13	(	(	PUNCT
dpc-6010	163	14	±	±	NUM
dpc-6010	163	15	5.9	5.9	NUM
dpc-6010	163	16	)	)	PUNCT
dpc-6010	163	17	-14.4	-14.4	NUM
dpc-6010	163	18	(	(	PUNCT
dpc-6010	163	19	±	±	NOUN
dpc-6010	163	20	8.6	8.6	NUM
dpc-6010	163	21	)	)	PUNCT
dpc-6010	163	22	<	<	X
dpc-6010	163	23	0.001	0.001	NUM
dpc-6010	163	24	1	1	NUM
dpc-6010	163	25	year	year	NOUN
dpc-6010	163	26	(	(	PUNCT
dpc-6010	163	27	n=21	n=21	NOUN
dpc-6010	163	28	)	)	PUNCT
dpc-6010	163	29	1.8	1.8	NUM
dpc-6010	163	30	(	(	PUNCT
dpc-6010	163	31	±	±	NOUN
dpc-6010	163	32	3.8	3.8	NUM
dpc-6010	163	33	)	)	PUNCT
dpc-6010	163	34	-15.0	-15.0	PUNCT
dpc-6010	163	35	(	(	PUNCT
dpc-6010	163	36	±	±	NOUN
dpc-6010	163	37	8.2	8.2	NUM
dpc-6010	163	38	)	)	PUNCT
dpc-6010	163	39	<	<	X
dpc-6010	163	40	0.001	0.001	NUM
dpc-6010	163	41	8	8	NUM
dpc-6010	163	42	original	original	ADJ
dpc-6010	163	43	article	article	NOUN
dpc-6010	163	44	|	|	ADV
dpc-6010	163	45	dermatol	dermatol	ADJ
dpc-6010	163	46	pract	pract	NOUN
dpc-6010	163	47	concept	concept	NOUN
dpc-6010	163	48	.	.	PUNCT
dpc-6010	164	1	2025;15(4):6010	2025;15(4):6010	NUM
dpc-6010	164	2	12	12	NUM
dpc-6010	164	3	.	.	PUNCT
dpc-6010	165	1	lebwohl	lebwohl	PROPN
dpc-6010	165	2	m	m	PROPN
dpc-6010	165	3	,	,	PUNCT
dpc-6010	165	4	menter	menter	X
dpc-6010	165	5	a	a	PRON
dpc-6010	165	6	,	,	PUNCT
dpc-6010	165	7	lain	lain	PROPN
dpc-6010	165	8	e	e	PROPN
dpc-6010	165	9	,	,	PUNCT
dpc-6010	165	10	han	han	PROPN
dpc-6010	165	11	g	g	PROPN
dpc-6010	165	12	,	,	PUNCT
dpc-6010	165	13	jacobson	jacobson	PROPN
dpc-6010	165	14	a.	a.	PROPN
dpc-6010	165	15	long	long	ADJ
dpc-6010	165	16	-	-	PUNCT
dpc-6010	165	17	term	term	NOUN
dpc-6010	165	18	skin	skin	NOUN
dpc-6010	165	19	clearance	clearance	NOUN
dpc-6010	165	20	with	with	ADP
dpc-6010	165	21	brodalumab	brodalumab	NOUN
dpc-6010	165	22	in	in	ADP
dpc-6010	165	23	patients	patient	NOUN
dpc-6010	165	24	with	with	ADP
dpc-6010	165	25	psoriasis	psoriasis	NOUN
dpc-6010	165	26	and	and	CCONJ
dpc-6010	165	27	inadequate	inadequate	ADJ
dpc-6010	165	28	response	response	NOUN
dpc-6010	165	29	to	to	ADP
dpc-6010	165	30	prior	prior	ADJ
dpc-6010	165	31	biologics	biologic	NOUN
dpc-6010	165	32	.	.	PUNCT
dpc-6010	166	1	j	j	NOUN
dpc-6010	166	2	drugs	drug	NOUN
dpc-6010	166	3	dermatol	dermatol	NOUN
dpc-6010	166	4	.	.	PUNCT
dpc-6010	167	1	2022	2022	NUM
dpc-6010	167	2	apr	apr	NOUN
dpc-6010	167	3	1;21(4):354	1;21(4):354	NUM
dpc-6010	167	4	-	-	SYM
dpc-6010	167	5	370	370	NUM
dpc-6010	167	6	.	.	PUNCT
dpc-6010	168	1	doi	doi	NOUN
dpc-6010	168	2	:	:	PUNCT
dpc-6010	168	3	10.36849	10.36849	NUM
dpc-6010	168	4	/	/	SYM
dpc-6010	168	5	jdd.6743	jdd.6743	PROPN
dpc-6010	168	6	.	.	PUNCT
dpc-6010	169	1	pmid	pmid	NOUN
dpc-6010	169	2	:	:	PUNCT
dpc-6010	169	3	35389586	35389586	NUM
dpc-6010	169	4	.	.	PUNCT
dpc-6010	170	1	13	13	NUM
dpc-6010	170	2	.	.	X
dpc-6010	171	1	sun	sun	PROPN
dpc-6010	171	2	x	x	PROPN
dpc-6010	171	3	,	,	PUNCT
dpc-6010	171	4	cui	cui	PROPN
dpc-6010	171	5	z	z	PROPN
dpc-6010	171	6	,	,	PUNCT
dpc-6010	171	7	wang	wang	PROPN
dpc-6010	171	8	q	q	PROPN
dpc-6010	171	9	et	et	PROPN
dpc-6010	171	10	al	al	PROPN
dpc-6010	171	11	.	.	PUNCT
dpc-6010	171	12	formation	formation	NOUN
dpc-6010	171	13	and	and	CCONJ
dpc-6010	171	14	clinical	clinical	ADJ
dpc-6010	171	15	effects	effect	NOUN
dpc-6010	171	16	of	of	ADP
dpc-6010	171	17	anti	anti	ADJ
dpc-6010	171	18	-	-	ADJ
dpc-6010	171	19	drug	drug	ADJ
dpc-6010	171	20	antibodies	antibody	NOUN
dpc-6010	171	21	against	against	ADP
dpc-6010	171	22	biologics	biologic	NOUN
dpc-6010	171	23	in	in	ADP
dpc-6010	171	24	psoriasis	psoriasis	NOUN
dpc-6010	171	25	treatment	treatment	NOUN
dpc-6010	171	26	:	:	PUNCT
dpc-6010	171	27	an	an	DET
dpc-6010	171	28	analysis	analysis	NOUN
dpc-6010	171	29	of	of	ADP
dpc-6010	171	30	current	current	ADJ
dpc-6010	171	31	evidence	evidence	NOUN
dpc-6010	171	32	.	.	PUNCT
dpc-6010	172	1	autoimmun	autoimmun	PROPN
dpc-6010	172	2	rev	rev	PROPN
dpc-6010	172	3	.	.	PROPN
dpc-6010	173	1	2024	2024	NUM
dpc-6010	173	2	apr;23(4):103530	apr;23(4):103530	PROPN
dpc-6010	173	3	.	.	PUNCT
dpc-6010	173	4	doi	doi	NOUN
dpc-6010	173	5	:	:	PUNCT
dpc-6010	173	6	10.1016	10.1016	NUM
dpc-6010	173	7	/	/	SYM
dpc-6010	173	8	j.autrev.2024.103530	j.autrev.2024.103530	NOUN
dpc-6010	173	9	.	.	PUNCT
dpc-6010	174	1	pmid	pmid	NOUN
dpc-6010	174	2	:	:	PUNCT
dpc-6010	174	3	38499168	38499168	NUM
dpc-6010	174	4	.	.	PUNCT
dpc-6010	175	1	14	14	NUM
dpc-6010	175	2	.	.	PUNCT
dpc-6010	176	1	reich	reich	PROPN
dpc-6010	176	2	k	k	PROPN
dpc-6010	176	3	,	,	PUNCT
dpc-6010	176	4	bianchi	bianchi	PROPN
dpc-6010	176	5	l	l	PROPN
dpc-6010	176	6	,	,	PUNCT
dpc-6010	176	7	khemis	khemis	VERB
dpc-6010	176	8	a	a	DET
dpc-6010	176	9	et	et	NOUN
dpc-6010	176	10	al	al	PROPN
dpc-6010	176	11	.	.	PROPN
dpc-6010	176	12	brodalumab	brodalumab	PROPN
dpc-6010	176	13	versus	versus	ADP
dpc-6010	176	14	guselkumab	guselkumab	NOUN
dpc-6010	176	15	in	in	ADP
dpc-6010	176	16	patients	patient	NOUN
dpc-6010	176	17	with	with	ADP
dpc-6010	176	18	moderate	moderate	ADJ
dpc-6010	176	19	-	-	PUNCT
dpc-6010	176	20	to	to	ADP
dpc-6010	176	21	-	-	PUNCT
dpc-6010	176	22	severe	severe	ADJ
dpc-6010	176	23	psoriasis	psoriasis	NOUN
dpc-6010	176	24	with	with	ADP
dpc-6010	176	25	an	an	DET
dpc-6010	176	26	inadequate	inadequate	ADJ
dpc-6010	176	27	response	response	NOUN
dpc-6010	176	28	to	to	ADP
dpc-6010	176	29	ustekinumab	ustekinumab	NOUN
dpc-6010	176	30	:	:	PUNCT
dpc-6010	176	31	a	a	DET
dpc-6010	176	32	randomized	randomized	ADJ
dpc-6010	176	33	,	,	PUNCT
dpc-6010	176	34	multicenter	multicenter	NOUN
dpc-6010	176	35	,	,	PUNCT
dpc-6010	176	36	double	double	ADJ
dpc-6010	176	37	-	-	PUNCT
dpc-6010	176	38	blind	blind	ADJ
dpc-6010	176	39	phase	phase	NOUN
dpc-6010	176	40	4	4	NUM
dpc-6010	176	41	trial	trial	NOUN
dpc-6010	176	42	(	(	PUNCT
dpc-6010	176	43	cobra	cobra	NOUN
dpc-6010	176	44	)	)	PUNCT
dpc-6010	176	45	.	.	PUNCT
dpc-6010	177	1	dermatol	dermatol	NOUN
dpc-6010	177	2	ther	ther	ADV
dpc-6010	177	3	(	(	PUNCT
dpc-6010	177	4	heidelb	heidelb	NOUN
dpc-6010	177	5	)	)	PUNCT
dpc-6010	177	6	.	.	PUNCT
dpc-6010	178	1	2024	2024	NUM
dpc-6010	178	2	feb;14(2):453	feb;14(2):453	NOUN
dpc-6010	178	3	-	-	SYM
dpc-6010	178	4	468	468	NUM
dpc-6010	178	5	.	.	PUNCT
dpc-6010	179	1	doi	doi	NOUN
dpc-6010	179	2	:	:	PUNCT
dpc-6010	179	3	10.1007	10.1007	NUM
dpc-6010	179	4	/	/	SYM
dpc-6010	179	5	s13555	s13555	PROPN
dpc-6010	179	6	-	-	PUNCT
dpc-6010	179	7	023	023	NUM
dpc-6010	179	8	-01092	-01092	NOUN
dpc-6010	179	9	-	-	PUNCT
dpc-6010	179	10	x.	x.	NOUN
dpc-6010	179	11	pmid	pmid	PROPN
dpc-6010	179	12	:	:	PUNCT
dpc-6010	179	13	38300408	38300408	NUM
dpc-6010	179	14	;	;	PUNCT
dpc-6010	179	15	pmcid	pmcid	ADJ
dpc-6010	179	16	:	:	PUNCT
dpc-6010	179	17	pmc10891028	pmc10891028	NOUN
dpc-6010	179	18	.	.	PUNCT
dpc-6010	180	1	15	15	X
dpc-6010	180	2	.	.	PUNCT
dpc-6010	180	3	papp	papp	PROPN
dpc-6010	180	4	k	k	PROPN
dpc-6010	180	5	,	,	PUNCT
dpc-6010	180	6	prajapati	prajapati	PROPN
dpc-6010	180	7	vh	vh	PROPN
dpc-6010	180	8	,	,	PUNCT
dpc-6010	180	9	maari	maari	PROPN
dpc-6010	180	10	c	c	NOUN
dpc-6010	180	11	,	,	PUNCT
dpc-6010	180	12	legault	legault	PROPN
dpc-6010	180	13	m	m	PROPN
dpc-6010	180	14	,	,	PUNCT
dpc-6010	180	15	barakat	barakat	PROPN
dpc-6010	180	16	m	m	PROPN
dpc-6010	180	17	,	,	PUNCT
dpc-6010	180	18	vender	vender	PROPN
dpc-6010	180	19	r.	r.	PROPN
dpc-6010	180	20	efficacy	efficacy	PROPN
dpc-6010	180	21	of	of	ADP
dpc-6010	180	22	brodalumab	brodalumab	NOUN
dpc-6010	180	23	in	in	ADP
dpc-6010	180	24	moderate	moderate	ADJ
dpc-6010	180	25	-	-	PUNCT
dpc-6010	180	26	to	to	ADP
dpc-6010	180	27	-	-	PUNCT
dpc-6010	180	28	severe	severe	ADJ
dpc-6010	180	29	plaque	plaque	NOUN
dpc-6010	180	30	psoriasis	psoriasis	NOUN
dpc-6010	180	31	after	after	ADP
dpc-6010	180	32	failure	failure	NOUN
dpc-6010	180	33	of	of	ADP
dpc-6010	180	34	previous	previous	ADJ
dpc-6010	180	35	biologic	biologic	NOUN
dpc-6010	180	36	therapy	therapy	NOUN
dpc-6010	180	37	:	:	PUNCT
dpc-6010	180	38	a	a	DET
dpc-6010	180	39	phase	phase	NOUN
dpc-6010	180	40	4	4	NUM
dpc-6010	180	41	,	,	PUNCT
dpc-6010	180	42	multicenter	multicenter	NOUN
dpc-6010	180	43	,	,	PUNCT
dpc-6010	180	44	open	open	ADJ
dpc-6010	180	45	-	-	PUNCT
dpc-6010	180	46	label	label	NOUN
dpc-6010	180	47	study	study	NOUN
dpc-6010	180	48	.	.	PUNCT
dpc-6010	181	1	j	j	PROPN
dpc-6010	181	2	am	be	AUX
dpc-6010	181	3	acad	acad	ADJ
dpc-6010	181	4	dermatol	dermatol	NOUN
dpc-6010	181	5	.	.	PUNCT
dpc-6010	182	1	2024	2024	NUM
dpc-6010	182	2	jun;90(6	jun;90(6	NOUN
dpc-6010	182	3	):	):	PUNCT
dpc-6010	182	4	1254	1254	NUM
dpc-6010	182	5	-	-	SYM
dpc-6010	182	6	1256	1256	NUM
dpc-6010	182	7	.	.	PUNCT
dpc-6010	183	1	doi	doi	NOUN
dpc-6010	183	2	:	:	PUNCT
dpc-6010	183	3	10.1016	10.1016	NUM
dpc-6010	183	4	/	/	SYM
dpc-6010	183	5	j.jaad.2024.01.025	j.jaad.2024.01.025	PROPN
dpc-6010	183	6	.	.	PUNCT
dpc-6010	184	1	pmid	pmid	NOUN
dpc-6010	184	2	:	:	PUNCT
dpc-6010	184	3	38290619	38290619	NUM
dpc-6010	184	4	.	.	PUNCT
dpc-6010	185	1	br	br	PROPN
dpc-6010	185	2	j	j	PROPN
dpc-6010	185	3	dermatol	dermatol	NOUN
dpc-6010	185	4	.	.	PUNCT
dpc-6010	186	1	2016	2016	NUM
dpc-6010	186	2	aug;175(2):273	aug;175(2):273	NOUN
dpc-6010	186	3	-	-	PUNCT
dpc-6010	186	4	86	86	NUM
dpc-6010	186	5	.	.	PUNCT
dpc-6010	187	1	doi	doi	NOUN
dpc-6010	187	2	:	:	PUNCT
dpc-6010	187	3	10.1111	10.1111	NUM
dpc-6010	187	4	/	/	SYM
dpc-6010	187	5	bjd	bjd	PROPN
dpc-6010	187	6	.14493	.14493	PROPN
dpc-6010	187	7	.	.	PUNCT
dpc-6010	188	1	pmid	pmid	NOUN
dpc-6010	188	2	:	:	PUNCT
dpc-6010	188	3	26914406	26914406	NUM
dpc-6010	188	4	.	.	X
dpc-6010	189	1	8	8	X
dpc-6010	189	2	.	.	X
dpc-6010	189	3	lebwohl	lebwohl	PROPN
dpc-6010	189	4	m	m	PROPN
dpc-6010	189	5	,	,	PUNCT
dpc-6010	189	6	strober	strober	ADV
dpc-6010	189	7	b	b	NUM
dpc-6010	189	8	,	,	PUNCT
dpc-6010	189	9	menter	menter	X
dpc-6010	189	10	a	a	PRON
dpc-6010	189	11	et	et	PROPN
dpc-6010	189	12	al	al	PROPN
dpc-6010	189	13	.	.	PROPN
dpc-6010	189	14	phase	phase	NOUN
dpc-6010	189	15	3	3	NUM
dpc-6010	189	16	studies	study	NOUN
dpc-6010	189	17	comparing	compare	VERB
dpc-6010	189	18	brodalumab	brodalumab	NOUN
dpc-6010	189	19	with	with	ADP
dpc-6010	189	20	ustekinumab	ustekinumab	NOUN
dpc-6010	189	21	in	in	ADP
dpc-6010	189	22	psoriasis	psoriasis	NOUN
dpc-6010	189	23	.	.	PUNCT
dpc-6010	190	1	n	n	CCONJ
dpc-6010	190	2	engl	engl	PROPN
dpc-6010	190	3	j	j	PROPN
dpc-6010	190	4	med	med	PROPN
dpc-6010	190	5	.	.	PROPN
dpc-6010	190	6	2015	2015	NUM
dpc-6010	190	7	oct;373(14):1318	oct;373(14):1318	PROPN
dpc-6010	190	8	-	-	PUNCT
dpc-6010	190	9	28	28	NUM
dpc-6010	190	10	.	.	PUNCT
dpc-6010	191	1	doi	doi	NOUN
dpc-6010	191	2	:	:	PUNCT
dpc-6010	191	3	10.1056	10.1056	NUM
dpc-6010	191	4	/	/	SYM
dpc-6010	191	5	nejmoa1503824	nejmoa1503824	PROPN
dpc-6010	191	6	.	.	PUNCT
dpc-6010	192	1	pmid	pmid	NOUN
dpc-6010	192	2	:	:	PUNCT
dpc-6010	192	3	26422722	26422722	NUM
dpc-6010	192	4	.	.	PUNCT
dpc-6010	193	1	9	9	X
dpc-6010	193	2	.	.	X
dpc-6010	193	3	papp	papp	PROPN
dpc-6010	193	4	ka	ka	PROPN
dpc-6010	193	5	,	,	PUNCT
dpc-6010	193	6	leonardi	leonardi	PROPN
dpc-6010	193	7	c	c	PROPN
dpc-6010	193	8	,	,	PUNCT
dpc-6010	193	9	menter	menter	X
dpc-6010	193	10	a	a	PRON
dpc-6010	193	11	et	et	PROPN
dpc-6010	193	12	al	al	PROPN
dpc-6010	193	13	.	.	PROPN
dpc-6010	193	14	brodalumab	brodalumab	PROPN
dpc-6010	193	15	,	,	PUNCT
dpc-6010	193	16	an	an	DET
dpc-6010	193	17	anti	anti	ADJ
dpc-6010	193	18	interleukin-17	interleukin-17	ADJ
dpc-6010	193	19	-	-	ADJ
dpc-6010	193	20	receptor	receptor	NOUN
dpc-6010	193	21	antibody	antibody	NOUN
dpc-6010	193	22	for	for	ADP
dpc-6010	193	23	psoriasis	psoriasis	NOUN
dpc-6010	193	24	.	.	PUNCT
dpc-6010	194	1	n	n	CCONJ
dpc-6010	194	2	engl	engl	PROPN
dpc-6010	194	3	j	j	PROPN
dpc-6010	194	4	med	med	PROPN
dpc-6010	194	5	.	.	PUNCT
dpc-6010	195	1	2012	2012	NUM
dpc-6010	195	2	mar	mar	PROPN
dpc-6010	195	3	29;366(13):1181	29;366(13):1181	PROPN
dpc-6010	195	4	-	-	SYM
dpc-6010	195	5	9	9	NUM
dpc-6010	195	6	.	.	PUNCT
dpc-6010	195	7	doi	doi	NOUN
dpc-6010	195	8	:	:	PUNCT
dpc-6010	195	9	10.1056	10.1056	NUM
dpc-6010	195	10	/	/	SYM
dpc-6010	195	11	nejmoa1109017	nejmoa1109017	PROPN
dpc-6010	195	12	.	.	PUNCT
dpc-6010	196	1	pmid	pmid	NOUN
dpc-6010	196	2	:	:	PUNCT
dpc-6010	196	3	22455412	22455412	NUM
dpc-6010	196	4	.	.	PUNCT
dpc-6010	197	1	10	10	NUM
dpc-6010	197	2	.	.	PUNCT
dpc-6010	197	3	mastorino	mastorino	PROPN
dpc-6010	197	4	l	l	NOUN
dpc-6010	197	5	,	,	PUNCT
dpc-6010	197	6	roccuzzo	roccuzzo	VERB
dpc-6010	197	7	g	g	NOUN
dpc-6010	197	8	,	,	PUNCT
dpc-6010	197	9	dapavo	dapavo	VERB
dpc-6010	197	10	p	p	PROPN
dpc-6010	197	11	et	et	PROPN
dpc-6010	197	12	al	al	PROPN
dpc-6010	197	13	.	.	PUNCT
dpc-6010	198	1	switching	switch	VERB
dpc-6010	198	2	from	from	ADP
dpc-6010	198	3	il23	il23	PROPN
dpc-6010	198	4	inhibitors	inhibitor	NOUN
dpc-6010	198	5	to	to	ADP
dpc-6010	198	6	il17	il17	ADJ
dpc-6010	198	7	inhibitors	inhibitor	NOUN
dpc-6010	198	8	:	:	PUNCT
dpc-6010	198	9	a	a	DET
dpc-6010	198	10	safe	safe	ADJ
dpc-6010	198	11	and	and	CCONJ
dpc-6010	198	12	effective	effective	ADJ
dpc-6010	198	13	practice	practice	NOUN
dpc-6010	198	14	?	?	PUNCT
dpc-6010	199	1	dermatol	dermatol	NOUN
dpc-6010	199	2	ther	ther	ADV
dpc-6010	199	3	.	.	PUNCT
dpc-6010	200	1	2022	2022	NUM
dpc-6010	200	2	sep;35(9):e15697	sep;35(9):e15697	NOUN
dpc-6010	200	3	.	.	PUNCT
dpc-6010	201	1	doi	doi	NOUN
dpc-6010	201	2	:	:	PUNCT
dpc-6010	201	3	10.1111	10.1111	NUM
dpc-6010	201	4	/	/	SYM
dpc-6010	201	5	dth.15697	dth.15697	PROPN
dpc-6010	201	6	.	.	PUNCT
dpc-6010	202	1	pmid	pmid	NOUN
dpc-6010	202	2	:	:	PUNCT
dpc-6010	202	3	35796147	35796147	NUM
dpc-6010	202	4	;	;	PUNCT
dpc-6010	202	5	pmcid	pmcid	ADJ
dpc-6010	202	6	:	:	PUNCT
dpc-6010	202	7	pmc9540258	pmc9540258	NOUN
dpc-6010	202	8	.	.	PUNCT
dpc-6010	203	1	11	11	NUM
dpc-6010	203	2	.	.	PUNCT
dpc-6010	204	1	kushnir	kushnir	NOUN
dpc-6010	204	2	-	-	PUNCT
dpc-6010	204	3	grinbaum	grinbaum	PROPN
dpc-6010	204	4	d	d	PROPN
dpc-6010	204	5	,	,	PUNCT
dpc-6010	204	6	ziv	ziv	PROPN
dpc-6010	204	7	m.	m.	PROPN
dpc-6010	204	8	drug	drug	PROPN
dpc-6010	204	9	survival	survival	NOUN
dpc-6010	204	10	of	of	ADP
dpc-6010	204	11	interleukin	interleukin	NOUN
dpc-6010	204	12	17	17	NUM
dpc-6010	204	13	inhibitors	inhibitor	NOUN
dpc-6010	204	14	after	after	ADP
dpc-6010	204	15	switch	switch	NOUN
dpc-6010	204	16	from	from	ADP
dpc-6010	204	17	interleukin	interleukin	NOUN
dpc-6010	204	18	23	23	NUM
dpc-6010	204	19	inhibitors	inhibitor	NOUN
dpc-6010	204	20	in	in	ADP
dpc-6010	204	21	psoriasis	psoriasis	NOUN
dpc-6010	204	22	:	:	PUNCT
dpc-6010	204	23	an	an	DET
dpc-6010	204	24	observational	observational	ADJ
dpc-6010	204	25	cohort	cohort	NOUN
dpc-6010	204	26	study	study	NOUN
dpc-6010	204	27	.	.	PUNCT
dpc-6010	205	1	j	j	PROPN
dpc-6010	205	2	am	be	AUX
dpc-6010	205	3	acad	acad	ADJ
dpc-6010	205	4	dermatol	dermatol	NOUN
dpc-6010	205	5	.	.	PUNCT
dpc-6010	206	1	2024	2024	NUM
dpc-6010	206	2	dec;91(6):1260	dec;91(6):1260	X
dpc-6010	206	3	-	-	SYM
dpc-6010	206	4	1263	1263	NUM
dpc-6010	206	5	.	.	PUNCT
dpc-6010	207	1	doi	doi	NOUN
dpc-6010	207	2	:	:	PUNCT
dpc-6010	207	3	10.1016	10.1016	NUM
dpc-6010	207	4	/	/	SYM
dpc-6010	207	5	j.jaad.2024.07.1514	j.jaad.2024.07.1514	PROPN
dpc-6010	207	6	.	.	PUNCT
dpc-6010	208	1	pmid	pmid	NOUN
dpc-6010	208	2	:	:	PUNCT
dpc-6010	208	3	39182683	39182683	NUM
dpc-6010	208	4	.	.	PUNCT